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―It is a sad reflection on society's incompetence that, more than thirty years after the methods 
for cure and prevention were evolved and before the advent of the HIV epidemic, there were 
already more patients with active tuberculosis in the world than there had been in the 1950s‖ 
(John Crofton) 
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Abstract  
Tuberculosis (Tb) has plagued mankind for many centuries and is still a leading cause of 
death worldwide. A worrying development is the emergence of drug-resistant Tb that poses 
further challenges to the control of the disease. The global Tb burden and high mortality rate 
indicate that new drugs are needed for Tb treatment. While no new anti-Tb agents have been 
introduced to the market for about three decades, drugs with novel mechanisms of action can 
amend the current Tb treatment regimen and may provide an effective solution to drug 
resistance.  
The main objectives of this study were to identify an appropriate in vitro model that could be 
used for anti-Tb drug high-throughput screening (HTS), and to use this model to identify a 
novel candidate anti-tubercular drug and its cognate cellular target. A sensitive growth 
inhibition assay was set up with a GFP-labelled Tb vaccine strain, M. bovis BCG, using 
standard first and second line anti-tubercular drugs. HTS of the drug libraries was performed 
with various in vitro models to evaluate their efficacy for use in anti-Tb drug discovery. 
Approximately 50% of the M. tuberculosis inhibitors were not detected in screening with the 
surrogate species, M. smegmatis; whereas, only 21% of hits were not detected with M. bovis 
BCG. A comparative genomic study revealed that 97% of M. bovis BCG proteins, compared 
to 70% in M. smegmatis have conserved orthologues in M. tuberculosis H37Rv. Therefore, M. 
bovis BCG represented a more sensitive model than M. smegmatis for detecting anti-M. 
tuberculosis compounds. M. bovis BCG was then used to screen for novel anti-Tb agents by 
HTS of compound libraries and various plant extracts, followed by validation of new 
compounds in M. tuberculosis H37Ra. A number of novel M. tuberculosis inhibitors were 
identified, including sappanone A dimethyl ether from plant sources and compounds 
NSC112200 and NSC402959 from NIH chemical libraries. The inhibitors that were validated 
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using M. tuberculosis H37Ra were also validated in the virulent Tb strain, M. tuberculosis 
H37Rv. In addition, their activity was further investigated using a suite of other clinically 
important human pathogens. 
One of the key anti-mycobacterial hits identified in this study, NSC402959, has previously 
been detected in screens for compounds that inhibit ribonuclease H (RNase H), an enzyme 
that is required for a number of essential cellular processes. NSC402959 inhibited RNase H 
proteins from HIV as well as from E. coli. Since HIV and Tb are major pandemics, 
previously-known anti-HIV RNase H compounds were imported and tested for their anti-
proliferative activity towards M. tuberculosis H37Ra. HIV RNase H inhibitors, NSC35676, 
NSC112200, NSC133457 and NSC668394, exhibited good anti-mycobacterial activity in this 
study. In silico analysis suggested a plausible interaction of these inhibitors with 
mycobacterial RNase HI. A biochemical assay further confirmed NSC112200 to be specific 
against RNase HI from M. tuberculosis. These interesting inhibitors were not only 
structurally different from existing anti-Tb drugs but some of them were also non-toxic to 
mammalian cells and may have a unique mechanism of action. Thus, these compounds 
showed good potential for development as dual inhibitors of Tb and HIV; therefore, future 
studies in animal infection models to determine their dual anti-mycobacterial and anti-HIV 
activities are warranted. 
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1. General Introduction to Tuberculosis Biology And Drug Discovery 
 
1.1. Tuberculosis 
Tuberculosis (Tb) is a debilitating and highly contagious disease that primarily affects the 
lungs [1]. It was declared a global health emergency in 1993 by the World Health 
Organization (WHO) when approximately 8 million Tb cases were estimated and 1.3-1.6 
million deaths occurred from the disease each year [2]. Tb is still a major public health 
concern as it is a leading bacterial cause of death worldwide [3]. A record number of incident 
cases of Tb, 8.8 million, were estimated in 2010 alone [4]. Pulmonary Tb is the most 
prevalent form of the disease and presents various signs and symptoms indicating an active 
state of the disease such as cough (could be non-productive at early stages), low-grade fever, 
night sweats, loss of appetite, fatigue and consistent weight loss [1, 5]. Unlike immuno-
compromised individuals, Tb occasionally can be extra-pulmonary affecting other parts of the 
body such as miliary Tb (disseminated disease), Tb meningitis or an oral Tb [1, 6]. Miliary 
Tb is a rare form of the disease that can complicate the primary infection [7]. It produces tiny 
lesions involving vital organs including lungs and can cause pulmonary failure [8-10]. Tb has 
consistently been a public health problem for decades (Figure 1.4), and therefore global Tb 
control strategies have to be thoroughly implemented in order to achieve effective control of 
the disease [11-12]. 
1.2. Causative Agent of Tb  
Mycobacterium tuberculosis (M. tuberculosis or Mtb) is the primary cause of Tb in humans 
and is also termed as tubercle bacilli [13]. It was first discovered by Robert Koch in 1882, 
who was awarded with a Noble prize for his remarkable discovery [14-16]. Cole et al. were 
the first to perform the complete genome sequencing of M. tuberculosis H37Rv in 1998 [17] 
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which was later revised in 2002 [18]. It has a genome size of 4.4 kb (4x10
6
 base pairs) and 
4056 genes with 3995 predicted proteins [18]. M. tuberculosis is an extremely slow-growing 
mycobacterial species, with a generation time of 18-24 hours [19]. Infection caused by M. 
tuberculosis is air-borne and spreads through an aerosol contamination [20-21]. The 
infectious dose (ID) for M. tuberculosis is very low and ID50 has been estimated to be <10 
bacilli in humans [22]. Predominant contagious factors are sneezing, coughing or spitting by 
infected patients, thereby releasing tubercle bacilli into the air. Therefore, healthy people are 
vulnerable to catching Tb infection through air-borne droplets containing viable bacilli [23]. 
Since airborne infection is highly contagious, a high level of supervision and a separate 
facility is required to contain this infectious (BSL3) pathogen within the transition facility 
[24]. Physical containment level three (PC3) is required to work with these pathogenic 
species [25]. Specific HEPA filters (High Efficiency Particulate Air) have to be in place in 
the Biological Safety Cabinets for personnel safety as well as for the safety of the 
environment [26]. 
1.2.1. Comparison of Latent Tb Infection and Active Disease  
Despite the presence of M. tuberculosis in a host, it may not produce disease symptoms due 
to an efficient host immune system [27]. In this case M. tuberculosis becomes non-replicative 
in vivo and the condition is termed as “latent tuberculosis infection” (LTBI) (section 1.6); 
whereas Tb disease refers to a highly contagious situation, in which disease signs and 
symptoms are produced causing damage to lungs (Figure 1.1) [5]. Apart from some clinical 
similarities, there are a number of differences between M. tuberculosis infection and Tb 
disease (Table 1.1). It is important to differentiate between these two conditions for proper 
clinical evaluation and case diagnosis (section 1.8.1).  
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Table 1.1: M. tuberculosis infection and pulmonary Tb disease 
M. tuberculosis Infection                Active Tb Disease 
M. tuberculosis is present         M. tuberculosis is present 
Clinical symptoms are not present        
1
Sign and symptoms are present for Tb
 
Not contagious          Highly contagious  
Tuberculin skin test is positive
     
           
2
Tuberculin skin test is positive 
Sputum smear negative for Zn stain        Sputum smear positive for Zn stain 
Sputum culture is negative for Mtb growth       Sputum culture is positive for Mtb growth 
Chest X-ray appears normal         
3
Chest X-ray shows lesions and lung damage 
9-month isoniazid monotherapy [28]        
4
Chemotherapy for drug-susceptible Tb 
1
Section 1.1, p2. 2Section 1.8.1, p19. 3Figure 1.1, p4. 4Table 7.1, p252 
 
 
Figure 1.1: Chest X-ray of a patient with pulmonary Tb (A) Normal chest X-ray revealing healthy lungs 
from an adult male (B) Chest X-ray showing lung damage due to an active Tb disease. Figures were adapted 
from Science Photo Library [29] and Carolyn et al. [30], respectively. 
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1.3.  Mycobacterium tuberculosis Complex  
There are various closely related mycobacterial species which are part of the M. tuberculosis 
complex (MTBC). Main species of MTBC are M. tuberculosis, Mycobacterium bovis (M. 
bovis) and Mycobacterium africanum (M. africanum). While they present some differences in 
their host range, morphology and virulence, they share a high genetic similarity with each 
other [31]. 
 
1.3.1. Mycobacterium tuberculosis 
M. tuberculosis (Mtb) is a member of the MTBC and is known to be a primary cause of 
human disease. A thick cell wall is one of the main features of M. tuberculosis that 
differentiates it from other bacterial species. It contains some unique glycolipids that may 
provide virulence and resistance to antibiotics [32]. It is an extremely slow-growing 
mycobacterial species compared to all other bacterial groups. M. tuberculosis survives and 
replicates within host macrophage cells. Despite extensive Tb research, little is known about 
M. tuberculosis pathogenicity as well as its intra-macrophage replication. M. tuberculosis 
grown in vitro differs from Mtb isolated from animal models (in vivo) in a number of ways 
[33]. The pathogenicity of M. tuberculosis affects the intensity of M. tuberculosis infection 
and its possible transmission. In order to transmit infection and to establish their 
pathogenicity, microbial species must leave their respective hosts. Likewise, an exit strategy 
of M. tuberculosis from the macrophage cells demonstrates one of its virulence factors [34]. 
M. tuberculosis has evolved ways to evade the host immune system, allowing it to survive 
within macrophages. It resists the action of reactive oxidative radicals within the these cells, 
thus demonstrating its pathogenicity and survival tactics within the host [35]. M. tuberculosis 
is known to cause apoptosis of infected human macrophages before the establishment of 
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extracellular persistence and dissemination and uses unique (M. tuberculosis-specific) signals 
for protein transportation within the host [36]. It is therefore extremely important to know the 
mechanisms involved in M. tuberculosis persistence and survival within macrophages and 
how it extends infections to other hosts [37]. Figure 1.2 shows several outcomes after initial 
mycobacterial infection in the host. 
 
 
Figure 1.2: Stages of M. tuberculosis infection. (1) Inhalation of M. tuberculosis cells establishes infection in 
the host. (2) Depending on the number of cells inhaled and competency of the host immune system (section 1.2), 
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active state infection cannot occur for several years (3) Or it can be developed into an active Tb disease (4) 
Chemotherapy is available for drug-sensitive Tb and is curable (5) At any stage in life, up to 10% of infections 
can be reverted and cause disease (6) Due to lack of proper treatment, drug-resistant Tb may develop (7) M. 
tuberculosis does not respond to available chemotherapy in a multiple drug resistant case, which may lead to 
death. 
 
1.3.1.1. Morphology and Staining Properties of Mycobacterium tuberculosis 
M. tuberculosis is an aerobic, non-spore forming and 1-5 µm long slightly-curved rod [22]. 
The bacilli are non-motile and are gram positive acid fast [38]. Ziehl-Neelsen (Zn) stain, a 
distinguished staining procedure for mycobacteria that has been considered sensitive for 
detecting acid-fast bacilli or AFBs [39]. M. tuberculosis cells stain red by taking up the 
colour of carbol fuchsin and holding it throughout acid decolourization (with acid alcohol), 
leaving a pink stain (Figure 1.3). Zn staining method was originally developed by Ehrlich in 
1882, who described the acid fast properties in mycobacteria [40] and the staining procedure 
was later modified in 1883 by Ziehl and Neelsen [41-42]. This acid-fastness is due to the 
amount of mycolic acid present in mycobacterial cell wall along with long-chain fatty acids 
(Figure 7.3-I) [43].  
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Figure 1.3: Ziehl-Neelsen staining of mycobacteria. M. tuberculosis H37Ra (pink) stained by the modified 
Ziehl Neelsen staining method. 
1.3.1.2. Cell Wall of M. tuberculosis 
M. tuberculosis possesses a unique cell wall structure (Figure 7.11) that makes it different 
from other bacteria in terms of surviving in a range of environmental stress conditions. 
Unlike other bacterial species, the amount of mycolic acid lipid content is higher in M. 
tuberculosis cell wall [44], and is relatively resistant to some chemical disinfectants [45-47]. 
However, satisfactory bactericidal efficiency can be achieved by using a 2% aqueous 
glutaraldehyde solution at room temperature for 20 minutes [48]. A highly impermeable and 
thick waxy coat of M. tuberculosis has been considered as one of the key factors associated 
with its pathogenicity [49]. It possesses some unique lipids such as lipoarabinomannan 
(LAM), phthiocerol dimycocerate and trehalose dimycolate, which are attached to the cell 
membrane and are thought to be associated with its virulence as well as persistence [50-51]. 
LAM is linked with M. tuberculosis pathogenicity in many ways. For example, in M. 
tuberculosis virulent strains like H37Rv and Erdman strain, LAM serves as a ligand to bind 
mannose receptors used for virulence-associated intracelluar trafficking [52]. LAM is also 
Chapter One – General Introduction 
 
9 
 
responsible for inducing tumour necrosis factor (TNF) release from resident macrophages 
[53].  
1.3.1.3. Phylogeography of M. tuberculosis 
There are six lineages of M. tuberculosis that are prevalent worldwide. Gagneux et al. have 
identified the main lineages and the global distribution of M. tuberculosis. Since the host 
immune response is strain-specific, different strains pose different risks with respect to their 
virulence that influences the host immunity [54-55].  
1.3.2. Mycobacterium bovis 
M. bovis is a member of the MTBC and is closely related to M. tuberculosis [56]. It is 
responsible for causing bovine Tb and can affect a range of cattle species and other mammals 
[57]. M. bovis usually does not cause disease in humans; however, occasionally humans can 
be affected either by consumption of infected milk or by close contact with an infected 
animal [58-59]. Moreover, evidence of a zoonotic infection of M. bovis in humans has also 
been documented in the UK [60]. 
1.3.2.1. Mycobacterium bovis BCG 
Mycobacterium bovis Bacillus Calmette-Guérin (M. bovis BCG) is a Tb vaccine strain used 
in a live-attenuated form to provide immunity from Tb infection. It was originally derived 
from M. bovis in the 19
th
 century. Two French scientists, Calmette and Guérin prepared this 
vaccine after 230 passages of M. bovis strain in vitro [61]. On continuous passaging, M. bovis 
lost its virulence and later research confirmed genome differences between avirulent M. bovis 
BCG and virulent M. bovis with three large genomic deletions (RD1-RD3) that are 
responsible for the loss of virulence in BCG [62]. These specific regulatory mutations were 
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found to be consistent in various avirulent BCG strains. Reinserting (RD1) gene into BCG 
induces significant growth and morphological changes making BCG virulent [63] (section 
4.3.1.1). M. bovis BCG has been used as a vaccine for Tb since 1921 in the public health 
system but controversy remains with respect to its use as an effective and complete Tb 
vaccine and the differential immune response it generates in different hosts [64-67]. It has 
also been used for protection against leprosy infections [68-69]. 
1.3.2.1.1. Tuberculosis Vaccine  
Cellular immunity is important to protect people against Tb. BCG is the only available 
vaccine whose efficiency is variable and provides up to 50% protection for an adult 
pulmonary disease and about 70-80% for more severe form of the disease [70-71]. While it 
has high efficacy against extra pulmonary disease in children [72], it is of no use to adult 
patients who already have Tb [73]. Moreover, protection from BCG vaccine is a concern in 
HIV-infected children who are immuno-compromised [74]. A study by Van der Wel et al 
shows that M. tuberculosis translocates from phagolysosomes to cytosol for replication, in 
contrast to the M. bovis BCG strain which does not [75]. This could be due to lack of 
activation of CD8+ cells and might be one reason why BCG is not effective in adults and 
immuno-compromised patients with an active disease.  
Apart from BCG booster vaccine [76-78], various Tb vaccines are in the clinical trial phase to 
replace the currently used BCG vaccine for improved efficacy. For instance, a more effective 
attenuated whole cell mycobacterial vaccine, M. tuberculosis vaccae was tested in HIV-
infected individuals, and yielded good outcomes for patients who had prior BCG 
immunisation [79]. Currently, it is in phase III for clinical evaluation as it seems more 
promising for developing a cellular-based immunity against Tb.  
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1.3.3. Mycobacterium africanum 
M. africanum is one of the group members of the MTBC and shares a high genetic homology 
to M. tuberculosis [80-81]. It causes human pulmonary Tb but occasionally can also affect 
other parts of the body i.e. skin and mucosa [82-83]. Castets et al. first identified M. 
africanum among West-African strains in 1968. It can be further sub-divided on the basis of 
phenotypic variations into M. africanum subtype I (West-African) and subtype II (East-
African) [84-85]. 
1.3.4. Mycobacterium leprae 
Mycobacterium leprae (M. leprae) is closely related to M. tuberculosis [86]. It causes leprosy 
and has a prolonged history of afflicting humans [87]. Leprosy primarily affects skin and 
peripheral nerves [88]. M. leprae infection is mainly transmitted through nasal droplets and 
its DNA can also be found in healthy individuals [89-90]. M. leprae is resistant to a range of 
environmental stresses outside the host [91], a complete understanding of M. leprae infection, 
transmission and distribution is important for enhanced vigilance of infection control and 
disease eradication [92].  
1.4. History of Tb   
Tb has a prolonged history of afflicting human populations, dating back to thousands of years. 
The earliest evidence of prehistoric Tb was found in skeletons dated back to 9000 years from 
a Neolithic Settlement in the Eastern Mediterranean [93]. The disease has been known by 
several different names in the past. For example, phthisis was known for pulmonary Tb 
during the Greek era and was later called as scrofula (Tb of the lymph nodes), a unique form 
of Tb which affects younger people and children [94]. The term white plague was coined 
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around 17
th
 century to describe worldwide adverse effects of pulmonary Tb [95]. Furthermore, 
evidence of Tb was found in the ancient Egyptian mummies responsible for the spinal 
deformities and bone infections known as pott’s disease [96]. Previous evidences do confirm 
the presence of Tb and its contagiousness since the era of antiquity [97-98].  
1.5. The Global Burden of Tb 
Tb is a medieval disease that has afflicted mankind for centuries [93], claiming millions of 
lives [99]. The WHO has estimated about 8.8 million incident Tb cases in 2010 and over a 
million deaths associated with Tb worldwide [100]. According to the WHO report 2011, the 
major contribution to the total number of Tb cases was from the developing world, especially 
Asia (59%) and Africa (26%) [100]. Nearly one third of the world‟s population is infected 
with M. tuberculosis [101-102], of which, 5-10% of latent infections can develop into an 
active disease at some stage [103]. At least twenty-two high burden Tb countries have been 
reported, which account for more than 80% of new Tb cases [104]. However, global Tb 
control efforts aim to not only reduce the mortality rate but also the annual Tb incidence rate 
[105]. Despite extensive control efforts, the overall Tb burden in some countries is not 
reducing at a constant rate [106].The „Stop Tb Partnership‟ by the WHO and the United 
Nations (UN), Millennium Development Goals (MDGs) have set their mutual targets for the 
complete implementation of Directly Observed Therapy Short-Course (section 1.8.2.2.1) for 
Tb. This is to ensure treatment success, especially in the resource-poor countries and to 
reduce the overall Tb burden by 50% by 2015 as compared to what it was in 1990 [107]. 
Figure 1.4 depicts the number of new Tb cases reported over the last decade. 
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Figure 1.4: Number of Tb cases reported annually. Increase in trend for the annual number of new Tb cases 
is obvious over the last decade. While recent reports show that number of new Tb cases have slightly decreased 
in some countries, drug resistance and Tb/HIV co-infection still pose threats to control efforts. Therefore, more 
potent drugs are required to make the current Tb treatment regimen more effective and to cope with the global 
disease burden and drug resistance problem [108].  
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A. Estimated Tb incidence rates, by country, 2010 
 
B. Estimated HIV prevalence in new Tb cases, 2010 
 
Figure 1.5: Global burden of Tb (A) Global incidence of Tb in countries with highest impact in Africa, India 
and China. (B) Impact of HIV in new Tb cases around the world (Reproduced with permission from WHO, 
Global Tuberculosis Control, report 2010) [104]. 
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1.6. Latent Tb 
Despite harbouring M. tuberculosis, people do not usually produce disease symptoms during 
latent Tb infections. However, infection can develop into an active Tb disease at some stage 
depending on the host immune system [109-110]. One third of the world population is 
latently infected with M. tuberculosis [102, 111]. It is a recalcitrant pathogen, which can 
resist host immunity within macrophages, unlike other bacterial species [112-113]. It enters 
into a dormant state against strong natural host defence and proliferates with a significantly 
slow growth rate [114]. During host immuno-compromised state, M. tuberculosis can revert 
from its dormancy into an active disease [115]. The dormant state and slow growth rate of M. 
tuberculosis hinder the process of effective control of the disease [116]. New interventions 
are required to eliminate latent infections as previously described [117].   
1.6.1. M. tuberculosis Dormancy and Persistence 
M. tuberculosis is believed to maintain two distinct growth phases, i.e. active state 
(replicative) and non-replicative state, referred to persistence or non-growth condition for 
longer time period [118]. The term “persisters” was first used for staphylococcus species 
which survived the initial penicillin therapy [119]. These cells are metabolically inactive but 
not dead and may provide drug tolerance [120]. The term persistence was later used for the 
prolonged survival of M. tuberculosis within tubercle lesions despite chemotherapy [121]. 
Various in vitro models have been previously used to study mycobacterial persistence by 
inducing hypoxia under oxygen-depletion conditions [122-126]. Hypoxia is one of the main 
environmental stresses that drives M. tuberculosis population into dormancy [127]. It leads 
the non-replicative M. tuberculosis phenotypes towards drug tolerance, which could be one of 
the factors responsible for prolonging Tb treatment [128]. It is hard to eliminate dormant 
mycobacteria that despite several months of chemotherapy, most drugs cannot easily target 
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non-replicating bacilli. These persister cells can revive later in life and develop into an active 
disease [129]. Therefore, control of M. tuberculosis infections at a global scale is perhaps 
more important than its eradication [130]. Nitroimidazole compounds (PA824) are the first 
class of drugs (currently in clinical trials) that also possess activity against persistent M. 
tuberculosis cells [131]. Figure 1.6 presents pathology of M. tuberculosis infections. 
 
          
Figure 1.6: Pathology of Tb. After inhaling M. tuberculosis-containing tiny droplets from environment, initial 
M. tuberculosis infection is established in primary lesions. (A) Depicts the morphology of the primary lesion 
and (B) Continuous infection spreads through the lung tissues and lymph nodes to cause an active disease by 
involving the apical area of the lungs (see Figure 1.1). M. tuberculosis has also been known to cause 
inflammatory pseudotumors (lesions) in the lungs among immunocompromised patients [132-133], including 
transplant patients and people suffering with HIV/AIDS [134-135]. Figure reproduced with permission from 
Stewart et al. [110]. 
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1.7. Tb in New Zealand 
The New Zealand Ministry of Health reported about 10 new cases of Tb per 100,000, along 
with a higher annual incidence rate among Pacific Islanders [136]. The number of new Tb 
cases was higher compared to cases reported by other industrialised countries like the United 
States and Australia [137]. However, the annual Tb incidence rate has been recently 
decreased to 7 cases per 100,000 in New Zealand [138]. According to the report published by 
the Institute of Environmental Science and Research Limited (ESR), there were a total of 661 
incident Tb cases in 2010 in New Zealand [139]. Generally the annual Tb incidence rates are 
5 times higher in Maori people compared to other New Zealanders [140], and is the rates are 
10 times higher in Pacific people compared to Europeans [138]. New Zealand has been 
included on the WHO list of countries where at least 0-3 cases of multiple drug-resistant Tb 
were reported during the period of 1994-2009 (Figure 1.7). Since, among immigrants, disease 
rates are higher in patients from Asian ethnic background [138], this could be due to a high 
influx of Asian immigrants to New Zealand and lack of proper case diagnosis [141]. 
Furthermore, a consistent increase in drug resistance is a concern for the NZ health industry 
(section 1.8.3.5.1). Apart from a rise in the annual number of MDR cases, Goh et al have 
recently reported the first ever XDR-Tb case in New Zealand history [142].  
Figure 1.7 highlights the distribution of MDR-Tb in new Tb cases from New Zealand and 
other countries worldwide. 
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Figure 1.7: Worldwide distribution of MDR-Tb among new Tb cases. A blue box on top left shows up to 
three MDR-Tb cases reported annually within New Zealand during the period of 1994 to 2010. Figure was 
adapted with permission from Anti-Tb Drug Resistance Surveillance, World Health Organisation, [143]. 
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1.8. Tb Treatment, Therapeutics and Control Measures 
 
1.8.1. Case Diagnosis  
Diagnostic laboratories have a major role in controlling Tb [144-145]. The tuberculin skin 
test is an old, yet currently used method to detect M. tuberculosis infections [28]. A delayed-
type hypersensitive reaction is produced in response to specific M. tuberculosis antigens 
(tuberculin) such as PPD (Purified Protein Derivative). Attenuated PPD is given 
intradermally to check the host immune response against M. tuberculosis-specific antigen 
after 48-72 hours and is highly sensitive for LTBI detection [146]. An induration of ≥5 mm 
(for people who have had a close contact with Tb patients) or ≥15 mm (for low-risk Tb 
patients) indicates a positive tuberculin reaction [28]. While previous BCG vaccination does 
not have any effect over tuberculin reaction [147], in some cases, the sensitivity and 
reliability of tuberculin test is low [148]. Highly Tb specific antigens ESAT-6 (Early-
Secreted Antigenic Target) and CFP-10 (Culture Filtrate Protein) are recommended for the 
detection of M. tuberculosis infection among BCG vaccinated individuals [149].  
Nucleic acid amplification has long been considered as effective diagnostic tool for the 
detection of mycobacterial infections [150-154], particularly real-time PCR (Polymerase 
chain reaction) [155]. Recent advances in the field of molecular biology have provided highly 
sensitive and efficient testing e.g. T-spot Tb test and interferon-gamma-release assays (more 
specific than conventional tests), performed on blood to detect latent infections more 
accurately [156-157], and these could be the methods of choice to diagnose Tb infections in 
the future [158]. For active Tb cases, smear testing has been considered as rapid, convenient 
and cost-effective tool to detect AFBs (Figure 1.3) in sputum samples [159-160]. Sensitivity 
of acid-fast smears can be improved by increasing volume of sputum samples [161]. A chest 
radiograph revealing lesions further helps to identify the active state of the disease (Figure 
1.1).  
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1.8.2. Tb Treatment   
WHO has put intensive efforts by implementing a stringent DOTS strategy (Directly 
Observed Therapy Short-course) to control the growing burden of Tb after it was declared a 
health emergency in 1993 [162]. For drug-sensitive Tb, a range of synergistic antibiotics are 
prescribed (Table 1.2) for an optimal therapy to clear the infection and to avoid relapses [163]. 
Both active disease and LTBI are treatable; however, patient‟s adherence to prescribed 
medicines is necessary in order to achieve complete cure. Treating LTBI can significantly 
reduce the subsequent disease burden [164]. First and second line anti-tubercular drugs, with 
different efficacies, are used to treat M. tuberculosis infections. Bacterial culture and 
susceptibility testing are usually required before and during the treatment to detect the 
sensitivity pattern of M. tuberculosis in order to appropriately alter the course and dose of 
antibiotics [165]. Standard frontline and reserve anti-Tb drugs are given in appropriate 
combinations depending on type and stage of infection (section 1.8.2.2.1). 
1.8.2.1. Standard Tb Drugs 
Current Tb treatment regimen is comprised of rifampicin (RIF), isoniazid (INH), ethambutol 
(ETH), streptomycin (STP) and pyrazinamide (PYZ) [166]. Most of first line anti-Tb drugs 
(Table 1.2, Figure 1.8) possess bactericidal activity and are highly active against M. 
tuberculosis. Second line drugs are not the preferred choice due to low safety but are in use in 
combination with first line drugs, particularly for the treatment of drug resistant Tb [167]. 
Reserve groups of these drugs derive from various antibiotic classes e.g. fluoroquinolones, 
aminoglycosides, cycloserine, thioamides, p-amino salicylic acid and polypeptides. For 
chemical structures of first and second line drugs, see figures 1.8 and 7.10, respectively. 
Specific mode of action of these drugs is presented in table 1.3.  
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Table 1.2: Standard anti-Tb drugs and year of discovery 
Drugs   Discovery year             Target      Activity 
First-line available drugs 
Rifampicin   1963    RNA polymerase  Bactericidal     
Isoniazid   1952         Cell wall     Bactericidal 
Pyrazinamide   1952         Ribosome      Bactericidal  
Ethambutol   1962         Cell wall     Bacteriostatic 
Second-line available drugs 
Streptomycin   1944        Ribosome   Bactericidal 
Ciprofloxacin   1987      DNA gyrase  Bactericidal  
Capreomycin   1960        Ribosome   Bacteriostatic 
Ethionamide   1956        Cell wall   Bacteriostatic 
Aminosalicylic acid  1949       thyA gene   Bacteriostatic 
Amikacin   1970          rRNA    Bactericidal 
 D–Cycloserine   1955        Cell wall   Bacteriostatic 
Reviewed in Ying Zhang 2005 [168] 
 
 
Figure 1.8: Current panel of Tb drugs comprising front-line defence (A) Pyrazinamide, MF C5H5N3O and 
MW 123.11 g/mol (B) Ethambutol, MF C10H24N2O2 and MW 204.30 g/mol (C) Isoniazid, MF C6H7N3O and 
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MW 137.13 g/mol and (D) Rifampicin, MF C43H58N4O12 and MW 822.94 g/mol (chemical structures of drugs 
were retrieved from the PubChem database). See figure 7.10 for chemical structure of second-line drugs and 
table 1.3 for their mode of action. MF, molecular formula. MW, molecular weight.   
 
Table 1.3: Standard anti-Tb drugs and mechanisms of action 
Drugs   Mode of Action      Reference 
Rifampicin (RIF) RIF blocks transcription by binding with the β-subunit of DNA- 
   dependant RNA polymerase               [169] 
Isoniazid (INH) INH is a pro-drug which gets activated by the katG gene product and 
   inhibits mycolic acid synthesis         [170] 
Pyrazinamide (PYZ) PYZ inhibits trans-translation          [171] 
Ethambutol (ETH) ETH inhibits the enzyme, arabinosyl transferases, involved in cell wall 
   biosynthesis            [172] 
Streptomycin (STP) STP inhibits protein synthesis by binding with the 30S ribosomal  
   subunit            [173] 
Ciprofloxacin (CIP) Halts DNA replication by inhibiting the DNA gyrase enzyme  
Capreomycin (CAP) Inhibits protein synthesis by interfering with ribosomal assembly [174]  
Ethionamide (ETM) Inhibits enoyl-ACP reductase coded for by the inhA gene involved in 
   mycolic acid synthesis for cell wall construction     [175-177] 
D–Cycloserine (CYS) Inhibits alanine racemase and blocks the synthesis of peptidoglycan 
Reviewed in the Handbook of Tuberculosis Drugs 2008 [178] and Gillespie. SH 2002 [179]  
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1.8.2.2. Tb Control Measures  
BCG is the only vaccine (section 1.3.2.1) available to protect children from M. tuberculosis 
infection with nearly no efficacy in patients who already have Tb. Therefore, new and 
improved vaccines are required to tackle the resurgence Tb [180].  
1.8.2.2.1. DOTS Therapy  
After the WHO had launched DOTS program in 1994 for more integrated infection control, 
drug-susceptible Tb is treated as per standard recommendations to ensure patients adherence 
and treatment success [166]. DOTS proved to be effective for disease control and has been 
successful in all countries and territories with a significant impact on reducing the Tb 
incidence [181]. For latent infections, a nine-month isoniazid monotherapy followed by 
rifampicin and pyrazinamide (daily for two months), is recommended with DOTS [28, 166, 
182-183]. However, regimen may be variable in medication doses, toxicities and monitoring 
requirements depending on individual patient‟s situation [28]. While nine-month isoniazid 
therapy is preferred, six-month isoniazid regimen may provide an equal protection in both 
non-HIV infected and HIV-infected patients [184-185]. For active Tb, treatment is given in 
two phases; initial phase and eradication phase, with a combination of first and second-line 
drugs. Initial intensive phase includes chemotherapy with rifampicin and isoniazid along with 
pyrazinamide and ethambutol for the first two months, followed by rifampicin and isoniazid 
for at least next four months in the continuation phase to complete the treatment course 
(Table 7.1).  
Anti-tubercular therapy associated toxicity such as skin rash, fever, peripheral neuropathy 
and liver toxicity, has been reported previously and may require discontinuation of the 
treatment [186-188]. Adverse effects generally appear in the early stages of the treatment 
therefore, evaluation of patient‟s tolerance towards anti-Tb drugs is important for the 
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successful treatment outcomes. Several risk factors for isoniazid-associated hepatotoxicity 
such as age (over 35 years), female gender and increase use of alcohol, have been 
documented [189-192]. Specific guideline for use of isoniazid in the treatment of LTBI are 
available including assessment of risk factors and clinical monitoring of hepatotoxicity [193].  
1.8.3. Drug Resistance 
Despite long and exhaustible Tb treatment, failure of DOTS strategy is not the only reason 
for the development of resistance to available drugs. An additional factor is lack of 
monitoring current drug resistance levels in communities with a high HIV burden [194]. 
Therefore, fast emerging drug resistant Tb has to be effectively controlled in order to 
successfully implement the mutual TB-HIV control programs [195]. M. tuberculosis has a 
resilient nature as it renders itself resistant towards the available drugs over time (section 
1.8.3.1), and this makes it hard and expensive to treat. Resistance can vary in type depending 
on the strains and severity of the disease e.g. multiple drug resistance (MDR), extensive-drug 
resistance (XDR) and extremely-drug resistant (XXDR) forms of Tb [196]. 
Extremely drug-resistant Tb indicates an endpoint for resistance where M. tuberculosis 
becomes resistant to all first-line and second-line anti-Tb drugs [197]. A number of factors 
are involved in developing drug resistance such as patient‟s non compliance towards 
treatment including self-medication, non standard regimens (lack of proper treatment), 
inadequate drug supply, status of the patient‟s immune system, antibiotic selective pressure 
and any pre-existing resistance present in the infecting strain [198]. While such factors can 
generate multi-drug resistant strains, there is a chance for dissemination of these resistant 
strains in the community. Other contributing factors include lack of awareness, poverty and 
socioeconomic issues. These risk factors need to be observed regularly to evaluate the impact 
of interventions [199]. 
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1.8.3.1. Resistance Due to Genetic Mutations 
While intrinsic resistance in mycobacterial species to some drugs is generally attributed to 
their thick and less permeable cell wall, genetic basis of drug resistance have been identified 
in mycobacteria [200]. Specific mutations in genes could lead to altered drug susceptibility 
patterns [201]. Role of mutations and associated drug resistance in M. tuberculosis has 
previously been demonstrated [116, 202] (section 4.3.1.1). A patient with active Tb could 
possibly be infected with more than one strain at a time, and therefore, genetic mutations 
could hamper successful treatment [203]. Gaining an insight into molecular mechanisms 
underlying drug resistance in M. tuberculosis (with availability of complete genome sequence 
[17]) would be helpful for the development of new anti-Tb drugs.  
 
Table 1.4: Genetic basis of drug resistance in M. tuberculosis 
Anti-Tb Drug Mechanism of action   Genes involved  References 
 
Isoniazid Inhibition of mycolic acid biosynthesis  katG, inhA and ahpC           Vilchèze  et al. 
[170]
              
 
Rifampicin Inhibition of transcription         rpoB                Wehrli et al. 
[204]
 
         (subunit of RNA polymerase) 
 
Streptomycin Inhibition of protein synthesis rpsL (ribosomal protein S12)        Chan et al.
 [173]
 
       rrs (16S rRNA)              Di Perri et al.
 [205]
 
 
Ethambutol Inhibition of arabinogalactan               embA/B                          Ramaswamy et al.
 [206]
 
  & lipoarabinomannan biosynthesis   (arabinosyl transferase)            Belanger et al.
 [207]
 
       embC              Goude et al. 
[208]
 
Pyrazinamide inhibits trans-translation 
[171]
                pncA                           Scorpio et al.
 [209]
  
             (pyrazinamidase-nicotinamidase)      Davies et al.
 [210] 
 
Fluoroquinolones    Inhibition of DNA gyrase    gyrA (DNA gyrase subunit A)    Telenti A. 
[202]
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1.8.3.2. Phenotypic Drug Resistance 
The term „phenotypic drug resistance‟ refers to M. tuberculosis cells that are not 
metabolically active and replicate at an extremely slow growth rate; therefore, these cells 
develop temporary resistance towards drugs. Persister cells have been found to promote drug 
tolerance that leads towards multiple drug resistance to the available chemotherapy [211]. 
1.8.3.3. Multiple Drug Resistant Tb (MDR-Tb) 
Multi-drug resistance (MDR) is defined as a state in which M. tuberculosis is resistant to the 
two major front line anti-Tb drugs, rifampicin and isoniazid [205]. MDR-Tb outbreaks have 
been reported by many countries worldwide [212-214], and it has been considered a serious 
concern for the global Tb drug resistance surveillance programs [215]. The WHO has 
estimated 0.65 million prevalent MDR-Tb cases from the pool of 12 million globally 
prevalent Tb cases in 2010 [100]. According to WHO report 2011, the annual number of 
MDR cases is increasing, with at least 27 high burden MDR-Tb countries reported so far 
[100]. Adequate control of MDR-Tb is required as these growing number of MDR cases is a 
worrying factor [216-217], that demands for the formulation of an effective regimen [218].  
1.8.3.4. Extensively Drug Resistant Tb (XDR-Tb)  
XDR-Tb is a more severe form of MDR-Tb, in which M. tuberculosis is resistant to at least 
two front line anti-Tb drugs, rifampicin and isoniazid along with resistance to 
fluoroquinolone and at least one of the three injectable aminoglycosides. XDR-Tb been 
considered a threat to human health [219], and also for the effectiveness of global Tb control 
programs [220]. It is virtually impossible to exterminate XDR-Tb along with complications 
such as age factor, treatment failure and death [221]. The possibility of re-infection with a 
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drug-resistant strain is not common during chemotherapy; hence, it is not usually the cause of 
treatment failure, indicating that the potential problem of drug resistance is a more serious 
concern [222]. 
1.8.3.5. XDR-Tb at the Global Level 
To date 58 countries have been reported by the WHO to have extensively drug resistant 
strains of M. tuberculosis [223], with Asia and Africa being the major contributors [224-225]. 
Growing numbers of XDR-Tb cases is a worrying factor and concern for meeting the target 
of reversing the incidence of Tb by 2015 compared to 1990 through the Stop Tb Partnership 
and Millennium Development Goals [226].  
1.8.3.5.1. XDR-Tb in New Zealand 
Fortunately, the situation for drug-resistant Tb is not threatening in New Zealand. However, 
New Zealand Institute of Environmental and Scientific Research has calculated the annual 
MDR-Tb incidence to be 0.8% with an XDR-Tb case reported in 2010 [142]. If not 
controlled, XDR-Tb could be a major challenge to disease eradication [227], and may also 
present potential concern for the Australasian health industry [228-229].  
1.8.3.6. Extremely Drug Resistant Tb 
A recently reported new form of Tb defined as super extensively drug-resistant Tb (XXDR-
Tb), exists in which M. tuberculosis does not respond to any anti-Tb drugs and is therefore 
impossible to treat [196], [230]. If the numbers of XXDR-Tb cases keep on rising, it will not 
only jeopardise the Stop-Tb plan worldwide but also will create further complications for 
global Tb control and management agencies.  
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1.8.3.7. Tb and HIV Co-infection  
Human Immunodeficiency Virus (HIV) infection serves as a driving force for the high 
prevalence of Tb, due to host immunodeficiency [231]. Therefore, the HIV pandemic has had 
a huge impact on the global Tb burden (section 5.1.1). Despite the availability of an anti-
infective chemotherapy, such dual infections continue to escalate relentlessly, especially in 
the developing world as the WHO has estimated 2.1 million HIV-associated Tb cases and 
0.35 million deaths in 2010 worldwide [100]. Furthermore, due to the synergistic effect of 
HIV on Tb infection, the prevalence and mortality rates for Tb are increasing. Unfortunately, 
currently available anti-Tb drugs are not compatible with most retroviral drugs used to treat 
HIV infection. Therefore, the situation requires modification to the current regimen by 
introducing new drugs with high compatibility for the treatment of dual infections (Chapter 
5).  
Nosocomial transmission of Tb infection to laboratory staff and official health care workers 
has been previously reported among immuno-compromised people [232]. People with low 
immunity occasionally can catch hospital-acquired infections caused by non-tuberculous 
mycobacteria as well, along with multiple infections as a result of their immune deficiency 
[233]. Moreover, smoking and alcohol have been considered as contributing factors to the 
disease [234-235]. There is an urgent need to produce new and more effective drugs to 
control and cure Tb. Sir John Crofton reviewed some aspects of past Tb research highlighting 
the lack of novel chemotherapies that has forced us to rely on old anti-Tb drugs for decades.  
―It is a sad reflection on society's incompetence that, more than thirty years after the methods 
for cure and prevention were evolved and before the advent of the HIV epidemic, there were 
already more patients with active tuberculosis in the world than there had been in the 1950s‖ 
John Crofton [236] 
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Tb research has undoubtedly made progress in terms of reducing the global Tb burden over 
the last decade [100], yet there are challenges that need to be overcome [237]. The current 
drug regimen is over three decades old and is complemented with a huge daily pill burden, 
requiring 6-12 months (depending on the type of infection) to treat drug-sensitive Tb (Table 
7.1). Novel anti-Tb drugs for use in combination therapy and with different mode of action 
are clearly required that are also synergistically active with anti-retroviral therapy against 
HIV infections. New drugs are also expected to reduce the treatment time and to overcome 
the growing burden of drug-resistant Tb [238]. 
1.8.4. Current Pipeline for New Anti-Tb Drugs 
While many candidates are currently in the clinical pipeline for Tb drug development, no new 
anti-Tb drugs have been marketed for over three decades. Only few of them have reached 
phase three such as moxifloxacin and gatifloxacin (Figure 5.20).  
1.8.5. Research Hypothesis  
Two important hypotheses were to be tested in this study;  
1. M. smegmatis is limited in its ability to detect inhibitors that are active against M. 
tuberculosis.  
2. Mycobacterial inhibitors with new modes of action can be found from non-targeted 
screening of chemical libraries. 
The main objectives of this research are given below (section 1.8.6.1). 
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1.8.5.1. Aims of This Research 
1. To develop a sensitive assay for determining inhibitory activity in the slow-growing 
Tb strains, M. bovis BCG and M. tuberculosis H37Ra. 
2. To compare various in vitro Tb models previously used for anti-Tb drug screening to 
demonstrate their better ability and sensitivity to specifically identify M. tuberculosis 
inhibitors. 
3. To validate newly-identified inhibitors against virulent M. tuberculosis in vitro which 
have the potential to be developed into therapeutic drugs. Also to test these inhibitors 
further with respect to their bactericidal activities against M. tuberculosis and their 
efficacy against other human pathogens. 
4. To test the hypothesis that development of a dual inhibitor of Tb/HIV is possible.  
There are several methods available for screening mycobacterial inhibitors e.g. in vitro 
models, intra-macrophage infection models and various in vivo models [239]. Due to the 
pathogenic nature of M. tuberculosis H37Rv, an avirulent Tb strain, M. bovis BCG, was 
employed as a drug-screening model in this study using a physical containment level 2 
laboratory that was available for high-throughput screens (HTS) at Victoria University of 
Wellington.  
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2.1. Bacterial Strains and Plasmids  
2.1.1. Bacterial Strains 
Various bacterial (and mycobacterial) strains were used in this study and are listed in table 
2.1 along with their types and relevant details. All bacterial strains were made up in 20% final 
concentration of glycerol and were stored at -80 
o
C. 
Table 2.1: Bacterial strains used in this study 
Strain             Type
a
         Virulence          Source or Reference 
E. coli DH5α        Plasmid storage strain  non-pathogenic       Hanahan D 1985 [240] 
E. coli lab strain      ATCC25922  non-pathogenic      ESR Labs
1
  
E. coli lab strain      BL21 (DE3)  non-pathogenic    Novagen 
Staphylococcus aureus  ATCC25923             non-pathogenic  ESR Labs
1
 
Staphylococcus aureus       Newman gfp labelled      non-pathogenic    Earl et al. [241] 
Pseudomonas aeruginosa  ATCC25668              non-pathogenic  ESR Labs
1
 
Mycobacterium smegmatis mc
2
155 ATCC607 avirulent strain    Snapper et al. 1990 [242] 
Mycobacterium bovis BCG Pasteur strain 1173P2   non-pathogenic              MIMR
2
    
M. bovis BCG-GFP  Pasteur strain 1173P2   non-pathogenic       Luo et al. 1996 [243] 
Mycobacterium tuberculosis H37Ra ATCC25177 avirulent strain      Wang et al. 2007 [244] 
Mycobacterium tuberculosis H37Rv ATCC27294    virulent
3
    Steenken et al. 1934 [245] 
a
American Type Culture Collection. 
1
Laboratory strains were imported from New Zealand reference laboratory, 
Institute of Environmental and Scientific Research (ESR), Porirua, Wellington. 
2
Malaghan Institute of Medical 
Research, Wellington, New Zealand. 3PC3 facility was used at Johns Hopkins Centre for Tuberculosis Research, 
USA.  
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2.1.2. Plasmids Used in This Study 
Several types of plasmids were used in this research including new constructs. Two new 
constructs, pET28a+_Rv2228c and pET28a+_Rv2902c were generated in this study and are 
listed in table 2.2. Plasmid speciality, relevant characteristics and their source are given in 
table 2.2 whereas, plasmid maps are presented in the appendix section 7.3 (Miscellaneous 
figures). 
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Table 2.2: Bacterial plasmids used in this study 
Plasmid     Description     Reference 
pHS201         Mycobacterial-E. coli shuttle vector with a high copy number          [246]       
         version of the pAL5000 mycobacterial replicon, BCG hsp60 
         promoter, gfp with a synthetic Shine-Delgarno sequence 
          kan
r
. Size 5.813 kb 
pSHIGH_hsp60     A high copy number E. coli shuttle vector for mycobacteria.             [247]        
         OriM, BCG hsp60 promoter, gfpmut2 and kan
r
. Size 5.6 kb 
pYL_gfp        BCG-E. coli shuttle vector. Two constitutively               [243] 
         expressed BCG promoters hsp60 and hsp70, kan
r
  
pET28a (+)        Protein over-expression vector, pBR322 origin,                Novagen 
         T7 promoter, T7 transcriptional start and terminator, 
         His•Tag
®
, MCS, Kanr – size 5.369 kb 
pCR
® 
2.1       TA cloning vector for direct ligation of PCR products,     Invitrogen  
         pUC origin, T7 promoter/primer site, LacZα fragment,  
         M13F and M13R priming site, Amp
r
, kan
r
. Size 3.9 kb 
pCG79         Mycobacterial-E. coli shuttle vector containing the                   [248] 
         pAL5000 and pUC18 mycobacterial replicons. Also carries 
         Tn611 sequence and cassette for kan
r
 – size 17.9 kb  
pET28a (+) _Rv2228c Derivative of pET28a (+) with a 1.095 kb PCR fragment   This study 
   Rv2228c, encodes RNase HI from M. tuberculosis H37Rv  
   cloned in EcoRI and XhoI, total size of plasmid 6.468 kb   
pET28a (+)_Rv2902c Derivative of pET28a (+) with a 0.795 kb PCR fragment      This study 
   Rv2902c, encodes RNase HII from M. tuberculosis H37Rv  
   cloned in EcoRI and XhoI, total size of plasmid 6.167 kb   
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Table 2.3: Mammalian cell lines used in this study 
Cell line        Description      
HL-60         Non-adherent human promyelocytic leukaemic cell line 
Vero          Non-adherent human cell line  
J774.A1        Adherent murine macrophage cell line 
 
2.2. Growth Media  
2.2.1. Growth Requirements for the Slow-growing Mycobacterial Strains 
All M. tuberculosis and M. bovis BCG cultures were grown at 37 
o
C in Middlebrook 7H9 
(Becton Dickinson Ltd) broth and on Middlebrook 7H10 agar plates for up to two and four 
weeks, respectively. 
2.2.1.1. Media Supplements 
 OADC 
OADC stands for Oleic acid, albumin, dextrose and catalase. It is a special nutrient 
supplement for the cultivation M. tuberculosis complex. Oleic acid provides long-chain 
fatty acids for metabolism, albumin binds any toxins to protect M. tuberculosis, dextrose 
is a energy source in the form of carbon and catalase enzyme catalyzes iron with 
molecular oxygen to stimulate revival of any damaged bacilli. Filter-sterilized OADC 
has to be added into 7H9 broth at about 50-55 
o
C to avoid denaturation of additional 
nutrients and essential proteins. 
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OADC Preparation (for 1L) 
1. Combine 925 mL deionised water and 8.5 grams NaCl in a 2 litre flask. Stir with a 
magnetic stir bar until salt is dissolved. 
2. Add 50 grams bovine serum albumin Fraction V and stir until completely dissolved. 
3. Add 20 grams dextrose and stir until completely dissolved. 
4. Add 50 mL (1%) sodium oleate solution and stir until completely mixed. The pH 
should be around 7.0. 
5. Filter sterilize through 0.22 µm Millipore syringe filter and store at 4 oC. 
 
A- Sodium Oleate Solution 
Sodium oleate is an additive for the OADC supplement for M. tuberculosis growth media.  
 
Ingredients (for 500 mL)  
 12.5 mL 2M NaOH  
 6.0 mL oleic acid (specific gravity for oleic acid, 1 g/1.2 mL)  
 481.5 mL water  
  
B- Protocol 
Combine the above ingredients in a (1 L) flask. Stir with a magnetic stir bar until completely 
dissolved. Filter sterilize through a 0.22 µm millipore filter. Store at room temperature 
wrapped in aluminium foil as oleic acid is light sensitive.  
 
 Tween80 
Tween80 is a detergent that is used as surfactant for mycobacterial cultures. Mycobacteria 
tend to make clumps during in vitro growth. Therefore, apart from mild agitation, Tween80 is 
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used to disrupt the clumps in culture and for smoother mycobacterial growth kinetics [249]. 
Stock solutions, 10% (w/v) were prepared in distilled and deionised water (ddH2O) and 
stored at 4 
o
C. Sterilization was achieved using an autoclave (Siltex 250D Global Science) at 
121 
o
C for 30 minutes. Unless otherwise stated, the final concentration of Tween80 was 0.05% 
(v/v) for all M. bovis BCG and M. tuberculosis cultures. 
 Glycerol 
Glycerol was used as an additional carbon source to yield better M. tuberculosis growth at 
final concentrations of 0.05%. Glycerol stocks of 80%, 50% and 10% were prepared with 
distilled water and stored at 4 
o
C after autoclaving in a standard laboratory autoclave used for 
complete sterilization. 
 
 Antibiotics 
Unless otherwise stated, all antibiotics were purchased from Sigma Aldrich Company and 
were resuspended in DMSO or water depending on their respective solubilities. All drugs and 
inhibitors (freezer stocks and working stocks) were stored at -20 
o
C. 
 
2.2.1.2. Enrichment Media for the Slow Growers 
All M. tuberculosis-specific media were supplemented for further enrichment with:  
 10% OADC (w/v) (Oleic acid, Albumin, Dextrose and Catalase)  
 0.05% Tween80 (v/v) and  
 0.5% Glycerol (v/v) 
Sodium oleate solution is light sensitive and therefore the Schott bottle was wrapped with 
aluminium foil to protect it from light. 
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2.2.1.3. Starvation Media for the Slow Growers 
 In contrast to the enriched culture condition, a starvation recipe (to achieve effective carbon 
starvation) was used to investigate the metabolic activity of the slow growers by formulating 
appropriate starvation conditions for in vitro culture. Objective of this exercise was to 
evaluate the response to various inhibitors of non-growing or extremely slow-growing M. 
tuberculosis cells that are still metabolically active. The aim was to use a medium that 
mimicked the hypoxic conditions of human granulomas. Effective carbon starvation was 
achieved when these medium conditions were used for M. bovis BCG (Figure 7.4, A-D). 
Cells were washed with PBS three times to reduce the nutrient carryover, and the 
mycobacteria were resuspended in sterile PBS before being seeded into assays. 
 7H9 broth 
 2.0% OADC (w/v) (Oleic acid, Albumin, Dextrose and Catalase) 
  0.025% Tween80 (v/v) and  
 0.1%, 0.05% and 0% glycerol (v/v)  
2.2.1.4. Culture Conditions for the Slow Growers 
Standard growth conditions for both M. tuberculosis and M. bovis BCG cultures are as 
follows; 
 Standard growth medium (sterile) 
 Temperature 37 oC 
 Shaking, 200 rpm (Shaking Incubator DK-S1020, Global Science) 
All mycobacterial cultures (solid and liquid) were grown at 37 
o
C. Solid 7H10 plates were put 
in a non-shaking incubator for 3-4 weeks. Figure 7.3-II shows the growth of M. tuberculosis 
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H37Ra on 7H10 plates supplemented with 10% OADC. Liquid cultures either in 50 mL or 15 
mL polypropylene tubes, 250 mL or 500 mL flasks or in 96-well plates (Ray Lab) were 
agitated in a shaking incubator with a shaking speed of 200 rpm. After placement of their lids, 
96-well plates were sealed with a thin cellulose transparent seal (Inter lab) to avoid culture 
evaporation during longer incubations. Assay plates were also wrapped tightly with parafilm 
afterwards and placed in a marked polythene bag prior to incubation. 
2.2.1.5. Freezer Stocks 
For the long-term storage of mycobacterial strains, freezer stocks were prepared in duplicate 
aliquots for storage in a -80 freezer. An aliquot (0.5 mL) of a logarithmically growing culture 
of M. bovis BCG was transferred into 1.8 mL Cryotube
TM
, 0.5 mL 80% glycerol was added 
and the cells were stored at -80 
o
C. Frozen cells were stable for several years.  
2.2.2. Mycobacterium smegmatis mc
2
155 
M. smegmatis was grown in Luria-Bertani broth (LB) as well as in 7H9 broth with and 
without supplements (section 2.2.1.1). M. smegmatis was cultured with 50 µg/mL kanamycin 
(for plasmids pHS201 and pSHIGH_gfp). All M. smegmatis liquid cultures were placed in a 
shaking incubator with a shaking of 200 rpm along with 0.1% (v/v) final concentration of 
Tween80. For solid growth, M. smegmatis cultures were streaked on LB agar plates and were 
incubated in a non-shaking incubator at 37
 o
C for up to 96 hours.  
2.2.3. Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus 
All strains were grown in Luria-Bertani broth (LB broth) along with relevant antibiotics, as 
required in the assay. To achieve solid agar growth, cultures were streaked on LB agar plates 
and incubated in a non-shaking incubator at 37
 o
C overnight (for all cultures). All liquid 
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cultures were grown without adding Tween80 and were incubated at 37 
o
C with (or without) 
shaking. 
2.3. Chemicals and Reagents 
Unless otherwise stated, all chemicals, reagent and drugs required for setting up growth 
inhibition assays were purchased from Sigma Aldrich. DNA markers, DNA loading buffer, 
dNTPs, IPTG, DNA ladder were purchased from Invitrogen, New Zealand. All individual 
novel chemical compounds identified in the screens as positive hits for validation 
experiments were imported from the National Institutes of Health (NIH), United States. 
2.4. Enzymes  
Unless otherwise stated, all restriction enzymes were purchased from New England Bio Labs 
(NEB, Auckland, NZ). RNase HI from E. coli and lysozyme were sourced from Sigma 
Aldrich. T4 DNA ligase and Bio Line‟s DNA Taq polymerase were purchased from 
Invitrogen and Qiagen, respectively.  
2.5. Oligonucleotides  
Oligonucleotide primers for DNA manipulation were designed using Gentle Software 
(version 2.1). The approximate primer length was about 30 bp with an average GC content of 
about 45-55%. Both forward and reverse complementation along with restriction site 
sequences were confirmed and verified before their synthesis by Integrated DNA 
Technologies (Belgium). All primers were resuspended in ddH2O (DNase and RNase free) to 
make 100 µM stocks and 10 µM working stocks were prepared for final use in downstream 
molecular biology applications. Primer sequences along with their respective genes from M. 
tuberculosis H37Rv are given in table 2.4. 
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2.5.1. Primer Sequences for M. tuberculosis Genes Coding RNase HI/II Proteins  
Primers used to amplify and clone RNase HI/II enzymes from M. tuberculosis are depicted in 
table 2.4. 
Table 2.4: Primers used in this work 
Primer Name   Gene  Product Primer Sequence [5’– 3’]  
Rv2228c_F  rnhA RNase HI      5'- CTAG GAATTCGTGAAAGTTGTCATCGAAGC -3' 
Rv2228c_R     –       –            5'-CTAG CTCGAG CTATAGATAGCCTGTCTGATT-3' 
Rv2902c_F  rnhB RNase HII     5'-CTAG GAATTC ATGACCAAGACCTGGCCACCG-3' 
Rv2902c_R     –       –            5'-CTAG CTCGAG CTAAGTGCCCTGAGCGCGACC-3' 
Sequencing Primer 
T7_F   – –  5'-CCCAGTCACGACGTTGTAAAACG-3' 
T7_R   – –  5'-AGCGGATAACAATTTCACACAGG-3'  
„F‟ denotes “Forward” and „R‟ denotes “Reverse”. The underlined sequences represent the restriction sites at the 
start of each primer (also see Table 7.8).  
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2.6. Chemical Compound Libraries 
2.6.1. Chemical Libraries 
A number of compound libraries have been used in this study in order to identify potential 
growth inhibitors of the MTBC (section 2.6.2). Five drug libraries were used for the 
identification of mycobacterial growth inhibitors. 
A) LOPAC Library1280 TM  
LOPAC
1280
 stands for Library of Pharmacologically Active Compounds (Figure 2.1). An 
entire collection of LOPAC was purchased from Sigma Aldrich Company and consists of 
1280 distinct compounds, with a wide range of biological targets. As the name of this library 
indicates, compounds in this library are already pharmacologically active; therefore, it was 
expected to yield compounds that were able to inhibit mycobacterial growth to optimise the 
screening procedure.  
B) Spectrum Collection 
The Spectrum Collection was purchased and imported from MicroSource Discovery System, 
Inc (U.S.A). This library had a range of active compounds, and the library consisted of 2,000 
compounds in total. There was an overlap of a few compounds in Spectrum library from 
LOPAC, which therefore, served as embedded controls during the high through screening 
(HTS). The Spectrum Collection has a wide range of compounds and natural products with 
biological activities. Potential hits identified from the HTS using the Spectrum library are 
discussed in Chapter 3. 
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C) NIH Diversity Set 
The NIH Diversity Set was imported from the National Institutes of Health (NIH). It 
contained 1990 compounds in total, to which, a set of natural products was also included 
(refer below). 
D) NIH Natural Product Set 
The NIH Natural Product Set contained about 240 compounds from natural sources. These 
compounds were screened against M. bovis BCG and M. tuberculosis H37Ra to identify 
novel growth inhibitors. Individual compounds that proved active in the HTS (and that were 
permitted to be imported into New Zealand by MAF, Biosecurity Department) were then 
obtained from overseas, by completing an NIH request form (available at 
http://dtp.cancer.gov/RequestCompounds/index.jsp) through their official website of the NIH, 
Developmental Therapeutics Program (NIH-DTP).  
E) Library of Plant Extracts from NZ Native Plants 
A library of New Zealand native plant extracts was collected and prepared to identify 
potential anti-mycobacterial activity they might have. Plant samples were collected across the 
country mainly from Karori Wild-life Sanctuary (Zealandia), Otari-wilton Bush and other 
suburbs including South Island by [250]. After sample collection, a mini plant extract library 
was prepared by dissolving extracts in various solvents i.e. methanol, ethanol and aqueous 
extracts (depending on their solubility) before they were tested for their medicinal activity 
(section 3.3.1.4). Figure 2.1 shows the number of libraries and compounds used to screen in 
high-throughput.   
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Figure 2.1: Chemical libraries used for high-throughput screening. (A) LOPAC (n=1280) (B) The Spectrum 
Collection (n=2000) (C) The NIH Diversity set (n=1990) (D) Natural Product set (n=240) and (E) New Zealand 
plant extracts (n=50). 
2.6.2. Plate Map for High Throughput Screening 
The first column of the standard 96-well plate was filled with 150 µL of sterile water in order 
to reduce evaporation of cultures from the plate during long incubation periods. The last 
column had a range of controls in duplicate (section 3.1.3.2), which were included in each 
plate used for HTS. The top two wells at position A12 and B12 had media controls (negative 
control), position C12 and D12 had the 100% growth controls (cells+media only), position 
E12 and F12 had 2% DMSO controls and the last two wells at position G12 and H12 had the 
antibiotic controls (positive controls), including rifampicin (RIF) and isoniazid (INH), 
respectively (Figure 2.2). 
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Figure 2.2: Plate map used for high-throughput screening. Column 12 shows the arrangement of controls 
used. A total of 80 compounds (represented as pink circles) were screened per plate and all screens were 
performed in triplicate. Each compound was dispensed at 20 µM final test concentration along with positive 
controls, rifampicin and isoniazid. 
2.6.3. Individual Compounds for Validation Experiments 
Potential growth inhibitors of M. tuberculosis identified from HTS were imported from the 
NIH (U.S.A) as well from Sigma Aldrich (New Zealand) in order to confirm their anti-
mycobacterial activity in dose-response assays. 
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2.6.3.1. NIH Chemical Compound Repository 
Unless otherwise stated, all individual chemical compounds obtained for validation 
experiments were suspended in DMSO. All compounds from the NIH library had a unique 
“NSC‟ ID number. 
2.6.3.2. 96-well Plates for Assay 
For all growth inhibition assays (section 2.7.2.1), dormicidal assays (section 2.7.3), resazurin 
reduction assays (section 2.7.4), and cytotoxicity assays (section 2.7.5), standard round-
bottom 96-well plates were used (BD Falcon
TM
). 
2.6.4. Sigma Plot for Data Analysis 
Unless otherwise stated, all data produced from growth inhibition assays, dormicidal and 
cytotoxicity assays were analysed with Sigma Plot Software (SYSTAT) version 11.0 to 
generate four-parameter logistic standard curves. 50% inhibitory and minimum inhibitory 
concentrations were determined using standard curves.   
2.6.5. Dose-Response Assays 
The plate map for dose response assays was the same as the map presented for HTS (Figure 
2.2) except for the arrangement of controls (Figure 7.12). 
2.6.5.1. Plate Map for Dose-Response Assays  
The set up for various dose-response and bacteriostatic assays was slightly different from the 
HTS format in terms of the arrangement of controls (Chapter 3). For all assays other than 
HTS, in the first row and 8
th
 row from wells A1-A12 and H1-H12, respectively, 150 µL of 
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sterile water was added to reduce evaporation of the medium. In the first column (A1-H1), 
sterile 7H9 medium (without antibiotics and cells) was added as negative controls for 
bacterial growth. The last column (right-hand side) wells B12 and D12, 100% growth 
(medium + cells) controls were added and a standard first line anti-Tb drug either rifampicin 
or isoniazid was included in triplicate as a positive control for the assay at well position 
numbers E12 to G12 (Figure 7.12). 
2.6.6. Novelty of Inhibitors 
For novel inhibitors identified from the HTS part of this study (Chapter 3), pre-set criteria 
were followed for selecting compounds for further characterization and data analysis. These 
selection criteria were based on two approaches, experimental approach and a literature-based 
approach (section 3.3.1.1.4).  
2.6.7. Import of Anti-HIV RNase H Compounds  
More than 50 HIV RNase H inhibitors were selected from the PubChem database and a list 
was prepared after prioritising all compounds on the basis of their specific activity (i.e. active 
against HIV but no inhibitory activity against human RNase H). All compounds were then 
imported from the NIH (U.S.A). 
2.6.8. Structure-activity Relationships  
A good structural and practical analysis of all compounds selected in an early discovery 
programme can be time and cost efficient. Chemical structures of prioritised compounds both 
in terms of high anti-mycobacterial activity and low cytotoxicity towards human cells were 
compared for structural similarity with currently in-use anti-tubercular drugs. An initial 
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structural comparison was performed to examine if such compounds had different structures 
and were likely to have a novel mechanism of action.  
2.6.8.1. Lipinski’s Rules to Evaluate Drug-like Properties of Lead Compounds 
Christopher Lipinski has described rule-of-5 to evaluate the likelihood of lead compounds to 
be developed into drugs [251]. These rules state that an ideal drug will have a low molecular 
weight (less than 500 Daltons) for better solubility and absorption. Compounds should have 
fewer rings with a smaller number of rotatable bonds. After following our selection criteria 
(section 3.3.1.1.4 and section 5.3.4), Lipinski‟s rule-of-5 was applied on compounds 
identified and selected for validation to confirm if these inhibitors had potential to be 
developed into drugs (section 5.7), as it was deemed appropriate to perform a brief 
comparison of compounds identified in this study with the available anti-tubercular drugs and 
to determine if they violated any of the rules (Chapter 5). Following that, structural analogues 
of active compounds were imported for validation experiments.  
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2.7. Methods 
2.7.1. Tuberculosis Screening Models – M. bovis BCG and M. tuberculosis H37Ra 
A slow-growing member of the MTBC and a Tb vaccine strain, M. bovis BCG (Table 2.1) 
was employed for screening of compound libraries. After preliminary screening assays, 
inhibitors were validated against another surrogate species, M. tuberculosis H37Ra. Both 
strains are slow-growing species and have a doubling time of 18-24 hrs. A fast-growing 
mycobacterial species, M. smegmatis mc
2
155 was also used in this work to compare 
screening data received from various Tb models (Chapter 4). 
2.7.2. Growth Inhibition Assays for Mycobacteria  
Growth Inhibitory Assay 
In a growth inhibitory assay, the percentage inhibition (or alternatively, a measurement of 
cell viability) of bacterial growth is determined for any active extract, inhibitor, chemical 
compound, or drug. The growth inhibition assay is also referred to as a bacteriostatic assay 
(to determine the activity of unknown compounds which are responsible for bacterial growth 
inhibition). Section 2.7.2 details the methodology of the bacteriostatic assays. 
2.7.2.1. Bacteriostatic Assay for M. bovis BCG  
Unless otherwise stated, all M. bovis BCG cultures were grown in 7H9 medium enriched with 
OADC as described (section 2.2.1). After initial culture inoculation, both M. bovis BCG and 
M. tuberculosis attain their log phase growth in about 2-3 days. Both species tend to make 
clumps of colonies during growth, which significantly affects assay readings, especially when 
reading optical density for cultures. Therefore, an OD600 and GFP fluorescence correlation 
were used to analyse the data from inhibitory assays (section 3.2.2). Tween80 was used in all 
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assays as a surfactant to facilitate bacterial growth with concentrations between 0.025-0.05 
percent; it causes emulsification and restricts cells adhesion. Shaking is another way to avoid 
bacterial clumping, which helps keep bacterial colonies a part; therefore, a mild sonication of 
mycobacterial cultures was performed before cells were seeded into an assay. Mid-
logarithmically growing M. bovis BCG and M. tuberculosis H37Ra cultures were used in all 
growth inhibition assays. Cells were used by diluting the culture down to an OD600 of 0.05 
(10 mm path length glass cuvettes).  
A two-fold whole plate dilution series of standard anti-Tb drugs was performed in triplicate. 
Depending on the MICs of the known anti-tubercular drugs published in the Handbook of 
Anti-Tuberculosis Agents [178], different drugs were added at starting concentration of at 
least 3-4 times higher than their MIC values in order to observe complete inhibitory 
concentrations and to determine a range of  inhibitory concentrations for calculating a 
concentration that inhibits growth by 50% (IC50). Fluorescent cultures of M. bovis BCG were 
diluted to an optical density of 0.1 at A600 nm, and 50 µL of a diluted cell culture was added 
to the drug-containing wells. All cultures were seeded at a final OD600 of 0.05. For the 
negative controls, sterile 7H9 medium was added without antibiotics and for positive controls, 
known standard drugs were added at a final concentration of 20 µM along with 50 µL cells 
(with final OD600 of 0.05). Details of the arrangements of controls and the use of test 
compounds are presented in the plate map for dose-response assays in figure 7.12. All assays 
were performed in 96-wells plates, and the final volume for all assays was 100 µL/well. 
Solvent controls (cells and medium only) were also included to compare 100% M. bovis BCG 
growth to drug-treated positive controls. All 96-well plates were covered with lids, sealed 
with a thin-seal cellulose film and wrapped again with parafilm to reduce media evaporation 
over long incubation time periods. A after complete labelling, all plates were placed in 
specific polythene bags and were stacked in a shaking incubator (DK-S1020, Global Science) 
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and incubated at 37 
o
C for 2 weeks with constant shaking of 200 rpm. After an appropriate 
incubation time, all assays were read by 25 point scan (5x5) using a Perkin-Elmer Envision
TM
 
Multi-Label Plate Reader for the measurement of optical density at 600 nm and the GFP 
signal (excitation 490 nm and emission 510 nm). The final results were based on the 
correlation of both OD600 and GFP fluorescence for M. bovis BCG. IC50 values (defined as 
the concentration of drug that inhibits fluorescence of the cultures by 50% compared to the 
no-drug positive controls) of all drugs tested were calculated through SigmaPlot version 11.0. 
2.7.2.1.1. Assay for M. tuberculosis  
All growth conditions and assay time points for M. tuberculosis H37Ra were exactly the 
same as for M. bovis BCG except that BCG harboured a pYL_gfp plasmid (Table 2.2) 
carrying GFP and kanamycin resistance (50 µg/mL) genes. In contrast, M. tuberculosis 
H37Ra did not have a GFP gene and therefore, results for validation of M. tuberculosis 
inhibitors are based on OD600 only. The OD600 values were comparable to GFP values 
obtained from the M. bovis BCG.  Figure 7.12 presents the arrangement of wells for the 
growth inhibition assay in M. tuberculosis H37Ra. Novel anti-Tb compounds detected in the 
present study were also tested against the virulent strain of Tb, M. tuberculosis H37Rv at 
Johns Hopkins University, Baltimore (U.S.A) with similar assay protocol as described 
(section 2.7.2).  
2.7.2.2. Bacteriostatic Assay for Mycobacterium smegmatis mc
2
155 
While M. smegmatis is fast growing mycobacterial species, which divides after every 2-3 
hours, it does not require special growth medium requirements compared to M. bovis BCG or 
M. tuberculosis H37Ra (section 2.2.1). Therefore, LB medium with or without antibiotics 
was used to culture M. smegmatis both on liquid as well as on solid agar plates. However, 
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when comparison of various Tb models was carried out to evaluate the efficacy of each 
model to pick up M. tuberculosis-specific inhibitors (Chapter 4), enriched medium was used, 
the same as used for M. bovis BCG and M. tuberculosis H37Ra (described in section 2.7.2.1) 
to keep the growth conditions identical across all species. M. smegmatis cells were diluted 
down to an OD570 of 0.1, and the final volume was 100 µL per well (as described in section 
2.2.2). Inhibitors were tested for bacteriostatic activity using M. smegmatis as previously 
described [252].  
2.7.2.3. Bacteriostatic Assay for Non-mycobacterial Clinical Strains 
Various non-mycobacterial clinical strains were used in this study (Table 2.1) to test the 
spectrum of mycobacterial inhibitors across a range of other clinically important bacterial 
species. Assay set-up for these strains was not different from M. smegmatis (section 2.7.2.2). 
However, media conditions (section 2.2.3) and time points were different. After challenging 
with drugs/compounds, all plates were left in the incubator at 37 
o
C for overnight incubation. 
Appropriate controls were included in each plate. Assays were read at 570 nm wavelength for 
their optical density and for resazurin readings as discussed in section 2.7.5 using the Perkin 
Elmer
TM
 Multi-label plate reader.   
2.7.2.4. Colony Forming Units for Mycobacteria 
2.7.2.4.1. CFU’s for M. tuberculosis 
The optical density of pure M. tuberculosis cultures was checked at OD600 in 1 mL (section 
7.2.1), and then culture was serially diluted in PBS (10-fold for 7 times) before plating them 
out in order to calculate the viable number of cells in each millilitre of M. tuberculosis culture 
(CFU‟s/mL). An aliquot of each dilution (100 µL) was plated at least in duplicate on 7H10 
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agar plates supplemented with 10% filter sterilized OADC (section 2.2.1.1) and 0.5% 
glycerol (with or without 0.1% Tween80) in a sterile environment. All plates for M. 
tuberculosis CFUs were wrapped tightly in parafilm and then with aluminium foil, and then 
the plates were incubated for 3-4 weeks at 37 
o
C before individual colonies were counted, 
each colony representing viable M. tuberculosis cell. The counted CFUs were also used to 
estimate the number of viable cells present in 1 mL of original M. tuberculosis culture. 
  CFUs/mL =   N
o
 of individual colonies x dilution factor (10
n
) 
     0.1 mL (volume plated) 
2.7.2.4.2. CFU’s for M. smegmatis  
The technique of counting CFUs for M. smegmatis was the same as for M. tuberculosis 
except for the medium and reading time points. After having serially diluted original culture, 
0.1 mL aliquot of the dilutions were aseptically plated on LB agar, and after carefully 
wrapping, the plates were incubated at 37 
o
C in a non-shaking incubator for 96 hours before 
counting the CFUs. 
2.7.3. Dormicidal Assay Used for Mycobacteria 
A dormicidal assay assesses the death of dormant mycobacterial cells caused by a compound. 
Novel inhibitors identified in this study were further tested to confirm the type of activity 
they had. The dormicidal assay confirmed whether anti-mycobacterial compounds identified 
under nutrient-rich conditions were also active against non-replicating and low metabolically 
active mycobacteria. M. smegmatis_pSHIGH_hsp60 was used in these assays. All cultures 
were grown for at least 10 days to ensure that cells had reached their stationary phase. Cells 
were tested for their optical density by centrifuging (CR3i Multifunction Centrifuge, Thermo 
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Scientific) and resuspending the pellet to an OD600 of 0.5 in PBS. Cells were washed (three 
times with PBS) to avoid any medium and nutrient carryovers and resuspended in sterile PBS 
before they were used in the dormicidal assay. The arrangement of test compounds, media 
and controls in 96-well plates was same as shown in figure 7.12 except that cells were 
suspended in PBS instead of 7H9 medium. Carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP) was used as a positive control to kill all growing and metabolically inactive cells. 
After 4 days of incubation at 37 
o
C, 30 µL of 0.02% (v/v) final concentration of resazurin was 
added to all wells and the plates were re-sealed and further incubated at 37 
o
C overnight (Ian 
Bassett, unpublished method). The data were analysed as described (section 2.6.4) and 
minimum dormicidal concentration (MDC) and 50% dormicidal concentration (DC50) values 
were calculated for the test compounds.         
 2.7.4. Resazurin Reduction Assay 
Resazurin reduction assay is robust and gives a reliable determination of redox-state of live 
cells and an easy interpretation of results. Resazurin is an oxidation-reduction indicator used 
to detect viability of cells [253], and was used in dormicidal assays instead of GFP 
fluorescence. Resazurin salt is a non- fluorescent to weak fluorescent blue dye which gets 
reduced to a pink fluorescent dye, indicating the viability of cells (Figure 2.3).  
 
Figure 2.3: Biochemical reduction of resazurin sodium salt into resorufin. The activity of cellular 
respiration indicates the viability of cells. Resazurin salt (MW 251.18 g/mol) is reduced by removal of one 
Chapter Two – Materials and Methods 
 
55 
 
oxygen atom (indicated by an arrow), yielding a MW of 235.18 g/mol of the fluorescent compound (pink). 
Chemical structures were retrieved from the PubChem database. MW, molecular weight. 
Unlike M. bovis BCG, M. tuberculosis H37Ra did not have a reporter system to detect cell 
viability; therefore, a resazurin reduction method was used. Similar assay conditions were 
adapted for resazurin assay as previously described [254], with slight modifications. At the 
end of the drug exposure time, 30 µL of 0.02% (w/v) final concentration of resazurin was 
added to all wells, and the plates were incubated without agitation at 37 
o
C overnight for M. 
tuberculosis and for six hours for M. smegmatis. Resazurin gets converted from its blue 
colour into pink, after being reduced by the mitochondrial enzymes of viable cells (Figure 
2.3). Plates were read for fluorescence by excitation and emission at 530 nm and 590 nm, 
respectively, in a Perkin Elmer – EnVisionTM Multi-label plate reader using a fluorescein 
isothiocyanate (FITC) filter.  
2.7.5. Cytotoxicity Assay 
The human leukaemic cancer cell line (HL-60) and the murine macrophage cell line (J774.A1) 
were used in this study to evaluate the level of toxicity of the novel compounds. All 
cytotoxicity assays were performed in 96-well plates (Ray-Lab) using a standard tissue 
culture facility in a sterile environment. The experimental protocol to determine cytotoxicity 
of compounds in the murine macrophage J774.A1 cell line was used as previously described 
[255]. 
2.7.5.1. Murine Macrophage J774.A1 Cell Line 
J774.A1 adherent cells were cultured in 250 mL T-75 flasks (Invitrogen) using the standard 
recommended RPMI-1640 medium supplemented with 10% filter-sterilized Fetal Calf Serum 
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(FCS), 0.25 Units/mL insulin and a combination of antibiotics, 1% penicillin-streptomycin 
(100 Units/mL penicillin and 100 Units/mL streptomycin). Cells were incubated at 37 
o
C in a 
5% CO2 air atmosphere (CO2 Incubator, SANYO) until cells had become 80% confluent.  
2.7.5.1.1. MTT Assay and Data Analysis 
Test compounds were added to 96-well plates (black-walled with flat glass bottom from BD 
Bioscience) and two-fold serial dilution were performed. Cells were then seeded into the 
required wells at a concentration of 1 x 10
5
 (50 µL of 10,000 cells/well), and the plates were 
incubated for 72 hours. No compound/drug was added to the control wells in order to observe 
complete cell growth. MTT (20 µL of 5 mg/mL solution) [3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenoltetrazolium bromide] (Sigma Aldrich), was added to all wells after three days of 
incubation. Plates were wrapped in a Gladwrap and incubated for two hours. A 100 µL of 
solubilizer (10% SDS in 0.01N HCl) was added to each well, and plates were further 
incubated at 37 
o
C overnight and read at 570 nm. All assays were performed in triplicate and 
data were analysed with Sigma Plot Software (version 11.0) using a four-parameter logistic 
standard curve analysis to determine IC50 values. 
2.7.5.1.2. Passaging the J774 Cell Line 
For continuous passaging of cells, 400 µL of trypsin enzyme was added to 80% confluent 
cells. Trypsin incubation at 37 
o
C for 5-10 minutes helps to detach the layer of adherent 
macrophage cells. Cells were spun down in a 15 mL centrifuge tube at 300 g for 5 minutes. 
The supernatant was discarded, and the cells were resuspended in 5 mL of fresh medium. 
Washed cells (100-200 µL) were then added to 10 mL of fresh medium and the passage 
number was recorded. If further passage was not required, cells were frozen at 1 x 10
6
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cells/cryovial in 10% DMSO in a total volume of 1 mL. Initially, cells were frozen in a -80 
freezer overnight then transferred to liquid nitrogen for long-term storage. 
 
Figure 2.4: Plate map for mammalian cell cytotoxicity assays. From column 3-9, two compounds were tested 
per plate in triplicate. Outer wells were left empty.  
2.7.5.2. HL-60 (Human Leukaemic) Cell Line 
Non-adherent human promyelocytic leukaemic cells were grown in 25 cm
2
 T-25 flasks (Ray-
Lab) using standard RPMI-1640 medium. For HL-60 cells, RPMI media was supplemented 
by 10% filter-sterilized FCS along with 1% penicillin-streptomycin (100 Units/mL penicillin 
and 100 Units/mL streptomycin). When the cells were 80% confluent, 50 µL of medium was 
added to each well of a 96-well plate followed by the test-compounds and two-fold serial 
dilutions was performed before 50 µL of 10,000 cells/well were added to the required wells 
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(Figure 2.4). For compounds that were dissolved in DMSO, the highest test concentration for 
such compounds was kept to 100 µM, thereby, not exceeding a 1% final concentration of 
DMSO. DMSO concentrations of >1% inhibit HL-60 cell growth. Plates were incubated at 37 
o
C for 48 hours in a tissue-culture incubator (Heraeus). 
2.7.5.2.1. Cell Count for Seeding  
To count viable cells in an Improved Neubauer Chamber (Haemocytometer), cells were 
stained with trypan blue (Sigma Aldrich). Trypan blue was used to differentiate between live 
and dead cells as it crosses the plasma membrane of dead cells only, leaving the live cells 
unstained due to an impermeable nature of the cell membrane of live cells. Cells (10 µL) 
were mixed with 10 µL of stain (1:1), and then 10 µL of this mixture was loaded onto 
haemocytometer. Cells were counted in the four outer large squares (Figure 2.5). An average 
of the four large squares was taken, and the number of cells was estimated using the formula 
C1V1=C2V2 to calculate the quantity of cells required from the stocks to make up working 
suspension of 4-5 mL of cells (2 x 10
5
 cells/mL).  
A 50 µL of cells was then added to each well except the blank wells where only 100 µL of 
medium was added. All assay plates were then incubated at 37 
o
C without agitation for 48 
hours. MTT solution and the absorbance of wells determined as described above in section 
2.7.5.1.1. All cytotoxicity assays were performed in Biological Safety Cabinet Class II (AES 
Environmental Pvt. Ltd.). 
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Figure 2.5: Improved Neubauer Chamber (Haemocytometer). HL-60 cells were counted in 4 squares, (A, B, 
C and D), (black squares); whereas, macrophage cells were counted in (E) the middle 25 squares (within large 
red square). A total sample volume of 10 µL was loaded onto the chamber for cells counting. 
2.7.5.2.2. Controls for Cytotoxicity Assay 
A known mammalian cell cytotoxic compound, epothilone A (Epo A), (Merck) was used as a 
positive control in the cytotoxicity assays. For observation of normal cell growth, growth 
controls were included without drug(s) (cells and medium, 50 µL each) in each plate. For the 
medium blank, only medium without cells or drug was added. The arrangement of controls 
and test compounds used in cytotoxicity assays are presented in figure 2.4.  
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2.7.6. Cloning of M. tuberculosis Ribonuclease HI/II Proteins  
Transformation of pET28a(+)/pET28a(+)_Rv2228c and Rv2902c into E. coli  Strains 
E. coli strains (DH5α and BL21-DE3) were transformed with various plasmids for the 
cloning procedures. A heat transformation method was used for most of E. coli strains rather 
than electroporation.  
2.7.6.1. Calcium Competent E. coli Cells 
E. coli cultures from -80 
o
C freezer stocks were streaked on agar LB plates and incubated 
overnight at 37 
o
C. Individual colonies were then selected and transferred into 5 mL of LB 
broth and further incubated overnight. This 5 mL of culture was sub-cultured into 50 mL of 
medium (1:10) the following day into a sterile 250 mL flask with a cotton plug on wrapped in 
aluminium foil. The culture flask was placed in a shaking incubator (with set speed of 200 
rpm) at 37 
o
C for a few hours until the optical density of the culture at 590 nm was ~0.5. 
OD590 nm was read in a spectrophotometer (Thermo Scientific). These logarithmically 
growing cells were then transferred into 50 mL polypropylene tube and the tube was placed 
in ice for at least 25 minutes. Cells were harvested by centrifugation at 4000 rpm for 20 
minutes. The supernatant was discarded and a 50 mL of pre-chilled and sterile 0.1 M calcium 
chloride (0.1 M CaCl2) was added to the pellets. Cells were then placed back on ice for the 
next 20 minutes after which they were recovered by centrifugation at 4000 rpm for 10 
minutes. This washing step was repeated twice by reducing the amount of CaCl2 by half (25 
mL) in the second wash. Finally, 2-4 mL of CaCl2 was added along with 14% glycerol. Cells 
were thoroughly mixed and 100 µL aliquots were dispensed and stored in a -80 
o
C freezer for 
later use.    
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2.7.6.2. Heat Shock Transformation 
If not using freshly-prepared cells, calcium competent cells (DH5αe- and BL21e-) were taken 
from -80 
o
C freezer stocks and thawed on ice for 10 minutes. The E. coli bacteria were 
transformed with both pET28a (+) plasmids carrying Rv2228c and Rv2902c sequences along 
with appropriate transformation controls (section 2.7.6.4). The DNA concentration averaged 
about 20-30 ng/mL for each plasmid. Plasmids were taken from -20 
o
C stocks and put on ice 
for about 5 minutes before 2 µL was added to the competent cells and mixed gently and left 
on ice for 10 minutes. The cells plus plasmid were then put on a heat block for heat shock 
transformation with a pre-set temperature of 42 
o
C and left for 90 seconds. After heat shock, 
the tubes were placed back on ice for up to 2 minutes. A 900 µL aliquot of antibiotic-free LB 
medium was added to the transformed cells, and the tubes were placed on a shaker at 200 rpm 
for an hour to allow the cells to recover and to allow the expression of the kanamycin 
resistance gene. After this incubation, cells were harvested by centrifugation at 14,000 rpm 
for 1 minute, the supernatant was discarded and the cells were resuspended in LB medium 
and gently mixed. A 100 µL aliquot of these cells was then plated aseptically onto LB plates 
with the required antibiotics. The plates were sealed and incubated at 37 
o
C overnight in order 
to select for transformants that expressed the kanamycin resistance gene.  
2.7.6.3. Electroporation of pHS201 into M. bovis BCG 
Both pSHIGH and pHS201 harboured a GFP gene used to confirm the viability of BCG cells 
in growth inhibition assays with good reliability. Both these plasmids also have kanamycin 
resistance genes, kan
r 
30 µg/mL (Table 2.2). GFP fluorescence was used as a viability 
indicator of mycobacterial cells and to make comparisons with optical density measurements 
to get more reliable results. pHS201 plasmid was electroporated into M. bovis BCG with 
Gene Pulser Xcell
TM
 (BIO-RAD). Plasmid preparations were cleaned using a plasmid clean 
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kit and DNA was quantified using a NanoDrop® – ND100 Spectrophotometer (NanoDrop 
Technologies, Auckland, New Zealand) (Table 7.7). Electrocompetent cells were thawed on 
ice for 5 minutes, and then 200 µL of 10% glycerol was added to the cells. Then, 7 µL of 
DNA was added to the aliquot containing the cells and glycerol, and the mixture was kept on 
ice for 5 minutes. All contents were thoroughly mixed and transferred into a pre-chilled 
electroporation cuvette. Cells were then placed on ice for 1-2 hours before proceeding with 
the electroporation step. As per settings described in mycobacteria protocols [256], cuvettes 
containing cells, DNA and glycerol were electroporated at the following settings; 
 Voltage 1250 V 
 Capacitance 25 µF 
 Resistance 1000 Ω  
 Cuvette 2 mm pathlength 
A time constant of 19.7 was recorded for this procedure (well within a range of 15-25 as 
being successful electroporation). pHS201 plasmid served as a positive control and Milli-Q
®
 
water was used as a negative control for electroporation. After electroporation, cells were 
transferred into 1 mL of 7H9 and incubated with gentle shaking at 37 
o
C for at least 48 hours 
before cells were plated out on 7H10 agar plates (supplemented with OADC) containing 
kanamycin 50 µg/mL. The plates were incubated at 37 
o
C for 3-4 week to select plasmid-
containing colonies. The resulting colonies were further grown in 7H9 and were confirmed 
for fluorescence using a FITC filter in an Olympus microscope (Provis AX 70TRF 
Fluorescent) microscope. Colonies yielding the best fluorescence were used to make freezer 
stocks in 20% glycerol final concentration for future use.     
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2.7.6.4. Transformation Controls 
Both positive and negative controls were included in all transformation experiments. Unless 
otherwise stated, pCG79 plasmid (Figure 7.1-A) with 20 ng/µL of DNA (Table 2.2) was used 
as a positive control in all transformation assays, which yielded many individual colonies 
indicating a successful transformation. For negative controls, only 2 µL of sterile water rather 
than DNA was used which produced no colonies on kan+ (50 µg/mL) plates. 
2.7.6.5. PCR Reaction Mix 
Rv2228c and Rv2902 from M. tuberculosis H37Rv (encode for RNase HI and HII 
respectively) were cloned into E. coli expression vector pET28a (+) (section 5.4.6). PCR was 
performed to amplify the required M. tuberculosis genes. All reactions were made on ice and 
mixed well before loading on to PCR thermal cycler, MJ Mini
TM
 and My Cycler thermal 
cycler (BIO-RAD). For a standard 50 µL PCR reaction, reagents were used in following 
order and quantities: 
 DEPC dH2O ……….………18 µL 
 DMSO ……………….........1 µL of 2% 
 Primer (F) ……….…………1 µL of 10 µM 
 Primer (R) ……….…………1 µL of 10 µM 
 DNA template ……..………2 µL 
 MgCl2 ……………….……..2 µL of 50 mM 
 Master Mix (Bio Line) …….25 µL 
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2.7.6.6. Confirmation of PCR Product through Restriction Digestion 
Since there are two natural restriction sites present in the R2228c DNA sequence i.e. BamHI 
and HindIII (Table 7.8). BamHI and HindIII restriction enzymes were used to perform 
restriction digestion to initially confirm the right amplification of Rv2288c. The amplification 
of product was later confirmed by DNA sequencing of PCR products by Macrogen, North 
Korea (section 2.7.8.2).  
pET28a (+) plasmid was extracted from the DH5α -80 oC freezer stocks in order to proceed 
with the cloning experiments. Restriction digestion was performed on both amplified genes. 
The same restriction enzymes were used in double digestion experiments. NEB double digest 
enzyme finder was used to find appropriate conditions and buffer types available at 
http://www.neb.com/nebecomm/DoubleDigestCalculator.asp. NEB buffer 4 is compatible 
with both restriction enzymes used in this study, i.e. EcoRI and XhoI. 
2.7.6.7. Restriction Digestion 
All restriction digestion reaction were prepared either with a total volume of 10 µL or 20 µL. 
Samples were incubated at 37 
o
C overnight, then gel electrophoresis was carried out to 
confirm a successful restriction by visualizing the correct size bands on a 0.8% agarose gel 
under UV light. The materials used and required to perform the restriction digestion along 
with their respective concentrations are tabulated in table 7.3. 
All restriction digests provided with cohesive-end DNA fragments that were suitable for 
subsequent ligation reactions. 
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2.7.6.7.1. Restriction Digestion Reaction 
Restriction digestion of both vector and PCR products were performed with similar 
restriction enzymes and conditions used for these experiments (Table 7.4). 
2.7.6.7.2. Heat Inactivation of Restriction Digest 
To halt the restriction enzyme activity to prevent DNA digestion, the reaction was incubated 
at 65 
o
C for at least 20 minutes, as recommended by New England Bio Labs (NEB enzymes, 
section 2.7.7.2).  
2.7.6.7.3. DNA Fragments Clean Up 
All resulting DNA fragments produced from either restriction digestion or from PCR reaction, 
were cleaned and concentrated with a PCR Purification Kit (Pure Link
TM
, Invitrogen) in order 
to purify the DNA by removing dNTPs, excessive salts and unwanted buffers etc. 
2.7.7. Ligation of Inserts into Vector 
After restriction digestion of amplified PCR products and plasmid, ligation was carried out as   
follows; 
2.7.7.1. Ligation Reaction 
For a 20 µL ligation reaction, a vector to insert molar ratio was first calculated in order to 
decide on the specific quantity to be used to set up a ligation reaction. A 1:3 molar ratio of 
vector-to-insert (insert 30 ng/µL and vector 20 ng/µL DNA concentrations) was calculated on 
the basis of their DNA concentration. Reaction conditions are given below in order of the 
reagent addition for setting up a reaction. 
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 Buffer (4) ……….2.0 µL 
 ddH2O ………….8.5 µL 
 Insert ……………5.0 µL 
 Vector …………..2.5 µL 
 ATP …………….1.0 µL 
 T4 DNA ligase ...1.0 µL 
The vector used in this work was pET28a (+) (Figure 7.1-B) and the insert was Rv2228c 
from M. tuberculosis for the expression of RNase HI protein in E. coli. The ligation reaction 
was incubated at 16 
o
C overnight before proceeding with the transformation experiments. 
2.7.7.2. Inactivation of T4 DNA Ligase 
T4 DNA ligase enzyme after ligation was inactivated by heating the reaction to 65 
o
C for 20 
minutes.  
2.7.7.3. Ligation Controls 
Along with pET28a (+)_Rv2228c transformation into competent BL21 E. coli cells, as a 
control, pET28a (+) without insert was also transformed in order to verify a successful 
ligation experiment before confirmation by restriction digestions and gels electrophoresis. A 
restriction digestion experiment was performed using EcoRI and XhoI restriction enzymes, 
followed by running a 0.8% gel to confirm that the plasmid was cut at the right position and 
has released the insert of correct size (Figure 5.9).  
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2.7.7.4. Confirmation of Ligation Reaction 
Ligation reactions were confirmed for inserts performing overnight double digestion with the 
same set of restriction enzymes. Agarose gel electrophoresis was done to confirm if ligation 
experiments was successful by visualizing the right size bands under UV light. Restriction 
digestion of pET28 (+)_Rv2228c was performed as per conditions given in table 7.4. 
2.7.7.5. Agarose Gel Electrophoresis 
Agarose gels (1%) were prepared by dissolving one gram of molecular grade agarose into 
100 mL of 1x TAE. The agarose was melted in a laboratory microwave, and after a few 
minutes of cooling, 5 µL of 10 mg/mL ethidium bromide was added into 50 mL of agarose 
gel. The solution was mixed well and poured into a gel caster in a pre-set electrophoresis 
assembly (Bio Rad). Appropriate gel combs were placed into the gel, and it was allowed to 
set at room temperature for at least 20 minutes. DNA samples were mixed with 5x DNA 
loading buffer (1:4) and loaded along with 5 µL of a DNA ladder to estimate the size of the 
DNA bands. Gels were run according to the conditions detailed in table 7.5; and after the 
separation of bands, DNA was visualized in an Ultraviolet-Transilluminator (EL Logic 100 
IMAGING SYSTEM). Gel photos were taken using a Gel Documentation System with high 
performance KODAK 1D
TM
 wide-zoom digital camera. Photos were printed using a Digital 
Graphic Printer, UP-D895 (Sony). 
2.7.8. Identification of Recombinant Clones 
After confirmation of the correct inserts via restriction analysis (section 2.7.7.4), the plasmids 
were transformed into the BL21 strain and grown overnight at 37 
o
C with kanamycin 50 
µg/mL. The plasmid was then extracted from these cultures with a plasmid extraction kit 
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(High-speed Plasmid Mini Kit, Geneaid Biotech Ltd.). Recombinant clones were identified 
by a colony PCR method (section 2.7.8.1).  
2.7.8.1. Colony PCR 
Individual colonies were picked up by micropipette tip dipped into PBS and were placed in a 
PCR reaction as a DNA template. PCR was run as per conditions presented in table 7.2 using 
appropriate primers (Table 2.4). The PCR screen confirmed the correct inserts, after 
amplification of the desired genes from M. tuberculosis, and confirming correct sizes on a 1% 
agarose gel (for Rv2228c, 1095 bp and Rv2902c, 795 bp). Plasmids carrying the genes of 
interest were grown in DH5α to make -80 oC freezer stocks, and the desired clones were 
selected for further analysis.  
2.7.8.2. DNA Sequencing 
All samples for DNA sequencing (PCR products, primers, and DNA samples for 
confirmation of orientation of correct inserts) were sent to the Macrogen DNA sequencing 
facility in North Korea. All samples were sent either in 200 µL PCR tubes or 1.5 mL 
eppendorf tubes, which contained PCR products to reconfirm the fidelity of the DNA 
polymerase enzyme and primers. The amount of DNA for plasmids was about 200 ng (20 µL) 
and for PCR products 50 ng (10 µL), for primers 5.0 pmol taken from a 10 µM (5 µL) stock. 
All DNA sample containing tubes were wrapped with bubble paper to avoid possible sample 
damage and to ensure safe transportation of DNA samples. Chromatogram files were studied 
using Chromas (Version 2.3) and vector NTI Advance
®
 11.0 software.   
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2.8. In Silico Analysis  
In silico analysis was performed to predict the interaction of novel anti-Tb compounds with 
RNase HI in M. tuberculosis (section 5.5). A number of docking software were used to 
examine if the interaction of previously-known HIV RNase H inhibitors with mycobacterial 
RNase HI (Rv2228c) is possible (section 5.5). These include QuacPac (version 1.3.1), Omega 
(version 2.4.3), FRED (2.2.5), VIDA (version 4.0.3) and OpenEye Scientific Software, Inc. 
Santa Fe, NM (U.S.A, available at www.eyesopen.com, 2010). 
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Chapter 3 
High Throughput Screening of Chemical Libraries 
for the Identification of M. tuberculosis Inhibitors 
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3.1. Introduction  
3.1.1. Purpose 
Tb continues to be a serious health concern [100], [257] owing to its unmet needs for drug 
discovery [258]. Apart from drug resistant Tb [259], the magnitude of the HIV-Tb co-
infection problem is remarkably huge, jeopardising the Tb control efforts worldwide [260]. It 
has been estimated that without proper containment, treatment and control programs, billions 
more will be infected and about millions of lives will be claimed by 2020 [261]. It is 
therefore necessary to find new drugs to strengthen Tb treatment regimen [262]. One of the 
effective ways of searching new drugs is random screening of chemical libraries to identify 
novel lead compounds [263]. 
3.1.2. High Throughput Screening 
While there is no preferred method to identify potential anti-tubercular compounds, high 
throughput screening (HTS) can discover novel leads with high probability [264]. HTS is a 
process that screens thousands of chemical or drug-like compounds in a relatively short 
period of time to select ideal candidates with good pharmacological potential. Once identified, 
these can be further characterized and modified to develop a highly active anti-mycobacterial 
drug. Broth macrodilution methods and plating colony forming units (CFUs) are traditional 
orthodox techniques to test compounds for their efficacy and antimycobacterial susceptibility, 
however, both these methods are time consuming and labour intensive. With the 
advancement of science and technology, new ways to discover inhibitors against various 
pathogenic species in a time-efficient manner have been developed. One such example is the 
development of drug libraries with a collection of compounds from a range of sources. These 
libraries are batch-screened against the desired microbes to identify potential growth 
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inhibitors. The process of screening drug libraries in high-throughput makes it even more 
convenient and time efficient. Thousands of compounds can be tested at a time against the 
organism of interest; hence HTS plays a pivotal role in drug discovery. Scientific and drug 
discovery research relies on HTS for accelerating the drug discovery process [265-267]. 
Section 3.1.2.1 describes the types of screening procedures for drug discovery. 
3.1.2.1. Types of Screens  
In vitro high throughput screen can be performed in various ways with their own advantages 
and limitations. Two main types of screens used for the identification of random and target-
specific inhibitors are discussed below; 
A. Targeted-based screening 
When cell-free and targeted-based screenings are performed against an array of 
biological targets, cell-free assays will only inhibit specific cellular processes. The 
approach of screening for specific enzyme inhibitors for drug development and its 
structure-activity relationships is well-known and documented [268-272]. However, 
target-based screenings have a limitation of selecting inhibitors with only one target at 
a time. In contrast, whole cell-based screens can detect inhibitors with a wide range of 
targets, which may have novel modes of action.  
 
B. Whole cell-based high throughput screening 
There are a number of advantages for using cell-based assay rather than cell-free 
assays for compound screening that include cost effectiveness, convenience and 
robustness [273-274]. Cell-based in vitro screening is a preferred method for the 
identification of active M. tuberculosis inhibitors [275-276]. A whole cell-based 
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screening approach was therefore selected in this study to perform a primary screen to 
detect novel M. tuberculosis inhibitors. The rationale for using a whole cell-based 
screen was to perform a random screen to identify mycobacterial inhibitors with 
multiple-targets in M. bovis BCG, which could then be validated in M. tuberculosis.  
3.1.3. Chemical Libraries for HTS 
The main objective of this part of the study was to perform random high-throughput 
screening against M. bovis BCG using five chemical compound and plant extract libraries 
(Figure 2.1 and section 3.3.1). 
3.1.3.1. Stock Concentration of Compound Libraries 
Unless otherwise stated, all libraries were imported with concentrated stocks in deep 96-well 
plates (10 mM stock concentration). Thereafter, chemical libraries were diluted (10-fold) to 1 
mM using DMSO in order to prepare working stocks. A 2 µL aliquot of these working stocks 
were then dispensed into wells of a 96-well plate with a final concentration of 20 µM for each 
compound tested. Libraries were dispensed directly from 1 mM working stocks using a 
Liquid-handling Robot System (section 3.1.4). 
3.1.3.2. Controls for HTS 
Each plate in an HTS assay had a number of controls. The positive control included two 
standard anti-tubercular antibiotics, rifampicin and streptomycin at 20 µM, negative controls 
with no drugs and media controls with no cells (Figure 2.2). Since the chemical libraries were 
resuspended in DMSO, a DMSO control was also included in each plate. All controls were 
run in duplicate. 
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3.1.4. Liquid-handling Robot System 
HTS were performed by using a Liquid handler CyBio-96
®
. All plates were dispensed with 
high efficiency and good well-to-well accuracy in standard 96-wells plates with 80 
compounds per plate, each compound at 20 µM concentration.  
3.1.5. Objectives  
 To screen chemical libraries against the slow-growing species, M. bovis BCG and M. 
tuberculosis H37Ra. 
 To identify and select potential growth inhibitors of M. tuberculosis. 
 To validate inhibitors identified in HTS in an in vitro model of Tb, M. tuberculosis 
H37Ra.  
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Figure 3.1: A schematic flow diagram of main research steps and objectives for this study (1) Develop a 
cell based assay to detect inhibitors of M. tuberculosis (2) Perform HTS of chemical libraries 3) Validate M. 
tuberculosis inhibitors using Tb model, M. tuberculosis H37Ra (4) Test for toxicity towards human cells (5) 
Characterize the possible drug target and (6) Finally select inhibitor(s) based on its therapeutic potential and 
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unique mechanism of action, which can then be developed as a novel anti-Tb drug in collaboration with Global 
Alliance for Tb Drug Development. 
3.2. Development of a Biological Assay for High Throughput Screening 
3.2.1. Growth Inhibition Assay  
A bacteriostatic assay was set up to determine growth inhibition of the slow-growing 
mycobacterial species, M. bovis BCG and M. tuberculosis H37Ra caused by the inhibitory 
activity of chemical compounds (section 3.2.3). 
3.2.1.1. Tb Models for HTS 
A slow-growing Tb vaccine strain was used as a surrogate species for screening of compound 
libraries (section 1.3.2.1). M. bovis BCG was transformed with an E. coli-BCG shuttle 
plasmid (pYL_gfp+kan
r
) which has a green fluorescent protein (GFP) cloned from Aequorea 
victoria and a kanamycin resistance gene (kan
r
) downstream of the mycobacterial hsp70 
promoter. The gene encoding for GFP fluorescence is constitutively expressed by the hsp70 
promoter [277]. This genetically modified strain (Figure 3.2) was used as a screening model 
for HTS in this study (Table 2.1) and growth cultures were maintained as previously 
described [256]. The fluorescence expression was observed as described in section 2.7.2.1.  
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Figure 3.2: M. bovis BCG Pasteur 1173P2 fluorescently labelled with pYL_gfp. 
3.2.1.2. M. tuberculosis H37Ra 
Another slow-growing species, M. tuberculosis H37Ra that is closely related to M. 
tuberculosis H37Rv, was used in screening and for subsequent validation of mycobacterial 
inhibitors (sections 3.2.4). While both strains produce similar drug susceptibility data (section 
4.1.1), H37Ra is non-pathogenic in nature which makes it a preferable choice to be used as a 
surrogate for H37Rv pathogenesis, in PC2 labs.  
3.2.1.3. M. smegmatis mc
2
155 
M. smegmatis is a fast-growing mycobacterial species with a doubling time of 4 hours. It was 
employed for the purpose of comparing inhibitors across the different model organisms used 
in HTS to evaluate the sensitivity of each species to detect anti-Tb compounds (section 4.1.1). 
3.2.2. Available Reporter Systems for Mycobacterial Assays 
Growth is an effective indication of cell replication but a simple means of measuring optical 
density is not reliable in determining cell viability because mycobacteria tend to clump in 
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broth cultures. Therefore, several techniques have been developed over the past decade to 
detect the viability of mycobacterial cells in HTS and growth inhibition assays. Examples 
include, a luciferase gene for bioluminescent signals [278], a gene encoding GFP harboured 
by a mycobacterial plasmid [279] or uptake of radio-labelled uracil by live cells [280]. 
Reporter systems have been widely used for several biological assays for viability and for 
monitoring cellular processes such as transcription. Like the Luciferase reporter, GFP has 
also been increasingly used in biological research with an efficient reporting ability in various 
biological models [281-282]. These reporter molecules, luciferase [283] and GFP [284], have 
the potential for drug screening in high-throughput with both reliability and cost effectiveness. 
However, unlike the luciferase gene-based assay, GFP does not require any exogenous 
substrates and/or cofactors [285-286]. Zafer et al. first reported the use of a reporter system in 
slow growing mycobacteria and the results from their study were based on a correlation 
between the fluorescence signal and CFUs [287]. Calculating CFU‟s is time consuming and 
can be labour intensive. Therefore, we used the correlation between OD600 values and the 
GFP signal. A close correlation between these two measurements ensured data reliability and 
accuracy. Table 3.1 presents the available fluorescence-based assays for drug screenings.   
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Table 3.1: Reporter assays for high-throughput screening 
Potential for HTS
1
                  Techniques 
         MABA
2 
         Luciferase based assay       GFP based assay 
Sensitivity of the assay   Sensitive  Sensitive  Sensitive 
Substrates/co-factors   Dye required    Co-factors required               Not required       
Requirement  
Reliability   Reliable  Highly reliable  Highly reliable 
Efficiency   Efficient  Efficient  Excellent 
Shaking requirements  Not required  Required  Required 
Reading device    Fluorometer               Luminometer      Fluorometer 
Expression analysis   MIC/FUs  RLUs   RFUs 
Fluorescence/CFUs       Yes    Yes   Yes 
Comparison    
Effect of vector on                Not Required  No effect  No effect 
Drug susceptibility  
Cost effectivity   Cost effective  Cost effective  Cost effective 
Assay reading
3    
Change in colour   Fluorescence  Fluorescence   
Use of mutant strains  No use      Yes   Yes 
Assay better than   BACTEC460 systems     Broth macro dilution assays    Luciferase assay 
1Efficiency and capacity of various screening assays. 2Microplate-based Alamar Blue Assay. 
3Assay reading 
time depends on optimum conditions and the type of strain used. GFP was exclusively selected for the 
determination of cell viability based on its efficiency [288]. RLUs, Relative Luminescence Units. RFUs, 
Relative Fluorescence Units. 
The reason for comparing various available techniques is cost. The GFP reporter system is 
cost effective and does not require exogenous co-factors and/or substrates and is more 
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convenient to use. Therefore, M. bovis BCG harbouring pYL_gfp plasmid was used for 
drug susceptibility testing in this study. 
3.2.3. Development and Optimization of a Fluorescence-based Assay  
All cell-based screening experiments were performed in 96-well plates with a total volume of 
100 µL per well as described (section 2.7.2) with appropriate controls in each assay plates 
(Figure 7.12). At the end point, plates were read for GFP fluorescence and OD600 (section 
2.7.2.1.2).  
3.2.4. Growth Curves for M. tuberculosis H37Ra and M. bovis BCG 
The optimal inoculum and end point of the assay was determined by testing the variables in 
growth curves. Cultures were grown in 7H9 medium under standard growth conditions for 
mycobacteria as described (section 2.7.2.1). The OD600 and fluorescence of cultures were 
determined every day after the first 6 days of incubation for up to 14 days. The growth was 
also verified by CFU counts from these cultures. A consistent increase in optical density of 
cultures indicated that both the slow growing strains used in this study (M. tuberculosis 
H37Ra and M. bovis BCG) were growing for up to two weeks, after which cultures entered 
into stationary phase. There was no change in OD600 after two weeks of incubation, 
suggesting stationary phase had occurred (Figure 3.3). Therefore, assay reading time was set 
at day 14, before the cultures reached growth saturation. Cultures of different ages were 
tested for growth rates and to determine exactly when M. tuberculosis cells reach stationary 
phase. A noticeable difference was observed in the number of viable cells in logarithmically 
growing cultures versus stationary cultures. The CFU counts of an M. tuberculosis culture 
(OD600 of ~1.0) was 1.54 x 10
5
 CFUs/mL for log-phase cultures; whereas stationary cultures 
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(more than four weeks old) gave a slightly lower number of viable cells i.e. 0.94 x 10
5
 
CFUs/mL. Figure 3.3 presents growth curves for both slow-growing mycobacterial species.  
 
Figure 3.3: Time point growth curve for slow-growing mycobacteria. There was almost no change observed 
in OD600 readings post two weeks incubation indicating a stationary time point (circled) in M. bovis BCG and M. 
tuberculosis H37Ra cultures; therefore, assay plates were read on day 14 of incubation for slow-growing 
mycobacteria. Both cell cultures were tested for OD600 every day and cells were mixed well to break their 
clumps and for their even distribution before readings. All OD600 values are the average of triplicate readings 
that were read each day from day zero to day 26. 
3.2.5. Reliability of a Bacteriostatic Assay 
A range of standard anti-Tb drugs were used in order to evaluate the reliability of the 
mycobacteriostatic assay. Published MIC values for standard anti-Tb drugs against M. 
tuberculosis H37Rv were compared directly with the MICs values determined against M. 
Chapter Three – High-throughput Screening  
 
 
82 
 
bovis BCG in this study. Growth controls without any drug and sterility controls (medium 
only) were also included in each assay plates.  
3.2.5.1. Confirmation of the Assay Sensitivity  
To ensure assay sensitivity, the inhibitory effects of known anti-tubercular drugs were tested 
against M. bovis BCG. A close correlation of MIC values was observed among standard anti-
tubercular drugs determined with M. bovis BCG to that of published values against M. 
tuberculosis H37Rv (Table 3.2). 
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Table 3.2: Comparison of MIC values between M. bovis BCG and M. tuberculosis H37Rv 
 
Anti-Tb Drug                  
1
H37Rv                         
2
M. bovis BCG 
        
     MIC (µM)        MIC (µM)             IC50 (µM)                
                                      
Rifampicin        0.48             0.15                0.006  
  
Isoniazid            0.183            0.188                0.08  
    
3
Pyrazinamide        100             >200                  –  
 
Ethambutol        2.5             2.8                 1.9  
     
Streptomycin        1.72             1.25                0.6 
 
Capreomycin        2.6             1.64                0.36 
 
Ethionamide        1.5             20                12.6 
 
D-Cycloserine        245             265                205 
 
Ciprofloxacin        1.5             1.55                0.98 
 
1Reported MICs for M. tuberculosis H37Rv adapted from the Handbook of Anti-Tuberculosis Agents [178]. 
2Comparison of MICs against M. bovis BCG and M. tuberculosis H37Rv strains to evaluate the sensitivity of the 
growth inhibition assay used in this study. 3While pyrazinamide is active against M. tuberculosis, bovine 
mycobacterial strains are naturally resistant to pyrazinamide due to a point mutation in pncA and therefore, no 
activity was observed at highest concentration tested (200 µM). The comparison of MIC values in M. bovis 
BCG with M. tuberculosis H37Rv suggests that there was no effect of having a plasmid in the working M. bovis 
BCG model used for screening. (–) not calculated. MIC, minimum inhibitory concentration. IC50 values were 
calculated by Sigma Plot version 11.0 (Dose-response curves for standard drugs against M. bovis BCG are 
presented in figure 7.5).   
3.2.6. Assay Validation – Dose Response Assays 
M. tuberculosis H37Ra, an unlabelled avirulent strain of Tb was used for the validation of the 
anti-tubercular compounds identified and to determine their in vitro efficacy. Unlike the 
screening model, M. bovis BCG, M. tuberculosis H37Ra does not have the GFP reporter 
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system or the antibiotic resistance cassette. Therefore, results for validation assays performed 
with M. tuberculosis H37Ra are based on optical density (OD600).     
3.2.7. Effect of DMSO on M. bovis BCG Growth 
Since chemical libraries (and individual compounds tested for validation) were dissolved in 
DMSO and 2 µL (of 1 mM library working stocks) of each compound was dispensed making 
2% final concentrations of DMSO in each well, it was deemed necessary to determine if 
DMSO itself had any inhibitory effect over M. bovis BCG growth. Figure 3.4 shows M. bovis 
BCG growth with up to 5% DMSO. 
    
 
Figure 3.4: Percentage M. bovis BCG growth in DMSO. There was no inhibition of M. bovis BCG growth 
observed in a bacteriostatic assay with up to 5% DMSO. 
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3.3. Results  
3.3.1. Compound Libraries for HTS 
Various chemical libraries consisting of over 5,000 distinct compounds were obtained as 
described (section 2.6) and were screened in high-throughput against M. bovis BCG (Figure 
2.1). 
3.3.1.1. LOPAC
1280TM 
LOPAC was prepared in 250 µL DMSO in 10 mM stocks in 96-well plates with one 
compound per well. The library has 16 plates in total consisting of 80 individual compounds 
per plate. It has a wide range of compounds with antibacterial activities and known drug 
targets e.g. DNA gyrase inhibitors, cell wall and various cellular enzyme inhibitors [289]. 
LOPAC itself served mainly as an assay validation library; a preliminary screen was run 
against M. bovis BCG to identify known M. tuberculosis inhibitors in the library (Table 3.3). 
Figure 3.5 presents the distribution and class of pharmacologically active compounds in the 
LOPAC library with their wide range of biological targets. 
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Figure 3.5: Distribution of compounds and range of drug targets in the LOPAC library. LOPAC has been 
designed to have a range of biological targets across bacterial, viral and fungal species [289].   
3.3.1.1.1. Scatter Plot for the LOPAC against M. bovis BCG 
An average of the triplicate values for each compound in a test plate was calculated, and the 
percentage OD600 and GFP fluorescence values were plotted together in a scatter plot to show 
hits, non-hits and values for a range of controls for HTS. Table 3.3 presents the positive anti-
mycobacterial hits identified from LOPAC screen including their biological activity and the 
percentage inhibition they caused whereas, figure 3.6 shows the distribution of hits and 
controls used in LOPAC screen. 
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Figure 3.6: Scatter plot for LOPAC screen against M. bovis BCG. OD600 (%) values were plotted on the x-
axis and GFP fluorescence (%) values on the y-axis. The red square shows the 25% cut off for the identification 
of a positive hit i.e. at least 75% growth inhibition and also shows a positive control (rifampicin) that was 
included in each plate. Readings for both GFP fluorescence and OD600 show a good correlation (R
2 value 
0.4269). The Z-factor was calculated to ensure fidelity of the screen, Z=0.91 and 0.92 for both positive controls 
rifampicin and streptomycin, respectively.  
In LOPAC scatter plot, while many inhibitors displayed only 50% inhibition of M. bovis 
BCG growth, some compounds had high fluorescence signal and their corresponding OD600 
values showed relatively less or no inhibition compared to 100% growth control recorded in 
this study. Since these inhibitors did not fit our compound selection criteria (section 3.3.1.1.4), 
they were not considered for further characterization. However, compounds which inhibited 
mycobacterial growth by >75% (n=24) from LOPAC screen are presented in table 3.3. Hits 
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that appeared active twice during a triplicate screen were validated against M. tuberculosis in 
a dose-response assay designed to achieve measureable inhibitory concentrations.  
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Table 3.3: Hits identified from LOPAC screen against M. bovis BCG and M. tuberculosis 
Compound   BCG Mtb %Inhibition  Class/Action 
APDC    + + 99 Reported anti-tubercular compound [290] 
Calmidazolium chloride + + 99 Inhibitor of Ca2+ ATPase 
Clotrimazole   – + 80 Inhibitor of Ca2+-activated K+ channels 
Cephapirin sodium  + + 99  Cell wall inhibitor [291]  
Calcimycin   + +        >75  Ca2+ ionophore [292] 
Diphenyleneiodonium Cl
- 
+ + 95 Nitric oxide synthase inhibitor [293] 
Dequalinium chloride  + +        >75       Anti-tubercular[294] 
Doxycycline hydrochloride + + 99  Antibiotic 
Demeclocycline HCl  + + 99  Antibiotic 
Fusidic acid sodium  + + 95      Protein synthesis inhibition in prokaryotes 
Ellipticine   + + 95  Anti-tubercular, TAACF [295]  
5-Fluorouracil   + – 75  Thymidylate synthetase inhibitor 
Idarubicin   + – 85  Anti-cancer (PubChem database) 
Lomefloxacin HCl  + + 99  Antibiotic/DNA gyrase inhibitor 
Minocycline HCl  + + 90  Protease inhibitor 
Methoctramine tetra HCl + + 90  Antagonist 
Nialamide   + + 85  Monoamine oxidase inhibitor 
Niclosamide   + + 90  Antibiotic/protonophore [295] 
Pentamidine isethionate + – 75  Known antimicrobial [296] 
Resveratrol   + – 85  anti-M.smegmatis [297]  
Seglitide   – + 75  sst2 somatostatin receptor agonist 
1, 10-Phenanthroline  + + 95  Metalloprotease inhibitor   
Tetraethylthiuram disulfide + + 99  Alcohol dehydrogenase inhibitor 
Vancomycin hydrochloride + + 99  Antibiotic (known) 
Compounds were further selected for validation in M. tuberculosis if they were found active at least twice 
during a triplicate screen with no previously reported anti-mycobacterial activity. A (+) sign indicates positive 
hit in HTS against M. bovis BCG and was also validated in M. tuberculosis H37Ra. Whereas, (–) indicates no 
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hit in that species. APDC, Ammonium Pyrrolinedithiocarbamate. TAACF, Tuberculosis Antimicrobial 
Acquisition and Coordinating Facility.  
3.3.1.1.2. Chromogenecity of Compounds 
Coloured compounds appeared to interfere with the GFP signal and the OD600 measurements. 
To overcome this, 100 µL of medium without cells was added to separate wells with these 
compounds and the readings for each well were subtracted from the growth readings of the 
test compounds to correct for the high background.  
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Table 3.4: Validated hits against M. tuberculosis from the LOPAC library 
Compound Structure    (MICs µM) in BCG      Mtb           Molecular Weight  Formula 
TETD           6.25                 3.125             296.52 g/mol        C10H20N2S4 
  
APDC           1.56                 0.781             164.28        C5H9NS2.NH3
  
      
2-CA                      12.5                 12.5      301.69           C10H12CIN5O4 
    
FAS                      3.125               1.56      538.71           C31H47NaO6
  
     
 
WB-64                                12.5        12.5                808.66      Br2C40H48N4O4 
    
Compounds were validated in M. tuberculosis H37Ra. TETD, Tetraethylthiuram disulfide. APDC, Ammonium 
Pyrrolinedithiocarbamate. 2-CA, 2-Chloroadenosine. FAS, Fusidic acid sodium. Compound images were 
retrieved from  [289]. 
 
 
 
Chapter Three – High-throughput Screening  
 
 
92 
 
3.3.1.1.3. Brief Description of Validated LOPAC Hits and their Biological Activity 
Except for WB-64, hits listed in table 3.4 were M. bovis BCG and Mtb-specific, which did 
not appear in screens with M. smegmatis (Chapter 4). A brief description of their biological 
activity and any anti-mycobacterial activity is noted below. 
A. Tetraethylthiuram Disulfide (TETD) 
 
TETD, also known as Disulfiram, is a low molecular weight compound (296.52 g/mol) 
that inhibits the enzyme alcohol dehydrogenase. Disulfiram has been considered to be 
a safe drug and was previously used for the management of alcohol abuse and 
intoxication as well as being used as a soil treatment agent in the agricultural sector 
[298-300]. It has also been used for the treatment of Tb [301]. 
B. Ammonium Pyrrolinedithiocarbamate (APDC) 
 
APDC is a low molecular weight compound (164.28 g/mol) and is non-toxic. It bears 
anti-corrosive properties and has been used as a metal chelator [302-303]. APDC has 
previously been found to be active against the slow-growing mycobacterial species 
with an MIC against M. tuberculosis H37Rv of 0.791 µM [290], in this study the MIC 
was 0.781 µM against M. tuberculosis H37Ra (Table 3.4). Inhibition of M. 
tuberculosis growth may be associated with its metal chelating activity. 
Pyrrolinedithiocarbamate compounds also seem to have anti-viral properties in vitro 
[304]. 
 
C. Fusidic Acid Sodium 
 
Fusidic acid was validated against M. tuberculosis H37Ra with an MIC value of 1.56 
µM. It has previously been reported to be anti-mycobacterial by Hoffner et al. (MIC 
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range for M. tuberculosis = 0.032-0.064 µg/mL or 0.06-0.2 µM) and was found 
synergistically active with ethambutol in combination therapy [305]. Fusidic acids are 
known to interfere with protein synthesis of prokaryotes and are highly active against 
M. leprae infections with an IC50 of 0.3 µM [306]. 
 
 
D. 2-Chloroadenosine 
 
This compound has been used in biological research for the modification of 
nucleoside and nucleotides. It has been shown by Mary et al. to be a metabolically 
stable analogue of adenosine, which acts as a selective adenosine receptor agonist. It 
also possesses anti-mycobacterial activity with higher inhibitory concentrations 
ranging from 3.0-33.3 µM [307]. While good anti-mycobacterial activity of 2-
Chloroadenosine was observed in this study (MIC 12.5 µM against M. tuberculosis), 
it displays cytotoxicity to mammalian cells by inducing cell apoptosis [308].   
 
E. WB-64 
 
WB-64 [N,N,N′,N′-tetramethyl-bis[(1,8-naphthylimid-9-yl)propyl]-N,N′-hexane-1,6-
diyl-bis(ammonium bromide)] is a white coloured and water soluble compound. It 
was one among many anti-mycobacterial hits against from the LOPAC screen and 
was detected with M. smegmatis with an MIC value of 50 µM [252]. The present 
study identified it as being active against M. bovis BCG in HTS, and this activity was 
also validated in M. tuberculosis H37Ra with an MIC of 12.5 µM (Table 3.4). 
However, it has recently been identified as an inhibitor of human apurinic 
endonuclease [309].  
LOPAC hits were primarily used to validate the HTS procedure used in this study and to 
evaluate the suitability of dose-response assays for the validation of compounds. However, 
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there have been many compounds identified from both the Spectrum Collection and the NIH 
libraries that may hold potential for further development in the drug discovery process 
(section 3.3.1.3). 
3.3.1.1.4. Selection Criteria for Novel Compounds Identified Through HTS 
Compounds identified from HTS were only considered appropriate for further 
characterization if they fulfilled following pre-set selection criteria. 
A. Experimental Approach 
 Compounds identified in the HTS have yielded >75% anti-mycobacterial activity 
in triplicate screens (tested at 20 µM). 
 Appeared active when re-tested at a higher concentration (100 µM) against M. 
bovis BCG in a dose-response assay. 
 Compounds are also validated against M. tuberculosis H37Ra and have low 
inhibitory concentrations.  
Compounds that retain good in vitro activity against M. tuberculosis H37Ra were put through 
an extensive literature search to confirm if a hit has potential to be further characterized.  
 
B. Literature-based Approach 
 Literature mining was performed to find any previously reported activity against 
M. tuberculosis for the inhibitors identified. 
 Databases such as PubChem, Toxnet, Chemblink, DrugBank, TAACF and journal 
articles were accessed as a primary source of information on inhibitors identified 
in this study. 
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 After novelty check based on previously published data, compounds were further 
assessed on the basis of their toxicity profiles. New mycobacterial inhibitors were 
excluded, if those compounds were previously found toxic towards mammalian 
cells (e.g. anti-mycobacterial hits from NIH library thaspine, mitxantrone and 
nogalamycin), it was excluded from further study. 
 If compounds were known to target human enzymes, they were excluded as they 
would not make good anti-microbials. 
 A compound found to have any promiscuous activity or identified as an 
interference compound (if a compound has been identified in previous multiple 
active screens) was also not considered as a positive hit for M. tuberculosis and 
was left out of the hit list. Novel inhibitors are being sought in the present study 
must not have biological targets in humans and ideally should have had no 
previous active screens.   
3.3.1.2. Spectrum Collection 
A set of 2,000 compounds known as the Spectrum Collection was purchased from Micro-
source Discovery Inc. Each compound had a minimum of 95% purity in the Spectrum library. 
3.3.1.2.1. Collection of compounds 
Spectrum library consisted of compounds containing drug-like properties from a range of 
resources. The majority of compounds (50% of the library collection) were drug-like 
components. Thirty percent of the compounds (n=580) were pure natural extracts and the rest 
of the compounds were non-enzyme inhibitors that might have biological activity (20% of the 
library collection). The distribution and type of Spectrum compounds are available from their 
website www.msdiscovery.com/spectrum.html. There was also an overlap of compounds, 
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approximately 12% with the LOPAC including some known anti-bacterials or drugs with 
known mechanism of action. These compounds served as embedded controls for HTS to 
determine the reliability of the screens as well as to cross verify hits between libraries. 
3.3.1.2.2. Spectrum Screen against M. bovis BCG 
A triplicate screen (three plates with three wells per plate per compound) was performed 
twice (two separate screens, a total of 6 plates, 18 wells) to identify potential growth 
inhibitors from the Spectrum Collection, in which a close correlation both in terms of number 
as well as types of hits was found (Figure 3.7). An average of approximately 62 hits was 
achieved with a hit rate of 3.1%. 
 
Figure 3.7: Number of hits identified in two independent triplicate Spectrum screens against M. bovis 
BCG. Results from triplicate screens were compared to ensure data integrity and to examine if type of hits were 
consistent in each screen (see figure 3.9). 
Chapter Three – High-throughput Screening  
 
 
97 
 
3.3.1.2.3. Scatter Plot for Spectrum Screen 
A scatter plot was made using the percentage OD600 and GFP fluorescence values to identify 
positive hits compared to positive controls (Figure 3.8). 
 
Figure 3.8: Scatter plot for Spectrum screen. The red-square dots within the cut off value (>75% growth 
inhibition, orange square) were identified as positive hits compared to the positive control, rifampicin, included 
in each plate.  
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Table 3.5: Validated hits against M. tuberculosis from Spectrum library 
Compound  BCG   Mtb   %Inhibition  Activity 
Aklavine HCl  +     +        99  Anti-malarial [310] 
Cloxyquin  +     +       99  Anti-tubercular [311]   
Disulfiram•  +     +       99  Anti-malaria [312] 
Ketoconazole  +     +       >75 Anti-M. tuberculosis [295]  
Mercaptopurine +     +       >75  Mycobacterium paratuberculosis [313] 
Clotrimazol  +     +       99       Anti-tubercular [295]  
Pasiniazid  +     +       99       Anti-tubercular    
Cefdinir  +     +       95              Cephalosporin class, antibacterial [314] 
Econazole nitrate +     +       95  Anti-tubercular [295] 
Alexidine HCl  +     +       99  Antibacterial/Anticancer activity [315] 
Orlistat  +     +       90  Mycolic acid biosynthesis inhibitor [316] 
Sappanone A*  +     +       99  Novel anti-Tb compound  
Dimethyl ether     [This study]     
Acivicin  +     +       99  Inhibits tumour angiogenesis [317] 
Nigericin sodium +     +       95  Disrupt membrane potential in Mtb [318]  
Carmofur  +     +       95            Anti-neoplastic agent [PubChem database] 
Except aklavine HCl, carmofur and clotrimazole, most compounds from Spectrum screens were detected with M. 
bovis BCG (and M. tuberculosis H37Ra) but not with M. smegmatis (data not shown). *Compounds with no 
previously published anti-mycobacterial activity. (•) Compound also appeared as a hit from the LOPAC library 
(Table 3.4) and was also active against the eukaryote parasite P. falciparum and was previously reported as an 
anti-tuberluar compound. 
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3.3.1.2.4. Description of Spectrum Hits with Anti-mycobacterial Activity 
While some compounds from the Spectrum libray are known to have antibiotic properties, 
many anti-mycobacterial hits identified in this study had been noted to have undetermined 
biological actitivity, (biological information of compounds was retrieved from MicroSource 
Discovery Inc). Compounds detected as positive hits in screens were not further pursued due 
to known toxicity or unfavourable therapeutic potential (section 3.3.1.1.4). However, 
compounds with no published reports of any specific anti-mycobacterial activity were 
considered novel such as sappanone A dimethyl ether, which may have good potential to be 
further characterized and developed into a drug (section 3.4). Some inhibitors have 
previously been reported to inhibit Plasmodium falciparum (P. falciparum) replication in 
vitro e.g. aklavine HCl and mitoxantrone [310]. These compounds also inhibited 
mycobacterial growth in the present study (Table 3.5), suggesting that these could be further 
investigated for mutual inhibitory activity against parasitic and bacterial pathogens (section 
6.3.3).  
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Figure 3.9: Comparison of hits from a triplicate Spectrum screen performed against M. bovis BCG and M. 
tuberculosis H37Ra. Hits appeared to be consistent with slow-growing mycobacterial species among all screens 
(see Table 3.5 for validated hits from the spectrum library and Figure 3.17 for common hits among all screens). 
3.3.1.3. NIH Library 
The NIH library has a wide range of structurally-diverse compounds with a range of 
biological activities. Plate-to-plate information and information on individual compounds 
were retrieved from the NIH website for Developmental Therapeutics Program 
(www.dtp.nci.nih.gov). The NIH library was divided into two portions. 
1. NIH Diversity Set constituting 1990 compounds and 
2. A mini library of NIH Natural Products containing 240 compounds 
After the libraries were screened, information on positive hits was retrieved from the official 
website of PubChem database, available at www.ncbi.nlm.nih.gov/pccompound.    
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3.3.1.3.1. Scatter Plot for NIH Screen 
 
 
Figure 3.10: Scatter plot for NIH screen performed against M. bovis BCG. NIH library contained Diversity 
and Natural product sets constituting 2230 compounds. Hits with positive control (rifampicin) are shown within 
the cut-off value of < 25% growth (green square). Novel growth inhibitors selected from the NIH library are 
presented in table 3.6. 
3.3.1.3.2. Potential Inhibitors of M. tuberculosis from NIH Library 
New hits identified from the NIH library screen that inhibited growth of M. bovis BCG and M. 
tuberculosis H37Ra have been listed in table 3.6. 
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Figure 3.11: Flow chart for NIH chemical library screen. A total of 90 anti-mycobacterial hits were detected 
from the NIH screens against M. bovis BCG. All compounds were tested individually in dose-response assays 
against M. tuberculosis H37Ra. Inhibitors validated against M. tuberculosis (n=13) are listed in table 3.6, see 
also table 4.2 for active inhibitors of M. tuberculosis H37Ra identified from the NIH library (n=28).  
3.3.1.3.3. Biological Evaluation of Hits from NIH Library 
After the hits have been identified as potential inhibitors of M. bovis BCG growth, they were 
evaluated for their biological activity from any previously published data. Biological activity 
and literature study indicated that many inhibitors such as NSC15381, NSC64111, 
NSC168466, NSC168467, NSC168468, NSC333003, NSC402959 and NSC603988 had no 
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previously established anti-mycobacterial activity. However, a few of them were previously 
tested in other biological assays (non-Tb assays) in which they appeared as inactive 
(PubChem database). All compounds were then selected for further biological/toxicity 
evaluation and characterization. 
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Table 3.6: Validated M. tuberculosis inhibitors from the NIH library 
Compound     Mycobacterial Species (MIC µM)  
    M. tuberculosis  M. bovis BCG  M. smegmatis 
NSC15381   0.781   0.39   nd 
NSC16865   12.5   25   6.25 
NSC62709   12.5   50   25 
NSC61586   1.56   25   25 
NSC64111   25    50   50 
NSC145611   6.25   50   100 
NSC145612   50   >100   >100   
NSC168466
•
   1.56   >100   >100 
NSC168467
•
   12.5   >100   >100 
NSC168468
•
   3.125   >100   >100 
NSC333003
•
   1.56   >100   >100 
NSC402959   12.5   25   >100 
NSC603988   0.39   0.39   nd  
Some compounds (•) did not exhibit inhibitory activity in dose-response assays against M. bovis BCG for up to 
maximum concentration tested (100 µM) and only demonstrated activity against M. tuberculosis (section 3.4). 
Compounds that showed an MIC of at least < 50 µM against M. tuberculosis are listed. nd, not done.  
3.3.1.3.4. Potential M. tuberculosis Inhibitor (NSC402959) and its Biological Activity 
NSC402959 was identified during HTS from NIH chemical library and has not been 
previously reported to have anti-mycobacterial effect. It has been found active in previous 
screens for an E. coli RNase HI (PubChem database). It was also tested against a number of 
cell lines in this study and its cytotoxicity appeared to be in an acceptable range with an IC50 
for both HL-60 and J774 cell lines being >150 µM (Figure 4.13 and Figure 7.8, respectively). 
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NSC402959 called attention towards the identification of a novel class of M. tuberculosis 
inhibitors (Chapter 5). Figure 3.12 shows bacteriostatic activity of NSC402959 against M. 
tuberculosis H37Ra. 
 
 
Figure 3.12: Dose-response of NSC402959 against M. tuberculosis H37Ra. MIC against the avirulent M. 
tuberculosis species (H37Ra) was 12.5 µM. NSC402959 also exhibited a similar level of inhibitory activity 
against virulent Tb model, M. tuberculosis H37Rv (also see Figure 4.12 and Figure 7.7). 
3.3.1.3.5. Structural Analogues of NSC402959 
Two structurally related compounds NSC15381 and NSC603988 were imported individually 
from the NIH compound repository (section 4.5). Being structurally similar (Figure 4.14), 
they were expected to show anti-mycobacterial activity. In dose response assays, they were 
found to be highly active against M. tuberculosis H37Ra with an MIC of 0.781 µM and 0.39 
µM, respectively (Table 3.6). NSC15381 also exhibited inhibitory activity against clinical 
strains tested being the highest activity against S. aureus with an MIC of 12.5 µM (Figure 
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3.13). However, unlike NSC402959, its structural analogues were toxic to HL-60 cell line 
compared to controls (section 3.3.1.3.7).  
3.3.1.3.6. Activity of the NSC402959 Analogue NSC15381 against Clinical Strains 
 
Figure 3.13: Activity of NSC15381 against clinical strains. Unlike NSC402959, its structural analogue 
NSC15381 showed a better inhibitory activity against S. aureus ATCC 25923 (IC50 8.8 µM ± 0.81) and mild 
inhibitory activity against P. aeruginosa ATCC 25668 and E. coli ATCC 25922. (±) sign indicates the standard 
error between triplicate readings. 
3.3.1.3.7. Cytotoxic Effect of NSC402959 Structural Analogues 
While NSC402959 was not itself cytotoxic to HL-60 cell line, both of its analogues 
(NSC15381 and NSC603988) showed toxicity against human cells (Figure 3.14). 
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Figure 3.14: Cytotoxicity of NIH compounds against HL-60 cell line. Despite good anti-mycobacterial 
activity, both compounds NSC15381 and NSC663988 exhibited toxicity towards HL-60 with 50% inhibitory 
concentrations of 3.77 µM and 8.90 µM, respectively. 
3.3.1.4. Library of New Zealand Native Plant Extracts 
Natural products from plants have long been recognised as potential therapeutics and used for 
various medicinal purposes in history [319-324]. Several plant extracts are known to have a 
wide range of antimicrobial activity. To test NZ native plants for their anti-mycobacterial 
activity, a mini library containing more than 50 plant extracts was prepared as described 
(section 2.6.1, E). Growth inhibition assays for M. bovis BCG were performed as described 
(section 2.7.2.1). Six plant extracts were found to be active against mycobacteria (Table 3.7). 
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Table 3.7: Anti-Tb activity of native New Zealand plant extracts  
Plant   Part  Extract           BCG          Mtb 
           MIC           IC50           MIC      IC50 
L novae-zealandiae* Bark  Aqueous  1.5 0.54 ± 0.03 4.16 2.39 ± 0.33 
L. bullata  Leaf  Methanol 3.12 2.59 ± 0.43 6.51 4.59 ± 0.32 
M. exelsa  Flower  Methanol 3.13 1.12 ± 0.12 4.18 2.19 ± 0.76 
P. tenuifolium  Leaf  Ethanol >10 5.37 ± 1.35 1.25 0.51 ± 0.11  
P. crassifolius  Leaf  Methanol 6.25 4.08 ± 1.76 3.58  1.74 ± 0.18  
P. colorata  Leaf  Methanol 7.15 5.95 ± 1.28 7.15 3.66 ± 0.39 
Control (rifampicin)   –       –  0.12 4.94 x 10-5 2.06   4.84 x 10-5 ± 
       x 10
-3
 ± 5.02 x 10
-6 
x 10
-4
   4.03 x 10
-5
  
*Laurelia novae-zealandiae was the only plant species in NZ biota that was previously used for traditional 
treatment of Tb lesions in Mâori populations [325]. MIC and IC50 values are given in mg/mL along with means 
of standard error (±). Only extracts with activity against slow-growing mycobacteria are listed. 
New Zealand native plant species have been used previously for a range of medicinal 
remedies [326]. New Zealand plants extracts were found to be active against mycobacterial 
strains in this study and their validated anti-tubercular activity against M. tuberculosis H37Ra 
indicated the medicinal potential as well as the diverse flora of this country [241]. Future 
research will determine their therapeutic efficacy to confirm whether these plant species can 
be developed as a remedy to treat human infections including Tb. 
3.3.1.5. 96-well Plate Template Used for HTS  
Figure 3.15 shows an HTS template along with a positive hit (at position, 5B) and the 
arrangement of controls for high throughput screening performed in this study.   
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Figure 3.15: A diagram of an HTS 96-well plate. Diagram shows a plate map for controls and a possible hit at 
plate position 5-B (red square). This compound caused complete growth inhibition of M. bovis BCG (5-B) 
compared to 100% growth controls (at positions 12 C-F). Cells viability was determined with GFP fluorescence 
(as shown in green). 
3.3.2. Data Analysis from HTS  
3.3.2.1. High-throughput Screening Data Normalization 
Data recovered from HTS were initially processed in Excel spread sheets. All OD600 and GFP 
fluorescence values were normalized against blanks (without cells), 100% growth controls 
and no growth controls in order to get percentage values for each well. 
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3.3.2.2. Statistical Analysis 
One of the problems with analysing high throughput data is the large amount of data output. 
Statistical significance was taken into account when analysing the data generated to ensure 
reliable results as there are often false positive hits in the screens. The signal-to-noise ratio 
(S/N) was calculated to remove any outliers that could affect screening results. 
3.3.2.2.1. Z-factor Calculations 
The solvent and 100% growth controls represented maximum signals while the positive 
controls (known anti-Tb drugs, rifampicin or isoniazid) yielded minimum-to-no signal. The 
z-factors for all screens were calculated using the formula below as previously described by 
Zhang et al. [327].  
Z-factor = 1 – (SD of sample + SD of control) 
    Mean of sample – mean of control 
 
3.3.2.3. Duplicate Screen Correlation 
A duplicate screen was performed against each mycobacterial species, and screening results 
were directly compared for the total number and types of hits that appeared in both screens. 
The two data sets were statistically correlated. The R
2
 value represents a linear correlation 
between two screens and indicates consistency and reliability of the results from screens 
performed under identical conditions (Figure 3.16).   
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Figure 3.16: Correlation of LOPAC screens performed against M. bovis BCG and M. tuberculosis H37Ra. 
After taking average OD600 values across rows for each library plate, a significant linear correlation (R
2 = 
0.8015) was observed between the two (data sets) screens performed against both species. Hits that appeared 
against initial M. bovis BCG screens were expected to show similar inhibitory activity when screened against M. 
tuberculosis H37Ra. 
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Table 3.8: Comparison of library hits against M. bovis BCG and M. tuberculosis 
Chemical Library  Compounds   Total No of hits in HTS
1
 
       M. bovis BCG  M. tuberculosis  
LOPAC   1280    38   37 
Spectrum   1990    67   62 
NIH-DS
2
   2000    76   51 
NIH-NPS
3
   240    37   44 
Total Compounds  5510    218   194  
1Comparison of total number of hits that were identified against both species in HTS (an average of triplicate 
screens). 2Diversity Set from National Institutes of Health. 
3
Natural Product Set. (M. bovis BCG hits 3.95%, M. 
tuberculosis 3.5%). 
 
 
Figure 3.17: Number of common hits between M. bovis BCG and M. tuberculosis H37Ra. More than 60% 
of the hits were common between both mycobacterial species.   
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3.3.3. Criteria to Remove Promiscuous Compounds Identified by HTS  
Use of a GFP reporter system and comparing results with OD600 measurements proved useful 
for establishing a reliable data analysis and correlation, as well as for determining false-
positive hits. If a compound had been identified as a positive hit in previous assays reported 
in the literature and appeared to have multiple targets or biological activities in humans, such 
compounds despite their novel anti-tubercular activity, were deemed as interference 
compounds and were filtered out of our active compound database, as described previously 
by Jonathan et al. [328].  
3.3.3.1. Embedded HTS Controls and Tb Screening Models 
Apart from controls and reference drugs used in this study, some previously-reported 
mycobacterial inhibitors from our lab were used as additional controls for HTS. These 
include idarubicin, resveratrol, methoctramine, 1-10 phenanthroline and pentamidine [252]. 
The selection of hits was variable between each Tb models used in HTS (Chapter 4).  
3.3.3.2. Selection of Leads 
There were many novel compounds identified as potentially active at the completion of HTS 
listed tables 3.4-3.6. Most hits had a range of biological targets (PubChem database); 
however, only a few of them were amenable in this research format due to the selection 
criteria as described (section 3.3.1.1.4) therefore, only a few compounds have been 
considered appropriate for further characterization.  
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3.4. Discussion 
New anti-Tb compounds that are structurally different from existing drugs and have a novel 
mechanism of action are needed. Novel drugs would help reducing the lengthy Tb treatment 
time [329]. The HTS part of this research has identified several mycobacterial inhibitors that 
should be considered for further development as novel anti-Tb drugs. Among active anti-M. 
tuberculosis compounds identified in this study, some inhibitors exhibited significant 
cytotoxicity towards mammalian cells lines HL-60 and J774 therefore, such inhibitors were 
excluded from further characterization (section 3.3.1.1.4). However, a few compounds with 
unique chemical structures and presumably with unique mechanisms of action were identified 
(e.g. NSC402959, Table 3.6) that were not toxic to human cells compared to positive controls 
and such compounds were considered to be suitable lead compounds. While identification of 
inhibitors is the initial step in anti-Tb drug discovery, there are a number of experimental 
phases involved that enable prioritizing of selected compounds before these can be entered 
into the development phase [265]. Therefore these hits were further characterized in the 
present study as potential leads for the development of anti-mycobacterial drugs. 
Comparative Activity of NIH Hits with LOPAC and Spectrum Compounds 
NSC402959 was one of interesting compounds detected from the NIH Diversity set in the 
present study. It showed consistent activity against M. tuberculosis H37Ra and displayed low 
cytotoxicity against human cells (IC50 >150 µM). NSC402959 was also validated against 
virulent M. tuberculosis strain (H37Rv) and was found to have a similar activity against both 
the virulent and the avirulent strains (MIC 12.5 µM). Information on NSC402959 from the 
PubChem database revealed that it inhibited RNase HI from E. coli previously. BLAST 
analysis of E. coli RNase HI showed approximately 31% similarity with M. tuberculosis 
RNase HI. After the confirmation of NSC402959‟s inhibitory activity across a range of 
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mycobacterial strains in vitro, it was hypothesized that it may be targeting the same enzyme 
in M. tuberculosis. This hypothesis was to be tested for further development of a novel class 
of M. tuberculosis inhibitors (Chapter 5).  
Sappanone A Methyl Ether 
Sappanone A dimethyl ether was discovered as a novel anti-mycobacterial compound from 
the Spectrum library (Table 3.5). It is derived from Caesalpinia sappan L, a flowering tree 
which is common in South East Asia and belongs to the family Caesalpiniaceae [330]. 
Compounds extracted from Caesalpinia sappan are Sappanone A/B and Brazilin. Some other 
compounds have also been isolated from this species that include flavonoids and phenolics, 
which are responsible for a range of biological activities. Apart from the commercial use of 
sappanwood, (e.g. paint/ink production from wood extracts) this plant species is known to 
have anti-bacterial and anti-oxidative activity. However, to our knowledge no previous 
reports have been made with respect to its specific anti-M. tuberculosis activity.   
Biological and therapeutic activities of Caesalpinia sappan L (Brazilin, Sappanone A and B) 
have been well documented [331]. For example, its traditional medicinal use as an 
anticonvulsant [332], anti-complementary agent [333], its possible hepatoprotective effect 
[334] and anti-viral activity [335] have been reported previously. It has also been traditionally 
used for skin diseases, as an anti-acne agent, and an agent for healing of wounds and skin 
burns as well as for remedial use for leprosy infections [336-337].  
A structural analogue of sappanone A [338], and its derivative 3-deoxysappanone B have also 
been reported as useful for medicinal purposes in the Encyclopaedia of Traditional Chinese 
Medicines [339]. Furthermore, Vidavalur et al. have recently evaluated the anti-oxidative 
potential of sappanone A and have shown that it was better than other commercially-available 
dietary anti-oxidants such as vitamin C and vitamin E and could be used for patients suffering 
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from asthma [340]. Other research efforts are underway to further evaluate the medicinal 
potential of Caesalpinia sappan [341]. Based on its inhibitory effect towards M. tuberculosis 
in the present study (99% growth inhibition in vitro, Table 3.5), further research is warranted 
to investigate its specific therapeutic potential for Tb. 
 
Figure 3.18: Chemical structure of sappanone A, a novel anti-Tb compound identified from the Spectrum 
library (A) Chemical structure of sappanone A, an active component of Caesalpinia sappan.  MW 312.33 
g/mol, MF C18H16O5 and (B) Pictures of C. sappan [342]. 
Key Biological Activity and Importance of Potential Hits 
Several mycobacterial inhibitors identified from the NIH library appeared to be specific in 
the inhibition of M. tuberculosis H37Ra upon validation. For example compounds NSC64111, 
NSC145611, NSC168466, NSC168467, NSC168468, NSC333003 and NSC402959 exhibited 
specific anti-M. tuberculosis activity (Table 3.6). None of these compounds were active 
against M. smegmatis in HTS nor did they show anti-M. bovis BCG activity in the dose 
response assays. The anti-Tb activity of compounds NSC168466, NSC168467 and 
NSC168468 may be due to their similar chemical structures (Figure 4.9). However, 
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NSC333003 is structurally different from these compounds (PubChem database) yet it 
exhibited similar level of inhibitory activity against M. tuberculosis and there have been no 
previous anti-Tb data available for NSC333003. These inhibitors were identified as hits 
against M. bovis BCG in HTS, but upon validation experiments they did not exhibit 
inhibitory activity at concentrations up to 100 µM (Table 4.2). Dose-response assays provide 
a more reliable measure for compound‟s activity and these M. tuberculosis-specific inhibitors 
were mostly inactive against M. bovis BCG upon validation. These compounds were 
therefore considered as false positive hits in the library screens. However, specific activity 
against M. tuberculosis but not M. bovis BCG suggests that there may be unique targets for 
such inhibitors in M. tuberculosis, given the small genetic difference between M. bovis BCG 
and M. tuberculosis.  
Some compounds that are highly active against M. tuberculosis in vitro may not show 
inhibitory activity against an established infection in vivo. Pethe et al. have presented 
examples from their study, in which they found M. tuberculosis inhibitors in vitro that 
possessed little or no activity in vivo [343]. While some compounds detected from the 
LOPAC, Spectrum and NIH libraries in the present study had no previous data for showing 
activity against Tb, many of them had been previously reported as anti-bacterial. A few 
inhibitors had recently been reported as anti-tubercular compounds e.g. cloxyquin [311]. 
However, anti-mycobacterial compounds from NIH library such as NSC333003, which 
showed marked inhibitory activity against M. tuberculosis, consistently, in at least three 
independent experiments, had also been reported to be active in a number of other screens 
including human proteins (PubChem database), suggesting that such inhibitors may not be 
suitable to be developed into drugs. A group of inhibitors were found to be active against M. 
bovis BCG but not against M. tuberculosis, and similarly, some compounds were active 
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against M. smegmatis but had no activity upon later validation in the M. tuberculosis model 
used in this study (section 4.4.6.2).  
3.5. Conclusion 
In conclusion, after successfully developing a growth inhibition assay for the slow-growing 
mycobacterial strains (M. bovis BCG and M. tuberculosis H37Ra), a number of M. bovis 
BCG inhibitors were identified that were validated in M. tuberculosis H37Ra. The most 
promising of these anti-Tb compounds was NSC402959 with no previously reported anti-
mycobacterial activity. Therefore, such compounds were considered to be novel growth 
inhibitors of M. tuberculosis in vitro. Further experimentation on these inhibitors for their 
anti-M. tuberculosis activity in vivo would help establish whether these inhibitors should be 
further developed as novel anti-Tb drugs.  
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Chapter 4 
Comparison of in vitro Models Used for Anti-Tb Drug Discovery 
 
Chapter Four – Tuberculosis Models Comparison  
 
120 
 
4.1. Introduction 
Due to a leading cause of death and increase in trend of drug-resistant strains [344], Tb drug 
discovery is one of the greatest challenges today [259, 345-346]. This has led to the search 
for new and more effective compounds against Tb and other human infections [347-348]. 
However, over the last three decades, less than 1% of 1556 new chemical entities introduced 
to global market for disease control were dedicated for the treatment of Tb [349]. An 
acceleration in the process of anti-Tb drug discovery is clearly needed to strengthen more 
than 40 years old Tb treatment regimen with more effective drugs that are also active against 
persistent M. tuberculosis [122]. One of the key aspects towards success of finding a new 
disease treatment is to have new compounds with novel mechanisms of action [350]. A new 
mechanism of action means drugs may retain their activity against some of the more resistant 
Tb strains. To screen for such drugs, this study first determined the applicability of various 
available in vitro screening models for anti-Tb drug discovery.  
4.1.1. Models for Tb Drug Discovery 
Various experimental models have been used for anti-Tb drug discovery and related Tb 
research to date [239, 351]. However, each model differs with respect to its sensitivity and 
reliability for specific mycobacterial inhibitors. While M. tuberculosis H37Ra was used to 
validate anti-BCG compounds identified (due to lack of a PC3 facility at Victoria University), 
subsequent validations studies for selective novel inhibitors were performed against M. 
tuberculosis H37Rv at Johns Hopkins Centre for Tuberculosis Research (Figure 4.1). 
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4.1.1.1 Comparison of H37Ra and H37Rv Strains 
While M. tuberculosis H37Ra has been considered a suitable model organism in primary 
screening to identify compounds that are likely to show anti-Tb activity [352], a close 
correlation in drug susceptibility data was observed in this study between M. tuberculosis 
H37Ra and M. tuberculosis H37Rv (Figure 3.12 and Figure 4.12). Based on the previous 
drug susceptibility reports [352-353] and a high genome similarity between M. tuberculosis 
H37Ra and M. tuberculosis H37Rv (98.9% of H37Rv genes have orthologues in H37Ra 
using a protein similarity cut-off of 50%), a good correlation between these two strains in 
library screens was expected (section 4.3). Since it is apparent from the available data that M. 
tuberculosis H37Ra could be a good model for M. tuberculosis H37Rv in drug screening, it 
was selected as one of the reference strains in this work, in conjunction with the other 
screening models of a slow growing species, M. bovis BCG and a fast growing species, M. 
smegmatis (Table 2.1 and Table 3.2).  
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Figure 4.1: In vitro models for anti-Tb drug screening. Three avirulent Tb models M. smegmatis mc2155, M. 
bovis BCG Pasteur 1173P2 and M. tuberculosis H37Ra (red) were employed in this study (PC2 lab at VUW) 
including validation studies by using H37Rv (green) in a PC3 facility at Johns Hopkins Centre for Tuberculosis 
Research.   
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Figure 4.2: Allocated funding for Tb research and development in 2010. Over 226 million US dollars were 
spent on the search for new drugs (36.7%) to cure Tb, which was more than any other Tb-related funding in the 
year 2010 [354].  
The above statistical figure indicates the urgency for the search of new drugs for treating and 
containing Tb infections worldwide. To conduct this research, an appropriate in vitro model 
is required for reliable screening of potential inhibitory compounds. 
 
4.2. Goals of This Study 
1. To evaluate the efficacy of the M. smegmatis model for the discovery of M. tuberculosis 
growth inhibitors. 
2. To determine the sensitivity of M. bovis BCG as a reliable screening model for drug 
discovery.  
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4.3. Comparative Genomic Analysis 
 
4.3.1. M. tuberculosis H37Rv Genome 
M. tuberculosis H37Rv is the widely used laboratory strain in Tb research due to its virulence 
in vivo and drug susceptibility [355]. The complete sequencing of M. tuberculosis H37Rv 
genome was accomplished in 1998 [17] and has undoubtedly helped researchers to 
understand Tb pathology and to develop efficient Tb diagnostic tools [356]. M. tuberculosis 
H37Rv has a GC rich genome (GC and AT contents 65.6% and 34.4% respectively) with 
over 4000 protein-coding genes (Figure 4.3) and is capable of synthesizing essential enzymes, 
co-factors and amino acids required for its growth under aerobic and anaerobic conditions 
[17-18]. M. tuberculosis genome sequences and annotations (first performed by Cole et al. 
[17]), has facilitated the development of new drugs and identification of their respective 
cellular targets.  
4.3.1.1. M. bovis BCG Genome Comparison with M. tuberculosis  
M. bovis genome was sequenced in 2003 and bears more than 99% similarity with M. 
tuberculosis at DNA level [56]. M. bovis BCG Pasteur 1173P2 is the Tb vaccine strain 
developed through repeated in vitro passages of M. bovis (section 1.3.2.1). Its complete 
genome sequencing was published in 2007 (Figure 7.13), which contains 3954 protein-coding 
genes [357] compared to 4034 protein-coding genes in H37Ra. Since the establishment of M. 
bovis BCG as a vaccine, it has been used for a number of research purposes [358-360] 
including drug susceptibility testing and random screening for inhibitors [361-363]. M. bovis 
BCG possesses a higher genome similarity with M. tuberculosis species than other screening 
models used for anti-Tb drug discovery (section 4.4.8). While a high percentage of protein-
coding genes are common between M. bovis BCG and M. tuberculosis H37Ra, approximately 
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30% of M. tuberculosis genes lack conserved orthologues in M. smegmatis compared to only 
3% in M. bovis BCG, making M. bovis BCG the preferred choice for modelling the Tb 
bacterium as compared to M. smegmatis. Furthermore, due to a closer genetic relationship 
with M. tuberculosis and non-virulent nature of M. bovis BCG [364-365], it was considered 
as an apt model system for the screening of M. tuberculosis inhibitors. This study was 
therefore designed to examine if M. bovis BCG is more sensitive and relevant than M. 
smegmatis for modelling M. tuberculosis. Growth conditions and culture requirements for 
these species are described in section 2.2. 
M. bovis BCG has three large genomic deletions (regions of difference) referred to RD1, RD2 
and RD3 compared to M. tuberculosis H37Rv (section 1.3.2.1). Mahairas et al. have 
evaluated these genetic differences between strains and have identified the sizes of (RD1-
RD3) genomic deletions to be 9.5 kb, 10.7 kb and 9.3 kb, respectively [62]. Unlike M. bovis 
BCG, genomic regions (covering RD1-RD3) are present in H37Rv genome and are 
conserved in other virulent mycobacterial species. RD1 encodes for several mycobacterial 
regulatory factors mainly associated with virulence (secretary antigens) such as ESAT6 and 
CFP10 (expressed by genes present in RD1), whose restoration in M. bovis BCG results in 
restoration of a protein profile nearly identical to M. bovis and M. tuberculosis H37Rv [62-63, 
366]. RD1 sequence can therefore be used as a target to differentiate M. bovis BCG from 
other MTBC species through PCR [367]. These large deletions of genomic regions are 
associated with mycobacterial survival and growth in vivo [368] and may even provide 
resistance to some drugs. In vitro evidence suggests that M. bovis BCG containing RD2 (M. 
bovis BCG-Japan, BCG-Russia and BCG Moreau) were resistant to macrolides compared to 
other macrolide-susceptible BCG strains including BCG-Pasteur, which did not had RD2 
[369]. Previous studies do suggest multi-drug efflux activity in M. tuberculosis [201, 358], 
and more recently, a regulator of mycobacterial efflux pump (Rv3066) has been described by 
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Bolla and Do et al. [370]. These pumps are associated with mycobacterial virulence as they 
play a vital role in conferring drug resistance by up regulating genes that encode for efflux 
pump and membrane proteins. Mutation in rpoB (β-subunit of RNA polymerase) gene leads 
to rifampicin resistance in M. tuberculosis has recently been associated with efflux [371-372], 
a similar efflux-related activity is responsible for pyrazinamide resistance [373-374]. It is 
therefore believed that efflux pumps are used to export drugs out of the cell thereby 
conferring intrinsic resistance to antibiotics [375], e.g. Rv1285c gene (encodes for the tap 
efflux pump) in M. bovis BCG is responsible for altered drug susceptibility and for inducing 
phenotypic change that affects cell growth [376]. Inhibitors that are able to block the activity 
of multi-drug efflux pumps can reverse the situation [358, 377-378]. However, an inhibitor 
has to evade the bacterial efflux pumps and get through the cell wall barriers to be able to 
effectively inactivate its cellular target [379], particularly an anti-mycobacterial agent [380]. 
Since, enhanced expression of genes encoding for multi-drug efflux pumps may extrude a 
wide range of drugs [376, 381], therefore, this should be considered while selecting lead 
compounds for in vivo studies. 
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Figure 4.3: The genome of M. tuberculosis H37Rv. Figure reproduced with permission from Cole et al. [17]. 
 
4.3.2. M. smegmatis Controversy in the Tb Field 
M. smegmatis is a fast growing mycobacterial species which replicates every 2-3 hours [382]. 
It has been used with a number of other species for in vitro modelling in Tb research [239, 
383]. M. smegmatis is a saprophytic mycobacterial species [384], and has been widely used 
in Tb research [385-390]. A letter entitled “Mycobacterium smegmatis: an absurd model for 
tuberculosis?" [391] provoked a useful discussion with respect to M. smegmatis applicability 
in studying Tb [392-393]. Furthermore, lack of M. smegmatis ability to survive within 
macrophages [394-396] and to cause a significant virulence within in vivo models have been 
shown previously [397], controversy therefore appeared to persist with respect to its ability to 
mimic the hallmark of Tb.  
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Although widely used as a convenient model organism, few if any studies have been 
conducted to determine the efficacy of M. smegmatis in drug screening. In this study, a direct 
comparison of M. smegmatis with another Tb model, M. bovis BCG was performed to detect 
novel inhibitors of M. tuberculosis by screening chemical libraries. Parallel screens were 
performed against a third Tb model, M. tuberculosis H37Ra under identical growth 
conditions, and the data produced from HTS were analysed to determine similarities and 
differences between these screening models (section 4.4). 
 
4.4. Results 
4.4.1. Results from Library Screens 
Three compounds libraries (section 2.6) were screened to identify inhibitors of mycobacterial 
growth. The anti-mycobacterial compounds identified with each Tb models were then 
compared for similarities. 
4.4.2. Comparison of M. tuberculosis Hits Identified Using Different Tb Models 
The inhibitors detected in HTS of the compound libraries using the three Tb models used in 
this study (Figure 4.1) were compared. The compounds were grouped on the basis of their 
inhibitory activity against one or more of the mycobacterial species. Using the selection 
criteria outlined in section 3.3.1.1.4, a total of 14, 27 and 24 hits were detected against M. 
smegmatis, M. bovis BCG and M. tuberculosis, respectively using the LOPAC library (Figure 
4.4). In the Spectrum Collection 36, 65 and 45 hits were obtained (Figure 4.7) and in the NIH 
Diversity Set 69, 126 and 91 hits were detected (Figure 4.8).    
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After analysing the data from the screens, it was obvious that a majority of anti-
mycobacterial inhibitors identified using the LOPAC library against M. smegmatis (n=12, 
85.7%) were also detected as being active against M. tuberculosis. However, a significant 
number of anti-M. tuberculosis compounds were not detected using M. smegmatis in the 
LOPAC library. At least 50% of the hits (n=12) were missed in the screens with M. 
smegmatis as a model organism for the detection of anti-mycobacterial compounds. A 
different situation existed for M. bovis BCG as only 5 hits (21%) of the M. tuberculosis hits 
were not detected with M. bovis BCG from the LOPAC library. Furthermore, the percentage 
of hits that were common between M. bovis BCG and M. tuberculosis H37Ra (33%) was 
higher than the number of hits (4%) that were common between M. tuberculosis and M. 
smegmatis (Figure 4.4). These results confirm M. bovis BCG as a more suitable model of Tb 
than M. smegmatis. 
To examine if the above findings were unique to LOPAC, the other two sets of chemical 
libraries, the Spectrum collection and the NIH Diversity Set were also screened against all 
model organisms. An even higher number of M. tuberculosis H37Ra hits in the Spectrum 
Collection were absent in M. smegmatis HTS i.e. 55.5% of the M. tuberculosis H37Ra (n=26) 
and 48.3% (n=44), respectively. However, the majority of inhibitors identified in these two 
compound libraries with M. smegmatis were also detected as active against M. tuberculosis 
H37Ra. Thus 50% of the M. smegmatis hits from the Spectrum collection were also seen with 
M. tuberculosis (n=18) and 68% of the hits from the NIH library were also seen in M. 
tuberculosis (n=47). Only 13.3% of M. tuberculosis hits (n=6) from the Spectrum Collection 
and 6.6% (n=6) from the NIH Diversity set were not also detected with M. bovis BCG. These 
data again suggest that the ability of M. bovis BCG to identify inhibitors in HTS that are also 
active against M. tuberculosis is better than M. smegmatis (Figures 4.7 and 4.8). 
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4.4.3. Dose-response Assays for the Validation of Mycobacterial Inhibitors 
All dose-response assays for validation of HTS hits were performed as described in section 
2.7. Compounds identified from LOPAC and NIH screens were validated for their inhibitory 
activity against all three model species. Compounds yielding an MIC of <25 µM against M. 
tuberculosis from the LOPAC and NIH Diversity set are listed in tables 4.1 and 4.2, 
respectively. Individual examples of compounds that were not detected with M. smegmatis 
but were identified with M. bovis BCG and inhibitory activity was validated in M. 
tuberculosis are noted in sections 4.4.4 and 4.4.6. 
4.4.4. LOPAC Compounds  
Hits obtained from the screens against the three mycobacterial species were compared and a 
Venn diagram was drawn to examine the difference between the ability of each species to 
detect M. tuberculosis inhibitors (Figure 4.4). Mycobacterial inhibitors identified from the 
LOPAC library that were detected by the slow growers but were not detected with M. 
smegmatis are listed in table 4.1. These inhibitors included ammonium pyrrolidine 
dithiocarbamate (APDC), 2-chloroadenosine, fusidic acid and tetraethylthiuram disulphide 
(TETD). APDC was detected only when M. bovis BCG was used in the screens and it was 
also validated against M. tuberculosis. MICs for APDC against M. bovis BCG and M. 
tuberculosis were 1.56 µM and 0.781 µM respectively (Figure 4.5). There was no anti-M. 
smegmatis activity of APDC observed at the highest concentration tested (100 µM) (Table 
4.1). Similarly, TETD was not detected with M. smegmatis but M. bovis BCG, and was 
validated in M. tuberculosis H37Ra (Figure 4.6). 
Niclosamide is a known inhibitor of M. tuberculosis, but it was not detected with M. 
smegmatis in this study. However, it did exhibit inhibitory activity against M. smegmatis in 
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dose-response experiments with an MIC of 25 µM. It was only identified in the M. bovis 
BCG HTS and it showed good activity against both M. bovis BCG and M. tuberculosis in a 
validation experiment with an MIC of 6.25 µM against both Tb strains (Table 4.1).  
 
 
Figure 4.4: Venn diagram for the LOPAC library showing the distribution of mycobacterial compounds 
detected with M. smegmatis mc2155, M. bovis BCG Pasteur 1173P2 and M. tuberculosis H37Ra. A total of 14, 
27 and 24 hits were detected against M. smegmatis, M. bovis BCG and M. tuberculosis H37Ra, respectively, in 
the LOPAC library. 
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Table 4.1: Validated mycobacterial inhibitors from the LOPAC library 
LOPAC Compound           MIC Values (µM) 
      M. smegmatis    M. bovis      M. tuberculosis 
Ammonium pyrrolidine dithiocarbamate   >100      1.56   0.781 
2-Chloroadenosine           >100      12.5   12.5 
Demeclocyclin dichloride         3.125      3.125  1.56 
Dequalinium dichloride         3.125      3.125  6.25 
Diphenyleneiodonium chloride        3.125      0.195  0.39 
Ellipticine           25                      12.5   12.5 
Fusidic acid sodium          >100      3.125  1.56 
Idarubicin           3.125      6.25   6.25  
Lomefloxacin hydrochloride         6.25      1.56   3.125  
Methoctramine hydrochloride        12.5      1.56   6.25  
Minocycline hydrochloride         12.5      1.56   3.125  
Niclosamide           25       6.25   6.25 
Ofloxacin           3.125      1.56   1.56 
Tetraethylthiuram disulphide         >100      3.125  6.25  
WB-64           12.5      12.5   12.5 
Underlined MIC values indicate M. tuberculosis inhibitors that were detected with M. bovis BCG during 
screening but not with M. smegmatis. Compounds were tested up to a maximum concentration of 100 µM across 
all species. Only LOPAC compounds which yielded an MIC of 12.5 µM against M. tuberculosis upon validation 
in dose-response assays are listed.   
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Figure 4.5: Dose-response curve of ammonium pyrrolidine dithiocarbamate against mycobacteria. Three 
mycobacterial species are M. smegmatis mc2155 (green), M. bovis BCG Pasteur 1173P2 (blue) and M. 
tuberculosis H37Ra (red). 
 
Figure 4.6: Dose-response curve of tetraethyl thiuramdisulphide (TETD) against mycobacteria, M. 
smegmatis mc2155 (green), M. bovis BCG Pasteur 1173P2 (blue) and M. tuberculosis H37Ra (red). There was 
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no inhibitory activity of TETD observed against M. smegmatis at concentrations up to 100 µM. TETD was 
identified in the M. bovis BCG screen (MIC 3.125 µM) but not with M. smegmatis screen (MIC >100 µM) and 
was validated against M. tuberculosis H37Ra (MIC 6.25 µM). 
4.4.5. Spectrum Collection  
Sappanone A was identified as a hit during Spectrum screens using M. bovis BCG. It was 
also identified as an active compound in the M. tuberculosis screen but was not detected with 
M. smegmatis. Sappanone A dimethly ether has no previously reported anti-M. tuberculosis 
activity and may therefore be a potential novel candidate for further development as an anti-
Tb agent (section 3.3.1.2.4). These differences in the identification of M. tuberculosis-
specific inhibitors using different Tb models demonstrate the importance of selecting an 
appropriate in vitro Tb model prior to screen for active inhibitors.   
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Figure 4.7: Venn diagrams for Spectrum library (A) Number of hits identified across the three mycobacterial 
species, M. smegmatis mc2155 (36 hits), M. bovis BCG Pasteur 1173P2 (65 hits) and M. tuberculosis H37Ra (45 
hits) and (B) Percentage of inhibitors detected in the total library. The total number of hits detected for each 
library were in agreement with the Venn diagram and also fulfilled our hit selection criteria of ≥75% inhibitory 
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activity and growth inhibition in at least 2 out of 3 independent screens (at 20 µM) for designation of 
compounds as anti-mycobacterial.  
4.4.6. NIH Diversity Set  
The two anti-mycobacterial compounds identified from the NIH Diversity set, NSC145611 
and NSC402959, were only identified using an M. bovis BCG model in the screens. These 
compounds demonstrated a significant growth inhibitory activity in dose-response assays 
against M. bovis BCG and upon subsequent validation experiment against M. tuberculosis 
H37Ra but not against M. smegmatis mc
2
155 at the maximum concentration tested (100 µM). 
The anti-M. tuberculosis activity of NSC145611 and NSC402959 was 6.25 µM and 12.5 µM 
(MIC), respectively (Table 4.2).     
 
Figure 4.8: Venn diagrams for the NIH Diversity Set (A) Distribution of mycobacterial compounds detected 
in M. smegmatis mc2155 (69 hits), M. bovis BCG Pasteur 1173P2 (126 hits) and M. tuberculosis H37Ra (91 hits) 
and (B) Percentage of inhibitors detected. Among the M. bovis BCG exclusive hits (26%), most compounds also 
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exhibited inhibitory activity against M. tuberculosis H37Ra in dose-response assays with only a slight difference 
in MIC values (data not shown).  
4.4.6.1. M. tuberculosis Specific Inhibitors 
Not all M. tuberculosis inhibitors were detected in the screens with M. bovis BCG. For 
example, NSC168467 was not detected in either of the screening models, yet exhibited a 
significant anti-M. tuberculosis activity upon validation experiments in M. tuberculosis 
H37Ra and therefore such compounds appeared to be M. tuberculosis specific hit in vitro. 
NSC168467 and other NIH compounds from the same series NSC168466 and NSC168468 
are structural analogues of each other (PubChem database). Even though closely related in 
terms of their chemical structures (Figure 4.9), NSC168467 was not detected with M. bovis 
BCG (Table 4.2).  
 
 
Figure 4.9: Chemical structures of anti-M. tuberculosis compounds (A) NSC168466, (B) NSC168467 and 
(C) NSC168468. MW for compounds A, B and C are 277.32 g/mol, 277.3205 g/mol and 308.29 g/mol, 
respectively (PubChem database). 
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As discussed in Chapter 3, many compounds from the NIH library had anti-tumour or anti-
cancerous activity, and despite their potent anti-mycobacterial activity, such compounds were 
not considered for further investigation due to known cytotoxic properties (section 3.3.1.1.4).  
4.4.6.2. False Positive Hits 
Some compounds were detected with M. bovis BCG in the screens but exhibited low anti-
BCG activity at the highest test concentration (100 µM) in the validation studies. These 
include compounds NSC17061, NSC47151, NSC95570, NSC181486, NSC267461 and 
NSC306960. Since these compounds had no anti-mycobacterial activity in the validation 
studies, they were considered to be false-positives. Therefore, if such compounds were not 
found active in any of the three species upon validation in triplicate at the highest 
concentration tested (100 µM), they were excluded from the list.  
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Table 4.2: Validated compounds with anti-mycobacterial activity from the NIH library 
NIH Compound       MIC Values (µM) 
       M. smegmatis             M. bovis BCG     M. tuberculosis 
NSC3907   25   12.5   3.125 
NSC5159   1.56   1.56   1.56 
NSC13480   12.5   12.5   12.5 
NSC17061 •   ≥100   >100   >100 
NSC17600   25   25   25 
NSC31660   50   25   12.5 
NSC51001   12.5   12.5   12.5 
NSC62709   25   50   12.5 
NSC82892   50   25   12.5 
NSC95570 •   ≥100                 >100                 >100 
NSC125066   3.125   3.125   1.56 
NSC145611   ≥100   50   6.25 
NSC168466   >100   >100   1.56 
NSC168467   >100   >100   12.5 
NSC168468   ≥100   >100   3.125 
NSC189794   12.5   25   6.25 
NSC267461   ≥100   ≥100   6.25 
NSC268879   3.125   1.56   3.125 
NSC285116   1.56   6.25   6.25 
NSC305787   25   25   6.25 
NSC306960   >100   >100   12.5 
NSC310551   6.25   12.5   6.25 
NSC311153   25   6.25   6.25 
NSC321206   25   25   3.125 
NSC333003   ≥100   >100   1.56 
NSC363182   50   25   3.125 
NSC402959   >100   25   12.5 
NSC659779   3.125   0.781   3.125 
Underlined values indicate the species in which an inhibitor was detected during screening. All compounds 
which gave an MIC of at least 25 µM in M. tuberculosis upon validation in dose-response experiments are listed. 
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Dose-response assays provide better indication of any differences in the inhibitory profiles, compounds marked 
(•) were detected with M. bovis BCG but had no inhibitory activity against M. tuberculosis H37Ra in validation 
assays and were therefore considered as false-positives. All compounds were tested at concentrations up to 100 
µM.  
4.4.7. Z-factor for Screens  
Data received from HTS were statistically analysed to determine data integrity and fidelity of 
screens from z-factors values calculated (section 3.3.2). Two antibiotic controls were 
included in each plate for HTS, rifampicin and streptomycin. The mean z-factors for 
rifampicin were 0.86 (M. tuberculosis), 0.91 (M. bovis BCG) and 0.95 (M. smegmatis). The 
mean z-factors for streptomycin were 0.87, 0.92 and 0.96 for M. tuberculosis, M. bovis BCG 
and M. smegmatis, respectively. Values for all controls were within the dynamic range of a 
screening window coefficient as described by Zhang et al. [327] suggesting that the screening 
results obtained in this study were reliable.      
4.4.8. Genomic Comparison of the Mycobacteria 
The variation in chemical library inhibitory profiles was compared with the level of variation 
at the genomic level for the three mycobacterial species, M. smegmatis mc
2
155, M. bovis 
BCG Pasteur 1173P2 and M. tuberculosis H37Ra. The Multi-Genome Homology tool (from J. 
Craig Venter Institute, available at http://cmr.jcvi.org/cgi-bin/CMR/CmrHomePage.cgi) was 
used to determine the level of similarity among the conserved orthologues between the three 
species. M. tuberculosis H37Ra was selected as the reference genome; whereas, M. bovis 
BCG Pasteur 1173P2 and M. smegmatis mc
2
155 were selected as comparison genomes. A 
cut-off of at least 50% protein similarity was used to determine similarities and differences 
between the three mycobacterial species. The genome analysis revealed that 2816 (69.8%) of 
the 4034 protein-coding genes of M. tuberculosis H37Ra has orthologues in both M. 
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smegmatis and M. bovis BCG. In addition, 1083 of the M. tuberculosis genes (26.9%) were 
also common to M. bovis BCG but are not present in M. smegmatis. Approximatley 50% of 
the M. smegmatis genome containing 3540 genes do not have conserved orthologues in M. 
tuberculosis H37Ra compared to only 87 genes for M. bovis BCG that lacked orthologues in 
M. tuberculosis H37Ra (Figure 4.10).  
 
Figure 4.10: Comparison of the mycobacterial species for the analysis of conserved orthologues genes across 
M. tuberculosis H37Ra [MTB, (A)], M. bovis BCG Pasteur 1173P2 [BCG, (B)] and M. smegmatis mc2155 
[MSMEG, (E)].  Reference proteins present in all comparison molecules and reference proteins not present in 
any of the comparison molecules are recorded. Using a 50% cut-off for protein similarity, approximately 1000 
M. tuberculosis genes were found to lack conserved orthologues in M. smegmatis in contrast to only 130 M. 
tuberculosis genes were absent in M. bovis BCG (A, B and E present total number of exclusive genes present in 
each species, whereas C, D and F present conserved orthologues between >1 species).      
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4.4.9. Novel M. tuberculosis Inhibitor Identified from the NIH Library 
 Of 2240 compounds screened for inhibitory activity from the NIH library, 60 compounds 
showed anti-M. tuberculosis activity at the 20 µM test concentration. While some compounds 
were known anti-bacterials or anti-Tb agents, many inhibitors had no previously reported 
inhibitory activity. For example, NSC402959 (8-iodo-N-(8-iodo-10-phenyl-5H-phenazin-2-
yl)-10-phenylphenazin-2-imine) was identified from the NIH library screen as a potential 
inhibitor, as it showed good anti-mycobacterial activity and was non-cytotoxic to mammalian 
cells (Figures 3.12 and 4.13, respectively). Furthermore, it was also tested against a virulent 
in vitro model of Tb (M. tuberculosis H37Rv) and retained decent activity with an MIC of 
12.5 µM (Figure 4.12).  
4.4.9.1. Dormicidal Activity of an RNase H compound 
There could be different populations in old in vitro bacterial cultures which could escape 
from potential drug action [398]. It is therefore necessary to evaluate the sterilizing effect of 
inhibitors using in vitro models. The dormicidal effect of NSC402959 was also determined in 
stationary-cidal assays because the new growth inhibitors of MTBC are also expected to be 
active against persisters in order to complement the directly observed short course and to 
reduce the lengthy treatment time for Tb. For the search of potential therapeutic agents that 
are active against non-replicating M. tuberculosis cells, Cole et al. have defined conditions 
for assay to identify such inhibitors [399].  Therefore, in order to examine if the effect of 
novel inhibitors (identified in this study) that are active against exponentially-growing cells, 
also retain similar activity after mycobacterial growth arrest; dormicidal assay was conducted 
(as described in section 2.7.3) with short-listed compounds against M. tuberculosis H37Ra 
(data not shown). NSC402959 showed bacteriostatic activity (rather than dormicidal) against 
M. tuberculosis H37Rv (Figure 7.9). Miller et al. have defined a range of culture/nutrient 
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conditions for specifically selecting anti-mycobacterial compounds. Modifications in the 
culture conditions may have effect over respective inhibitory profiles of anti-mycobacterial 
compounds [252]. In this work, a carbon-limited condition in mycobacterial cultures was 
achieved by reducing the amount of glycerol by 10 fold (from 0.5% to 0.05% v/v) or by 
removing glycerol completely (Figures 7.4, A-D), to examine effect on BCG growth and 
inhibitory activity of the test compounds. Figure 4.11 presents a dose-response curve in a 
nutrient-limited (C-) condition for M. tuberculosis H37Ra. There was no difference observed 
in anti-mycobacterial activity for NSC402959 during carbon starvation compared to nutrient 
rich culture conditions. The MIC for NSC402959 under both conditions against M. 
tuberculosis was in the 6.25 µM to 12.5 µM range (Figure 3.12 and Figure 7.7).  
 
Figure 4.11: Anti-mycobacterial activity of NSC402959 against M. tuberculosis H37Ra under carbon 
starvation. Glycerol concentration for this experiment was 0.05% (v/v) 10 times lower than the standard growth 
condition for the cultivation of slow-growing mycobacteria. 
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Figure 4.12: Growth inhibitory activity of NSC402959 and rifampicin in M. tuberculosis H37Rv. MICs against 
the virulent M. tuberculosis strain H37Rv for NSC402959 and rifampicin are 12.5 µM and 0.19 µM, respectively. 
Studies were conducted under standard PC3 conditions at Johns Hopkins Centre for Tuberculosis Research, USA. 
 
Figure 4.13: Cytotoxicity of NSC402959 against the HL-60 cell line. NSC402959 was not toxic to HL-60 
cells yielding an IC50 of 146 µM, compared to rifampicin control (IC50 >400 µM). 
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4.5. Activity Profile of Structural Analogues of NSC402959 
NSC402959 (8-iodo-N-(8-iodo-10-phenyl-5H-phenazin-2-yl)-10-phenylphenazin-2-imine) 
was identified as a new M. tuberculosis inhibitor in this study during HTS (Chapter 3). Based 
on its activity against mycobacteria, structural homologues of NSC402959 (Figure 4.14 A-B) 
were also imported from the NIH library to determine their efficacy. A preliminary structural 
analysis revealed that compounds NSC15381 (2-N,5-diphenyl-3-phenyliminophenazine-2,7-
diamine) and NSC603988 (N,5-dicyclohexyl-3-cyclohexyliminophenazin-2-amine) bear high 
structural similarity with NSC402959 and contain aromatic amide groups and radicals 
(Figure 4.14). While NSC15381 and NSC603988 were potent against M. tuberculosis in this 
study, unlike NSC402959, both of its analogues do not inhibit the activity of RNase H 
enzyme in HIV (PubChem database) and are toxic to mammalian cell line (Figure 3.14). In 
contrast, NSC402959 did not exhibit toxicity to any of the three cell lines tested (HL-60, 
Vero and J774.A1). NSC402959 is flanked by an iodine group which may play a role in it 
being less toxic to human cells (Figure 4.14-C). Both analogues and NSC402959 were also 
tested against a set of clinical strains of E. coli, S. aureus and P. aeruginosa to evaluate their 
activity profile. Only NSC402959 exhibited inhibitory activity against E. coli (Table 5.3); 
however, one of its analogues, NSC15381 has shown mild inhibitory activity against both E. 
coli and S. aureus (Figure 3.13).  
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Figure 4.14: Chemical structures of (A) NSC15381, (B) NSC603988 and (C) NSC402959. MWs and MFs 
are (A) 453.54 g/mol - C30H23N5, (B) 456.67 g/mol - C30H40N4 and (C) 779.41 g/mol - C36H23I2N5, respectively. 
Despite inhibitory activity of NSC402959 against human RNase H, it appears to be an interesting inhibitor and 
thus chemical derivatisation could be pursued to generate more effective analogues that are active against HIV 
and M. tuberculosis but do not target human RNase H. Chemical structures of the compounds were retrieved 
from the PubChem database. 
The structures of NSC168466, NSC168467 and NSC168468 are very similar to one another 
(Figure 4.9), and so also were their anti-M. tuberculosis activity (Table 3.6). Likewise, 
NSC145611 and NSC145612 are high molecular weight compounds from the NIH library 
and have complex chemical structures but also appear very similar (Figure 4.15). 
Interestingly NSC145611 appeared to be highly active against M. tuberculosis H37Ra (MIC 
6.25 µM) but its structural homologue NSC145612 did not exhibit a similar level of 
inhibitory activity and thus was not considered as the anti-mycobacterial of choice in this 
study (Table 3.6).  
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Figure 4.15: Chemical structures for anti-mycobacterial compounds. (A) NSC145611 and (B) NSC145612, 
MWs and MFs are 809.94 g/mol - C43H59N3O12 and 754.86 g/mol - C40H54N2O12, respectively.  Structural 
information for the chemical compounds NSC145611, NSC145612 and other adjacent compounds in the NIH 
series were retrieved from the PubChem database.  
NSC145611 has an extra nitrogen atom (Figure 4.15-A) which may play a role in its 
enhanced anti-mycobacterial activity (MIC 6.25 µM) compared to its analogue NSC145612 
(MIC 50 µM), which has only 2 nitrogen atoms. NSC145611 in particular is closely related to 
a known anti-tubercular, rifamycin (PubChem database). Nitric-oxide (NO) has previously 
been shown to have potent anti-microbial effects [400], and the findings above are in 
agreement with previous reports for the antimicrobial effect of NO [401], such as  its activity 
against mycobacteria [402]. This may explain the better efficacy of chemical entities with 
extra nitrogen and oxygen groups. However, Thomas et al. have suggested that the enhanced 
anti-mycobacterial effect of these compounds is associated with the presence of the phenyl-
N1 group on the side chains rather than their increased lipophilicity [403-404]. The inhibitory 
activity of such compounds against M. tuberculosis could be attributed to their intrinsic 
antibacterial property rather than the lipophilic nature of these compounds. 
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4.6. Discussion 
Understanding the genetic variability and virulence of the disease-causing mycobacterial 
strains is important to select a suitable model for screening drugs and unknown inhibitors. In 
this study, the sensitivities of M. smegmatis and M. bovis BCG were evaluated as surrogate in 
vitro models for the detection of anti-M. tuberculosis compounds. 
M. smegmatis has long been regarded as an environmental saprophyte of no clinical 
significance. A number of reports have described clinical effects of M. smegmatis infection 
[405-407]. For example, M. smegmatis has been associated with pleuro-pulmonary disease 
[408]. A review published in 2002, described a range of community-acquired and health-
care-associated diseases that were attributed to M. smegmatis including cellulitis, soft tissue 
necrosis, lipoid pneumonia and catheter sepsis [384]. While it is apparent that it may not be 
possible to strictly define M. smegmatis as a non-pathogenic species of mycobacteria, number 
of known clinical cases caused by M. smegmatis is extremely low relative to nearly nine 
million new cases of Tb occurring each year. M. smegmatis has been employed in Tb 
research for a range of studies because it offers several advantages over other Tb models e.g. 
fast growth, no special nutrient requirements and minimum risk to health workers. M. 
smegmatis on its own presents many similarities to the slow-growing pathogenic species of 
Tb, H37Rv. For instance, the hypoxia response of M. smegmatis mimics the response in M. 
tuberculosis [124, 409-411]. Pathogenic and non-pathogenic species can also be made more 
comparable, if genetically manipulated [412]. However, the relevance of its use with respect 
to Tb drug discovery is questionable. The M. smegmatis controversy with respect to its use 
and whether it represents a suitable model for studying the pathogenicity of M. tuberculosis 
was initially raised in 2001 [391] (section 4.3.2). The issue of its reliability in terms of 
detecting M. tuberculosis inhibitors, however, has not been previously addressed. Since it is 
important to select the most appropriate model for the discovery of new agents that could be 
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developed into drugs for the treatment of multi-drug resistant and latent forms of the disease. 
This study was conducted to directly measure the ability of M. smegmatis HTS to detect anti-
M. tuberculosis compounds. Three mycobacterial species were used to screen the compound 
libraries, and the data produced from the screening were compared for each Tb model with 
regard to similarities and variations in anti-mycobacterial hits relative to the reference strain, 
M. tuberculosis H37Ra. M. tuberculosis H37Ra was selected as a representative model 
organism of M. tuberculosis in this work since a good correlation between the H37Ra and 
H37Rv has been previously reported with regard to drug susceptibility [352].  
An initial data analysis from the library screening in this study revealed that 48-58% of M. 
tuberculosis inhibitors could not be identified when M. smegmatis was used, representing 
approximately only a 50% sensitivity for detecting M. tuberculosis inhibitors in the library 
screens. However, with M. bovis BCG employed as an in vitro model for drug screening in 
parallel screens performed under identical growth conditions, a substantially higher 
percentage of M. tuberculosis inhibitors were detected, 66% and 93% for LOPAC and the 
NIH chemical libraries, respectively (section 4.4). 
These data suggest that M. bovis BCG is more effective in vitro model than M. smegmatis for 
the detection of M. tuberculosis inhibitors. An example of a compound that was identified by 
using M. bovis BCG but not detected with M. smegmatis includes ammonium pyrrolidine 
dithiocarbamate (APDC). APDC has previously been reported to be an active inhibitor of M. 
tuberculosis H37Rv with an MIC of 0.125 µg/mL (0.761 µM) [290]. APDC has also been 
found to be active against persistent cells with a minimum bactericidal concentration (MBC) 
as low as 0.5 µg/mL [413]. Similarly, another M. tuberculosis inhibitor tetraethyl thiuram 
disulphide (Disulfiram) was also detected from the LOPAC library with M. bovis BCG but 
not with M. smegmatis. Disulfiram has previously been used for the treatment of alcoholism 
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in Tb patients [301]. Other examples include 2-chloroadenosine and niclosamide (Table 4.1 
and section 3.3.1.1.3). 
From these findings in the present study, it is evident that some of the potential M. 
tuberculosis inhibitors were not detected with M. smegmatis screening, although the 
inhibitors were active against both avirulent and virulent Tb strains, M. tuberculosis H37Ra 
and M. tuberculosis H37Rv (Figures 3.12 and 4.12, respectively). For example compounds 
from the NIH library, NSC333003 and NSC402959 (section 4.4.9) were not detected with M. 
smegmatis but were identified by M. bovis BCG in the screens. Both compounds were also 
tested against the virulent Tb strain, M. tuberculosis H37Rv and were found to exhibit good 
anti-mycobacterial activity. NSC402959 in particular appeared to be bacteriostatic in its 
activity against M. tuberculosis H37Rv (Figure 7.9) and did not exhibit cytotoxicity towards 
a number of mammalian cell lines (Table 2.3) HL-60 (Figure 4.13), Vero (Figure 7.6) and 
J774 (Figure 7.8), (section 4.4.9.1). NSC402959 had been previously shown to have an anti- 
E. coli RNase HI activity (PubChem database). Ribonuclease H1 (RNase HI) is an 
endonuclease responsible for cleaving the RNA strand of RNA-DNA hybrids [414]. This 
RNA-DNA cleavage is an essential cellular activity required for nucleic acid replication and 
repair in prokaryotic and eukaryotic species [415-419]. In M. tuberculosis, RNase HI and 
RNase HII activities are encoded by the rnhA and rnhB genes (ORFs Rv2228c and Rv2902c, 
respectively) [420]. We hypothesized that NSC402959 may have RNase HI as a primary 
protein target in M. tuberculosis. To determine this, further work was carried out to examine 
if RNase HI inhibitors possess specificity for Rv2228c, which is described in Chapter 5.  
While few inhibitors that were active against M. tuberculosis could not be detected with M. 
smegmatis, many hits identified with this species in HTS were also validated in M. 
tuberculosis (Tables 4.1 and 4.2). Moreover, a new anti-Tb drug, TMC207 had previously 
been identified during HTS using M. smegmatis [421]. This demonstrates that it could still be 
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useful in Tb research. The data obtained in the present study however indicate a lower 
sensitivity and ability of this model to detect positive hits compared to M. bovis BCG. The 
reason for differential inhibitory responses of different drugs in these mycobacterial species is 
not known, but is likely to be the fact that 30% of M. tuberculosis genes lack conserved 
orthologues in M. smegmatis. The higher genetic similarity of M. bovis BCG with M. 
tuberculosis along with its non-pathogenic nature makes it a more attractive model for anti-
Tb drug discovery. However, the slow growth rate of this species (two weeks are required for 
bacteriostatic drug screening for M. bovis BCG compared to four days for M. smegmatis) 
needs to be taken into account for its use in drug screening. 
4.7. Conclusion 
The research undertaken in this chapter highlights the importance of selecting an appropriate 
model for the screening M. tuberculosis inhibitors in vitro. Data produced in this study lend 
support to M. bovis BCG as more sensitive and reliable model than M. smegmatis to detect M. 
tuberculosis inhibitors.  
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Chapter 5 
RNase HI as a Target for Dual Inhibitors of Tb and HIV 
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5.1. Introduction 
In Chapter 4, a new mycobacterial inhibitor was described, NSC402959. This compound has 
been shown to inhibit RNase H from a number of pathogens including HIV (PubChem 
database). We reasoned that NSC402959, and other RNase H inhibitors could potentially 
function as dual inhibitors of both M. tuberculosis and the Human Immunodeficiency Virus 
(HIV). 
5.1.1. Tb and HIV – the Two Pandemics 
HIV is a retrovirus that impairs the function of immune system and is responsible for AIDS 
(Acquired Immunodeficiency Syndrome) in humans [422-424]. HIV primarily targets the 
host immune system and makes it weak and incompetent, which further jeopardizes patient‟s 
health by making them vulnerable to a number of other opportunistic infections, such as Tb 
[425-426]. With the emergence of the HIV pandemic, there has been a resurgence of Tb 
[427]. Tb is the most common HIV-related opportunistic infection [428-430], and HIV has 
been considered as the inducing factor for the development of M. tuberculosis infection into 
an active disease due to malfunctioning of the immune system [431]. Moreover, reactivation 
of latent M. tuberculosis is quite common among HIV positive patients [432].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
5.1.1.1. HIV/Tb – A Lethal Combination 
M. tuberculosis and HIV co-infection is a lethal combination since both infections fuel each 
other, [433]; therefore the death rate is very high among such individuals due to synergy 
between these two infections [434-435]. HIV targets CD4 immune cells (T lymphocytes) 
which are required to activate macrophages in M. tuberculosis infections in order to halt their 
active replication. Therefore, patients with an ongoing HIV infection are highly vulnerable to 
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catch an M. tuberculosis infection [436], especially in the resource-scarce communities where 
the Tb incidence rate is already high.   
5.1.2. Global Facts about HIV/Tb Syndemic 
Highly Active Anti-retroviral Therapy (HAART) became available in 1995 with a positive 
health impact for HIV-infected individuals [437]. AIDS patients lived longer [438-439], and 
the number of HIV cases started to fall after the advent of HAART [440]. Despite this new 
approach to disease control, 5.8 million new cases of HIV were still reported in 1997 along 
with 2.3 million AIDS-related deaths [441]. However, with the continuous rise in annual Tb 
incidence worldwide (Figure 1.4), the situation became even worse than it was before, 
indicating a global HIV epidemic [442]. A total of 39.5 million people were estimated to be 
infected with HIV including those newly-infected (4.3 million) from a deadly viral infection 
which claimed 2.9 million lives in 2006 [443]. In 2010 alone, an estimated 2.7 million new 
HIV cases along with approximately 1.8 million deaths were reported [444]. Despite the 
availability of HAART, the number of people living with HIV was still 34 million in 2010 
[445]. The HIV epidemic therefore poses serious risks for worldwide Tb control management 
[446]. Tb currently claims a life every 20 seconds (about two million lives each year) [447].  
Current Tb infection can accelerate the onset of HIV infection [448], highlighting the 
importance of new drug treatments that have a combined action against these two pandemics. 
5.2. Demand for Amendments to the Current HIV Therapeutic Regimen 
The 2010 WHO global report indicated that most countries would not be able to achieve the 
Millennium Development Goal (MDGs) No. 6 of halting and reversing the spread of HIV 
transmission [445]. Since both Tb and HIV cause high mortalities and there are antagonistic 
effects of anti-retroviral agents on current anti-Tb chemotherapy [449], it is important to 
Chapter Five – RNase H Inhibitors of Tb/HIV  
 
 
155 
 
search for more potent and compatible drugs that not only contain and reduce HIV infections 
but are also effective against co-infecting Tb infections.  
Some of the problems associated with both anti-mycobacterial and anti-viral therapies are 
presented in sections 5.2.1 and 5.2.2, respectively. 
5.2.1. Current Anti-Tb Therapy and Associated Problems 
 Multi-drug regimen, a high daily pill burden (section 1.8.2 and Table 7.1). 
 Prolonged treatment – relapse issue (Figure 1.2). 
 Adverse effects of the Tb treatment regimen [167, 186-188, 450-451]. 
 Drug-resistant Tb does not respond to currently-available anti-Tb drugs (section 1.8.3.4).   
5.2.2. Current Anti-HIV Therapy and Associated Problems 
 Only non-nucleoside reverse transcriptase (RT) inhibitors introduced in 1997 are 
available for the successful suppression of viral replication e.g. Nevirapine (NVP), 
Delavirdine (DLV) and Efavirenz (EFV), all approved by the US Food and Drug 
Administration (FDA). 
 Antagonistic effect of anti-Tb drugs with antiretroviral therapy. Some drugs that lead to 
toxicities are contra-indicated. 
 Adverse effects of available antiretroviral drugs [452-453]. 
 Development of drug resistance and lack of effective vaccine production. 
5.2.2.1. Mutual Detrimental Effect of Bacterial and Viral Infections  
 Adverse effects of HAART therapy in TB co-infections is common [454]. 
 Mortality rates are higher in HIV/Tb co-infected individuals, if left untreated [455]. 
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5.2.3. Possible Solution – A Dual Therapy 
It is apparent that drug resistance and regimen incompatibility between two therapies is the 
common problem associated with treatment of Tb/HIV infections. This could possibly be 
simplified by targeting something that is essential for both the bacteria and the virus (section 
5.3.2). RNase H is a class of enzymes that non-specifically degrades the RNA strand of 
RNA-DNA hybrids [414]. There is a diverse range of RNase H found in both prokaryotes 
[456] as well as eukaryotes [419]. RNase H activity was not described in M. tuberculosis 
until recently [420]. RNase H is present in both species and appears to be essential for their 
life cycles [457]. HIV RNase HI has approximately 31% identity at protein level with RNase 
HI from M. tuberculosis [420, 458]. This enzyme may present a potential target in both HIV 
and M. tuberculosis (section 5.6). The current literature has very few reports on RNase H as a 
novel drug target in HIV and few inhibitors of RNase H activity have been identified [459-
463]. No anti-HIV RT-RNase H specific drugs are available for therapy nor has this class of 
enzymes been investigated for their therapeutic potential for the treatment of Tb. Given that 
RNase H is a common drug target in HIV/Tb, co-inhibition of these two diseases could be 
possible. We hypothesise common inhibitors that specifically target RNase HI can be 
identified and developed. Therefore, RNase H could potentially serve as a new target in M. 
tuberculosis as well as cause simultaneous inhibition of HIV replication. New RNase H 
specific inhibitors, with different mechanism of action to drugs currently in use, would be 
expected to also have activity against drug-resistant strains, which would be crucial in 
containing these infections.  
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5.2.4. Aims for this Study 
1. To develop a repertoire of RNase H inhibitors of HIV-I and HIV-II. 
2. To test anti-HIV RNase H compounds for their anti-mycobacterial activity in vitro 
against M. tuberculosis H37Ra in growth inhibition assays. 
3. To identify a single-target dual inhibitor of M. tuberculosis and HIV that does not 
interfere with human RNase H enzymes.  
4. To develop a biochemical assay that specifically detects anti-RNase HI activity of our 
active compounds against the purified proteins (Rv2228c and Rv2902c) from M. 
tuberculosis. 
 
5.3. Dual Inhibitors of M. tuberculosis and HIV  
5.3.1. Definition of a Dual Inhibitor 
A dual inhibitor is a chemical compound and/or natural product that has a common target (e.g. 
RNase H) in two separate biological species (e.g. bacterial and viral) and shows a consistent 
inhibitory activity against such species in in vitro replicative assays. These compounds hold 
the potential to achieve co-inhibition of the two important human infections Tb and HIV.  
5.3.1.1. Novelty in Approach 
RNase H has recently been investigated for its potential to be a valid drug target for HIV but 
RNase H has never been studied in M. tuberculosis in this regard (section 5.3.2). Therefore 
the identification of single-target (RNase H) inhibitor in M. tuberculosis is the first step in the 
development of a dual therapy for both diseases, thus making this study unique.  
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5.3.2. RNase H as a Viable Target in HIV and M. tuberculosis 
The genome of HIV (9.8 kb) encodes only 9 genes consisting of two structural and six 
regulatory genes that encode approximately 15 proteins including an important enzyme 
reverse transcriptase (RT) [464]. HIV-RT also possesses an RNase HI activity [465]. Recent 
studies to explore novel drug targets in HIV have shown that RNase H represents a viable 
drug target and is essential for the life cycle of HIV [466-469]. However, little is known 
about the specific binding of RNase H inhibitors to their active sites on the enzyme. In some 
of the studies that are available, it has been suggested that there might be multiple binding 
sites for various RNase H inhibitors [460, 470]. 
Cole et al. has sequenced the genome of M. tuberculosis H37Rv, and this has helped 
scientists make significant advancements in the field of Tb biology [17]. However, the 
function of the open reading frames (ORFs) of H37Rv has not been completely determined. 
Watkins et al. have recently demonstrated associated RNase H (type I) activity in M. 
tuberculosis [420]. The genome of M. tuberculosis (section 4.3.1) contains the rnhA gene 
(ORF Rv2228c) and rnhB gene (ORF Rv2902) that have been functionally determined to 
possess RNase HI and RNase HII activities, respectively. RNase HI (Rv2228c) is a multi-
functional protein and also seems to have associated cobC and acid phosphatase activity 
[420]. RNase HI activity appears to be essential for all prokaryotes [471], and can be used in 
scaling up the inhibitory activity of anti-RNase H compounds. Given specific activity of 
inhibitors (such as NSC112200, Figure 7.14) identified in this study, RNase HI could be a 
viable drug target in M. tuberculosis (section 5.4.3).  
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Figure 5.1: RNase H activity required for DNA replication in (A) M. tuberculosis and (B) HIV, RT.  RNase 
H activity is essential for the replication of DNA strands in both species because of its cleavage of the RNA 
strand of RNA-DNA hybrids. RNase H in HIV is a bifunctional enzyme having the RT activity for making 
cDNA from RNA (DNA polymerase) as well as an RNase H activity for nicking the RNA strand of an RNA-
DNA hybrid. RT, reverse transcriptase enzyme. 
5.3.3. Biochemical Assay to Detect RNase H Activity 
RNase H enzyme is responsible for cleaving the RNA strand of RNA-DNA hybrids before 
the DNA replication step (Figure 5.1). The specific activity of the RNase HI inhibitors 
identified in this study was measured using a biochemical assay as previously described [472].  
5.3.3.1. Principle of an RNase H Assay 
To measure the specific activity of RNase H enzyme and to detect the specific inhibitory 
activity of their inhibitors, DNA and RNA strands are labelled with dabcyl and fluorescein, 
respectively. When RNase H enzyme cleaves the RNA strand off the DNA strand, it produces 
fluorescence that can be detected by a spectrophotometer. However, in the presence of an 
inhibitor, the activity of RNase H enzyme is blocked and therefore no detectable fluorescence 
indicates the specific activity of an RNase H inhibitor (Figure 5.2).  
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Figure 5.2: Principle of the RNase H assay.  DNA and RNA strands are labelled with dabcyl (quencher) and 
fluorescein, respectively (Sigma Aldrich) (A) Shows no inhibition of the enzyme and therefore, an RNase H 
enzyme cleaves the substrate at the 3‟ end of an RNA strand and produces detectable fluorescence monitored by 
a spectrophotometer and (B) Shows enzyme inhibition by an RNase H inhibitor. The inhibitor blocks the 
activity of RNase H enzyme; therefore, it does not cleave the RNA strand thereby producing no detectable 
fluorescence in the presence of a dabcyl quencher.  
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5.3.4. Criteria for the Selection of Dual Inhibitors of Tb and HIV 
Compounds were selected on the basis of their inhibitory activity if; 
1. They are known inhibitors of an HIV RNase H. 
2. They inhibit M. tuberculosis growth in vitro with an IC50 of < 25 µM in this study. 
3. They are not cytotoxic towards the mammalian cell lines, HL-60 and J774.A1 tested. 
4. They are active against M. tuberculosis RNase H in an enzyme inhibition assay. 
5. They do not inhibit human RNase H. 
5.4. Results 
5.4.1. Anti-HIV RNase H Compounds 
All HIV RNase H inhibitors were selected from the PubChem database 
[www.ncbi.nlm.nih.gov/pccompound] and imported from the NIH to expand the repertoire of 
our RNase H inhibitors (section 2.6.7). Compounds, which gave an IC50 of 25 µM or less 
were selected for further analysis and are listed in table 5.1.  
 
The following work was completed to evaluate the anti-mycobacterial potential of the HIV 
RNase H inhibitors. 
1. In vitro whole cell-based activity of anti-HIV RNase H compounds was monitored 
against M. tuberculosis H37Ra in dose-response experiments. 
2. All compounds were also tested against a number of other clinical strains (Table 5.3) 
to determine the spectrum of inhibitory activity based on their inhibition of M. 
tuberculosis H37Ra growth in vitro. 
3. Compounds were then prioritised on the basis of their growth inhibitory potential and 
were further tested to evaluate their dormicidal activity against M. tuberculosis 
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H37Ra (performed on over four week old cultures). Selected compounds were also 
tested for any shift in their inhibitory activity in nutrient-limited culture conditions (C).  
4. Cytotoxicity assessment was done using HL-60 human cells to evaluate toxic effect of 
the inhibitors. 
5. New RNase HI inhibitors of M. tuberculosis were identified that have previously 
shown activity against the HIV-RNase H enzymes. 
6. Structural analysis was performed on the compounds identified in this study for 
comparison with the known inhibitors and current anti-HIV and anti-Tb drugs. Any 
previously-known biological activity of the inhibitors was also noted. 
5.4.2. In vitro activity of HIV RNase H inhibitors against M. tuberculosis 
All anti-HIV RNase H compounds were tested against M. tuberculosis in a dose-response 
assay as described in section 2.7.2, and their IC50 values are tabulated below (Table 5.1). 
These inhibitors were tested at concentrations up to a maximum of 100 µM and were ranked 
according to the level of inhibitory activity against M. tuberculosis. Compounds that 
exhibited mild-to-no inhibitory activity against M. tuberculosis H37Ra (with an IC50 value 
of >25 µM) were considered inactive and were excluded from the list (section 5.3.4).  
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Table 5.1: Activity profile of RNase HI inhibitors  
RNase H Inhibitor     Species (IC50 µM) 
     
a
M. tuberculosis         HIV-I         HIV-II      E. coli Human
b
       
 
NSC14543           25                 +             +         –           –  
NSC20410           25                 +     +         –                +  
NSC35676           6.25                 na     +         na    + 
NSC45382           25                 na     +         +                –  
NSC51535           25                 na     +         +                +  
NSC56351           1.56                 na     +         –                +  
NSC73300           12.5                na     +         –                +  
NSC80693           25                 +     na        na               na 
NSC83217           25                na     +         –                –  
NSC88915           25                na     +        na                +  
NSC112200*           3.125                na     +         –                –  
NSC117949           6.25                na      +          +                +  
NSC128437           12.5                na      +         –                +  
NSC130796           1.56                na     +         –                +  
NSC133457           25                 +     +         –                –
NSC143101           25                na     +         –                +  
NSC228148           25                na      +         –                +  
NSC338268           12.5                na      +         –                +  
NSC402959∆           6.25                na      +         +                +  
NSC600285           12.5                na      +         –                +  
NSC600286           25                na      +         –                +  
NSC605657           12.5                na      +         –                +  
NSC610930           25                na      +         +                +  
NSC610984           25                 +     na       na               na 
NSC613575           6.25                na      +         –                +  
NSC668394•           1.56                na      +         –                +  
aInhibitory activity of (previously-known HIV) RNase H compounds against M. tuberculosis in vitro (this study). 
bApart from M. tuberculosis, data for in vitro enzyme activity against HIV-I/II, E. coli and human were retrieved 
from the PubChem database. ∆Lead compound – non-toxic to human cells. *Dual Inhibitor – single target. (•) a 
triad inhibitor, active against M. tuberculosis (this study), HIV RNase H and P. falciparum (PubChem database). 
+/– Compound is active (+) or does not inhibit the RNase H enzyme (-) from such species. na, not available. 
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After initial evaluation of anti-RNase H compounds for their growth inhibitory activity 
against M. tuberculosis H37Ra, compounds were prioritized according to pre-defined criteria 
(section 5.3.4). Compounds that met the criteria were further characterized, and their activity 
profiles across other species (clinical strains) are tabulated in tables 5.2 and 5.3. This was also 
done to confirm whether or not they inhibited E. coli in dose-response assays. To examine 
this, inhibitors were tested in vitro against three clinical strains (Table 2.1). The compounds 
were prioritized based on their inhibitory activity against M. tuberculosis in vitro and anti-
HIV RNase H activity. Table 5.2 presents further data for cytotoxicity of individual 
compounds and their activity profile in nutrient-rich and carbon-starved conditions. 
 
Table 5.2: Anti-mycobacterial Efficacy and toxicodynamics for RNase HI inhibitors of M. tuberculosis 
RNase H Inhibitor          50% Inhibitory Concentration (µM) 
    MW (g/mol)             M. tuberculosis              C-limited Mtb              
b
HL-60 
NSC20410         634.02            25   –           – 
NSC35676         220           6.25   –           – 
NSC56351         546.48           1.56   –           – 
NSC112200         590           3.125   –         <10 
NSC130796         392.33           1.56   –           – 
NSC133457         212.19           25   –        >100 
NSC143101         611           25   –          50 
NSC338268         384           12.5   –           – 
NSC402959         779.41           6.25            3.125         >100 
NSC605657         716.5           12.5   –           – 
NSC613575         627.64           6.25   –           – 
NSC668394         452.1           1.56   –          <10 
Compounds were tested up to a maximum concentration of 100 µM. Compounds exhibiting inhibitory activity 
against M. tuberculosis H37Ra up to maximum concentration tested (100 µM) are given. For comparison of 
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inhibitory profile of the anti-RNase H compounds against M. tuberculosis H37Ra, IC50 values for both nutrient 
rich and nutrient limited conditions are given. . b50% inhibitory concentrations of RNase HI compounds against 
HL-60 cells. The symbol (–) indicates, not done. MW, molecular weight.  
5.4.3. Activity of HIV RNase H Inhibitors Against M. tuberculosis RNase HI 
After compounds were tested in the growth inhibition assays against M. tuberculosis H37Ra, 
all anti-HIV RNase H compounds were ranked on the basis of their anti-mycobacterial 
activity. Selective HIV RNase H inhibitors were then tested in a biochemical assay (at the 
University of Auckland) to validate their anti-RNase HI activity in M. tuberculosis. Inhibitors 
were tested at two concentrations of 100 µM (being highest) and 5 µM (being lowest) to 
initially evaluate their activity in vitro. Compounds NSC112200 and NSC668394 inhibited 
the activity of RNase HI (Rv2228c) in vitro at concentrations 5 µM and 100 µM, respectively 
(Figure 7.14). Data obtained from biochemical assay for these compounds (Figure 7.14) are 
consistent with the data received from growth inhibition assays (Table 5.2) and in silico 
analysis on these inhibitors (Figure 5.10), except that compound NSC668394 was not 
effective at lowest concentration tested (5 µM) compared to NSC112200 suggesting that 
NSC668394 is not specific to mycobacterial RNase HI and may have a different target in M. 
tuberculosis. However, they displayed good anti-mycobacterial activity against M. 
tuberculosis H37Ra in dose response assays (Table 5.1), and NSC112200 (does not interfere 
with human enzyme, PubChem database) appears to be anti-M. tuberculosis RNase HI 
specific (this study). All other inhibitors that displayed good anti-mycobacterial activity in 
dose response assays are listed in table 5.2.   
Apart from NSC112200, NSC133457 was one of potential inhibitors identified that met the 
objectives of this study i.e. HIV RNase H inhibitors that exhibit anti-mycobacterial activity 
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and do not inhibit human RNase H enzyme (section 5.3.4 and table 5.2). The dose-response 
curve for NSC133457 is given below (Figure 5.3). 
 
Figure 5.3: Dose-response curve for anti-HIV RNase H compound NSC133457 against M. tuberculosis 
(see Figure 5.5 for chemical structure of NSC133457). 
5.4.4. Evaluation of the Cytotoxic Properties of the Inhibitors Identified 
Prioritized anti-HIV RNase H compounds that exhibited inhibitory activity against M. 
tuberculosis in the growth inhibition assay were also counter screened for activity in a human 
cell line HL-60 in order to specifically identify potential leads that would be non-toxic to 
human cells. Table 5.2 presents 50% inhibitory concentrations (IC50) of inhibitors compounds 
tested for cytotoxicity. Compounds NSC133457 and NSC402959 were of paramount 
importance as they presented favourable toxicities against HL-60 cells (Figure 5.4 and Figure 
4.13, respectively) and were also active against M. tuberculosis with an IC50 of 25 µM and 
6.25 µM, respectively (Table 5.2). 
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Figure 5.4: Activity of NSC133457 against the human cell line, HL-60. 
NSC133457 (Figure 5.5) showed a reasonable anti-mycobacterial activity against M. 
tuberculosis in dose-response assays (IC50 25 µM). It is not reported as an RNase H inhibitor 
of E. coli and also does not inhibit human enzyme (Table 5.1). It was therefore deemed 
appropriate to further test it against E. coli (Table 5.3). Given that NSC133457 is a known 
RNase H inhibitor of HIV (PubChem database); we hypothesized that its anti-mycobacterial 
activity may also be due to its inhibition of the same enzyme in M. tuberculosis (Figure 5.11). 
Lipinski‟s rule [251] suggested that an ideal drug will have to have low molecular weight and 
fewer rings with a smaller number of rotatable bonds (section 5.7), from this prospective, 
NSC133457 fitted these criteria. While most anti-Tb drugs do not follow Lipinski‟s rules, 
these criteria may only serve as guideline in finding compounds with drug-like properties and 
selecting leads in the initial stages of drug discovery. 
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Figure 5.5: Chemical structure of NSC133457. MW 212.19 g/mol and MF C10H12O5 (A) 2D structure and (B) 
3D structure. 
5.4.5. Inhibitory Profile of RNase H Compounds against Clinical Strains 
Anti-mycobacterial compounds were also tested for their activity against a number of 
clinically important pathogens as described in section 2.7.2.3. While compounds displayed 
good anti-mycobacterial activities, none of the compounds were active against E. coli in the 
growth inhibition assays except NSC402959 (Table 5.3), which is also an inhibitor of E. coli 
RNase H (PubChem database). Additionally, these compounds were tested against S. aureus 
and P. aeruginosa. None of the compounds tested in dose-response assays were active 
against P. aeruginosa probably due its highly efficient efflux pumps. Therefore, compounds 
with significant anti-mycobacterial activity were selected for in silico analysis to determine if 
they specifically bound at the active site of RNase H enzyme in M. tuberculosis H37Rv 
(Figure 5.10).   
NSC402959 (Chapter 3) served as an entry point into this new class of anti-Tb agents, and 
RNase HI (Rv2228c) could well be a viable drug target for such inhibitors, e.g. NSC112200 
Chapter Five – RNase H Inhibitors of Tb/HIV  
 
 
169 
 
displayed good activity against purified Rv2228c and can serve as a potential member of a 
larger class of (RNase HI) M. tuberculosis inhibitors (Figure 5.10 and Figure 7.14).  
 
Table 5.3: Activity profile of RNase HI inhibitors against clinical strains 
RNase H Inhibitor             Species (MIC µM) 
     M. tuberculosis         
1
E. coli             S. aureus          P. aeruginosa 
NSC20410            50        >100         >100  >100 
NSC35676            12.5        >100         >100  >100  
NSC56351            3.125                >100         12.5  >100  
NSC112200            6.25           >100         12.5       >100 
NSC130796            3.125                 >100         >100  >100 
NSC133457            50         >100           >100  >100 
NSC143101            50         >100         >100  >100 
NSC338268            25         >100         >100  >100 
NSC402959            12.5                   50                 >100  >100 
NSC605657            25         >100         >100       >100 
NSC613575            12.5         >100         >100  >100  
NSC668394            3.125                >100          6.25  >100 
1Detail on each clinical strain used in this study, are presented in table 2.1. Data available on PubChem database 
for individual anti-HIV RNase H compounds against clinical strains were cross verified by testing these 
compounds against clinical strains in dose response assays to confirm if they also inhibited growth of these 
species in vitro. All compounds were tested up to a maximum concentration of 100 µM. (+) indicates activity of 
inhibitor in that species and (–) indicates no inhibition detected at 100 µM. MIC, minimum inhibitory 
concentration.  
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5.4.6. Cloning of M. tuberculosis RNase H proteins into E. coli BL21 (DE3) 
Cloning experiments were initiated to express RNase HI and RNase HII from M. tuberculosis 
in the E. coli BL21 expression strain. Figure 5.6 presents the steps of the cloning experiments. 
 
Figure 5.6: Cloning steps for Rv2228c and Rv2902c from M. tuberculosis in the E. coli strains. (A) 
Confirmation of cloning of Rv2228c in correct orientation through sequencing of pET28a (+)_Rv2228c (B) 
After confirmation, -80 oC freezer stocks of E. coli cells expressing Rv2228c were made and (C) Expression of 
Rv2228c using the same vector in E. coli BL21 expression strain to over express Rv2228c protein. 
5.4.6.1. PCR-amplification, Restriction Digestion and Ligation of Rv2228c and Rv2902c 
into an E. coli Expression Vector, pET28a (+)  
Rv2228c encoding RNase HI in M. tuberculosis was cloned into E. coli BL21 (Figure 5.6) 
and sequenced (Figure 7.2). Subsequent steps for protein expression were performed as 
described in the methods section (Chapter 2). Figure 5.7 shows the PCR amplification and 
restriction digestion of M. tuberculosis genes (section 2.7.7.1). The amount of DNA was 
quantified using a Nano Drop™. 
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Figure 5.7: Confirmation of PCR Rv2228c and Rv2902c. Sizes of the PCR bands for Rv2902 and Rv2228c 
were 795 bp (lane 2) and 1095 bp (lane 3), respectively. Detail of primer design and restriction sites are given in 
table 2.3. All PCR products were analysed as described in section 2.7.7.5. A total of 5 µL of sample was loaded 
on to 1% molecular biology grade agarose in 1x TAE buffer stained with ethidium bromide.  
Figure 5.8 shows a restricted digest of the PCR product of Rv2228c. Restriction digestions of 
PCR products and the vector were performed as described in section 2.7.6.7. 
 
Figure 5.8: Size fractionated analysis of a restriction digest, Rv2228c. The BamHI restriction site was 
present at position 423 bp in Mtb‟s ORF Rv2228c. It yielded two bands (lane 2) of sizes 670 bp and 423 bp, 
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respectively. Lane 3 shows the band for Rv2228v (PCR-amplified), used as a positive control for the restriction 
experiment. Lane 4 was a negative control (ddH2O) whereas lane 1 and lane 5 had standard MW ladders. 
 
 
Figure 5.9: Confirmation of ligation of Rv2228c into pET28a. Lanes (1) Hyper ladder showing 1 kb and 5 kb 
bands for insert and vector, respectively (2) A restricted vector pET28a (2a) Digesting the correct size band at 
the 1095 bp-position (2b) Insert released by the vector pET28a_Rv2228c (+), (3) A control band for insert, 
PCR-amplifed Rv2228c, product size 1095 bp, (4) Linearized plasmid pET28a (+) digested with EcoRI and 
XhoI, (5) pET28a (+) uncut – 30 ng/µL, fresh stock, (6) pET28a (+) uncut – 28 ng/µL, previous stock, (7) 
pET28a (+) uncut – 20 ng/µL, old stock, (8) Control plasmid pCG79 10 ng/µL, (9) No DNA negative control, 
dH2O and (10) Hyper ladder. Approximately 5 µL of sample was loaded on to 1% molecular biology grade 
agarose in 1x TAE buffer stained with ethidium bromide (sequencing results for Rv2228c are presented in 
figure 7.2.  
 
5.5. Molecular Docking Simulations 
In silico analysis of compounds provides insight into which residues of the target they will 
bind to. To support the idea of developing a single-target dual inhibitor of Tb-HIV, in silico 
analysis on the novel inhibitors identified in the present study was performed. Chemical 
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compounds were docked on the RNase HI protein structure of M. tuberculosis H37Rv using 
the modelling programmes as described (section 2.8). Table 5.4 presents known HIV RNase 
H inhibitors that also interacted with mycobacterial RNase HI. The more negative the total 
score, the more significant the interaction is. 
Table 5.4: Binding scores for interaction of compounds with M. tuberculosis RNase HI 
RNase H Inhibitor*        Binding Scores  
         Steric         Desolvation       Acceptor       Donor        Metal      Total Score 
 NSC35676        -9.266            12.981             -2.493  -5.562         -57.117        -61.456 
NSC112200        -14.218       4.959      -9.803   0.00         -24.503     -43.563 
NSC668394        -27.329       9.827      -6.391  -0.389         -23.481     -47.763 
Compounds that gave the highest binding scores for the proposed binding sites are given. A negative score 
implies a spontaneous free energy of binding. NSC112200 is a novel anti-Tb compound identified in this study 
that is also a known HIV RNase H inhibitor (PubChem database). In silico analysis gave a positive interaction 
of NSC112200 with the RNase HI domain (Rv2228c) in M. tuberculosis (Figure 5.10). Interaction of inhibitors 
was studied only with the crystal structure of the RNase H domain. A more in-depth analysis may reveal 
missing interaction with the rest of the protein to determine the model‟s ability to predict stronger interactions. 
Modelling was carried out using docking software as described in section 2.8. *HIV RNase H inhibitors.   
 
The divalent ions Mg
2+
 or Mn
2+
 are required for RNase H activity and are thus a significant 
part of the binding simulations in the docking studies; therefore, the metal ions were added 
computationally to the proposed binding sites on the crystal structure of an RNase HI. 
Compounds mentioned in table 5.3 were docked on mycobacterial RNase HI but only a few 
inhibitors got through the selected filters and docked with reasonable binding scores.  
NSC668394 was found to bind more strongly than NSC112200, and had a comparatively 
better cumulative score (Table 5.4). However, NSC112200 had a lower desolvation score 
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than NSC668394 requiring less energy for its docking on the binding site. Results from the in 
silico analysis showed that an interaction of these HIV RNase H inhibitors with the 
mycobacterial RNase HI was plausible (Figure 5.10). However, the docking score for 
inhibitors (Table 5.4) was lower than the decoy ligands selected from the Spectrum 
Collection which were used to examine comparative binding scores with M. tuberculosis 
RNase HI (data not shown), suggesting that either the binding site model is limited or these 
ligands work through other means.  
This was further confirmed by testing selected inhibitors in an enzyme inhibition assay to 
elucidate their specific inhibitory activity against RNase HI in M. tuberculosis. These 
findings may eventually help in the development of a new class of M. tuberculosis inhibitors. 
Since these inhibitors are effective against both HIV and M. tuberculosis, they can also be 
tested for their antagonistic or synergistic activities with other clinical anti-retroviral drugs. 
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Figure 5.10: Molecular docking of HIV RNase H inhibitors on M. tuberculosis RNase HI (A) NSC668394 
and (B) NSC112200. Unlike NSC668394 (MIC of 3.125 µM), NSC112200 does not interfere with the human 
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enzyme (Pubchem) but was found active against M. tuberculosis H37Ra with an MIC of 6.25 µM (this study). 
These compounds had better binding scores (Table 5.4) compared to other inhibitors that were docked on to M. 
tuberculosis RNase HI in the presence of divalent ions (Mg2+), suggesting a positive interaction between HIV 
RNase H inhibitors and a mycobacterial RNase HI protein (colours: grey = carbon, red = oxygen, blue – 
nitrogen and white = hydrogen). M. tuberculosis RNase HI = red ribbon. (A) NSC668394 = grey aromatic rings 
and (B) NSC112200 = a grey ring with two oxygen atoms (red). Regions that interact strongly with a point 
positive charge are coloured red, those that interact strongly with a point negative charge are coloured blue; 
whereas, more pale colours denote a weaker electrostatic potential. Figure courtesy of Associate Prof Paul 
Teesdale-Spittle (also see figure 7.14 for specific activity of NSC112200 against mycobacterial RNase HI in 
vitro). 
5.6. Discussion 
The HIV epidemic along with high Tb burden is a huge concern for disease control agencies 
[473]. Drugs with novel mechanisms of action are required as they are expected to be more 
effective since little natural resistance will have arisen against their targets. One of the main 
aims of this thesis was to identify inhibitors that may have a novel target; hence, the search 
for RNase H inhibitors. This study identified a number of interesting M. tuberculosis 
inhibitors from previously identified anti-RNase H compounds such as NSC402959 (Chapter 
4). It may have a similar target (RNase H) in M. tuberculosis in vitro as of HIV and thus it 
may lead to the development of a new class of inhibitors that have not yet been explored.  
Previously-known inhibitors of the HIV RNase H were found to be active against M. 
tuberculosis H37Ra in this study (Table 5.1), suggesting that they may have the same target 
in both species. Based on the percentage similarity between HIV and P. falciparum RNase HI 
proteins, these compounds were expected to have an inhibitory activity against malarial 
species as well [474]. One such compound NSC668394 (Table 5.3) is a known M. 
tuberculosis inhibitor (MIC 3.125 µM in the present study) and is also active against P. 
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falciparum (PubChem database), (section 6.3.2). NSC668394 and NSC112200 interacted 
with mycobacterial RNase HI in computer docking studies (Figure 5.10) and this was further 
confirmed by an in vitro enzyme inhibition assay (section 5.3.3), (Figure 7.14).  
 
Figure 5.11: Analysis of sequence similarity between Rv2228/N and its structural homologues. Green box 
reveals the differences in sequence alignments of Rv2228c (involved in recognition), human and HIV RNase H 
between α2 and α3 helices, which may have implications for determining the specificity of RNase H inhibitors. 
Figure was adapted with permission from Watkins et al. [420].  
 
Novel Class of Mycobacterial Inhibitors 
Several anti-HIV RNase H compounds exhibited a consistent inhibitory activity against M. 
tuberculosis H37Ra with an IC50 of 25 µM or less (Table 5.1) e.g. NSC14543, NSC20410 
and NSC51535. The structures and molecular weights of these compounds are not very 
similar (Figure 5.19) yet they all inhibit HIV RNase HI enzyme (PubChem database). 
NSC133457 (propan-2-yl 3, 4, 5-trihydroxybenzoate) is a colourless compound (Figure 5.5) 
that has been previously tested in several biological assays but not against M. tuberculosis. It 
is a known RNase H inhibitor of HIV type 1 and type 2 and does not inhibit human RNase H 
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(PubChem database). Given its considerable inhibitory activity against M. tuberculosis, it is 
an attractive lead that could be further characterized and subsequently developed as a new 
inhibitor for Tb and HIV (section 5.4.3). Furthermore, it presented no toxicity towards human 
cell lines (Figure 5.4). Since in vitro biochemical assays are more sensitive than growth 
inhibition assays [475], active compounds in biochemical assays may only show a slight 
inhibition of bacterial growth [476]. Therefore, validation of anti-M. tuberculosis-specific 
activity of these compounds was confirmed by a biochemical analysis.  
Anti-mycobacterial compounds that are highly active against M. tuberculosis in vitro may not 
retain good in vivo activity [343]. The lack of an in vivo activity might be due to involvement 
of the host immune system, the specific environment of the infected tissue or the amount and 
type of cells present in that tissue. It is therefore important to evaluate the in vivo efficacy of 
the validated in vitro inhibitors. This can be tested in suitable in vivo models or in ex vivo 
models, which mimic the conditions of an in vivo system. For example, Turner et al. have 
described an ex vivo model that could potentially predict the in vivo effectiveness of 
inhibitors [477].  
NSC402959 identified in this study (Chapter 4), has proven to be a possible entry point to 
this novel class of M. tuberculosis inhibitors. NSC402959, however, interferes with human 
RNase H activity (PubChem database) and may therefore have to go through structural 
modification before it could be used clinically. NSC133457 however, meets the criteria set up 
for this project (section 5.3.4) and is thus a more promising candidate for a lead compound.    
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Anti-HIV RNase H Compounds 
The criteria used to initially select anti-HIV RNase H compounds in this study were that they 
exhibit decent anti-mycobacterial activity against M. tuberculosis and do not inhibit human 
RNase H proteins. Many compounds that are known HIV RNase H inhibitors exhibited good 
inhibitory activity against M. tuberculosis and did not inhibit human RNase H enzyme. 
Examples included NSC14543, NSC45382, NSC83217, NSC112200 and NSC133457. Other 
compounds e.g. NSC20410, NSC35676, NSC112200, NSC402959 and NSC668394, 
exhibited good anti-mycobacterial activity in vitro (Table 5.2) but were also active against 
human RNase H (PubChem database). A few compounds (NSC80693 and NSC610984) may 
not have been tested against human or E. coli RNase H at all but were active against HIV-I 
RNase H and had an IC50 against M. tuberculosis of 25 µM. Such compounds could possibly 
be chemically modified to alter their activity against human RNase H, while retaining decent 
inhibitory activity against the mycobacterial and HIV RNase H. 
Based on the structural similarity of HIV's RNase H and integrase, Andre´ola et al. have 
suggested that RNase H inhibitors may also have anti-HIV integrase activity [463]. In support 
of this, Pommier et al. have recently patented their approach to treating HIV infections with 
the compounds NSC18806 and NSC310618 describing them as inhibitors of HIV integrase. 
From this perspective, if the RNase H inhibitors NSC133457 and NSC402959 (identified in 
this study) do cause specific inhibition of RNase H in M. tuberculosis, which has homology 
with HIV RNase [420], it could also be proposed that HIV integrase/RNase H dual targeting 
is possible by such anti-RNase H compounds. Marchand et al. have demonstrated a dual 
effect of madurahydroxylactone derivatives on the above two enzymes [478]. Therefore, 
based on the structural similarities of inhibitors, it may be possible to target integrase and 
RNase H simultaneously.  
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Figure 5.12: Chemical structure of NSC143101, MF C30H26O14, MW 610.52 g/mol (A) 2D structure and (B) 
3D structure. 
NSC133457 (Figure 5.5) and NSC143101 (Figure 5.12) have an MIC of 50 µM against M. 
tuberculosis (Table 5.3). At least 5-fold and 2-fold difference was observed between the 
MICs against M. tuberculosis and HL-60 cells, respectively. Anti-M. tuberculosis activity 
and favourable toxicity make such compounds important to be considered for further 
development in collaboration with Global Alliance for Tb Drug Development. Furthermore, a 
programme of chemical derivatisation could be pursued to further strengthen their anti-
mycobacterial activity. 
 Efficacy of anti-HIV and Novel Inhibitors of M. tuberculosis 
After the initial discovery of active compounds, a range of in vitro research methods have 
been developed in order to rank novel compounds for their therapeutic potential before they 
are to be tested against in vivo models. For example, hypoxic conditions in tubercle 
granuloma have been modelled in vitro using an oxygen depletion assay [122-123]. In 
addition, lack of several key nutrients used in nutrient starvation assays may mimic in vivo 
models for nutrient stress [479]. Other in vivo stress conditions include M. tuberculosis 
growth in an acidic environment and nitric oxide treatment. This unfavourable environment 
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for M. tuberculosis replication may help to explain phenotypic drug resistance of these cells 
and may also explain the altered gene expression of bacteria [480-481]. It is important to 
completely evaluate the differential anti-mycobacterial effect of new inhibitors between in 
vitro drug susceptibility assays and an intra-macrophage infection assay in order to examine 
their potential to invade human macrophages and specifically target latent M. tuberculosis. 
These properties may vary considerably between drugs [482]. The inhibitors identified in the 
present study were tested under carbon-limited medium conditions for inhibitory activity 
against M. tuberculosis H37Ra, but potential inhibitors must eventually be tested in vivo to 
completely scale and evaluate their efficacy. 
5.7. Structure-Activity Relationship Study 
Novel anti-Tb agents are required to have a good lipophilicity to be able to penetrate through 
the lipid-enriched cell wall of M. tuberculosis (Figure 7.11) [379-380]. This cell wall is 
known to have specialized barriers for selective transportation of solutes and drugs compared 
to other bacteria [483]. New compounds identified through primary screenings with anti-
mycobacterial activity and reduced mammalian cell toxicity could be made more promising 
drug candidates by performing chemical modifications to increase their lipophilicity and anti-
mycobacterial action. A SAR study is an important step in drug discovery. Any chemical 
compounds or drugs identified as an inhibitor in mycobacteria are also likely to have some 
toxicity in human cells. It is therefore important to perform SAR studies in order to design 
more effective and less toxic inhibitors through derivatisation to generate more effective 
analogues by making structural modifications that do not compromise their anti-bacterial 
activity. For example, ethambutol is a frontline ant-Tb drug (Table 1.2) that affects 
arabinogalactan synthesis in the M. tuberculosis cell wall (Table 1.3) and is considered to be 
the least effective among four standard drugs prescribed in the initial therapy against Tb. 
Chapter Five – RNase H Inhibitors of Tb/HIV  
 
 
182 
 
SQ109 is structurally similar to ethambutol (Figure 5.13) but has a much higher potency 
compared to ethambutol. The in vivo efficacy of SQ109 in a mouse model is 1 mg/kg 
compared to that of ethambutol, which is 100 mg/kg [484-485]. Ethambutol-derived 
analogues have also shown better inhibitory activity than ethambutol [486], suggesting that 
enhanced inhibition can be obtained by performing structural modification. Chemical 
modification of compounds may therefore enhance the inhibitory activity and can generate 
analogues that are more effective than the parent compound.  
 
Figure 5.13: Structures of anti-Tb drugs. (A) SQ109 and (B) its structural analogue ethambutol.   
Despite better pharmacokinetics, none of the current anti-Tb drugs follow these rules unlike 
the anti-viral drugs e.g. acyclovir, which matches the rules better. However, given their high 
anti-mycobacterial activity, inhibitors identified in the present study have the potential to be 
lead compounds (Table 5.2) as they fulfil two of the main criteria described by Lipinski [251], 
namely their molecular weights are under 500 g/mol and they have < 3 rotatable rings.  
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5.8. SAR of RNase H Inhibitors 
A brief structural analysis was performed in this study on of HIV-RNase H inhibitors that 
were identified as being also active against M. tuberculosis H37Ra in this study. The 
structures were compared on the basis of chemical backbone, with known anti-HIV RNase H 
compounds to evaluate their likely therapeutic potential. This comparison showed a 
significant structural similarity between the compounds, suggesting they may be targeting a 
common enzyme in M. tuberculosis and HIV (Figures 5.15-5.20).  
5.8.1. Comparison of HIV and M. tuberculosis Inhibitors 
Only a few RNase H inhibitors of HIV have been reported to date, including the diketo acids 
[487], pyrimidinol carboxylic acids [488], hydroxylated tropolones [489], natural products 
like illimaquinone [490] and N-acyl hydrazones [491], which effectively inhibit the RNase 
HI activity of an HIV reverse transcriptase enzyme (HIV-RT). Gong et al. have recently 
described the interaction of acylhydrazones with HIV-RT [460], comparing their activity with 
existing inhibitors in order to identify the specific potential of these novel compounds. 
Acylhydrazones have previously been described to have anti-inflammatory and anti-
thrombotic activity [492]. Moreover, a recent study by Ming et al. suggests that such 
compounds also possess anti-HIV-Ca activity, and thus like acylthiourea [493], are active 
against viral capsid proteins [494].  
Chapter Five – RNase H Inhibitors of Tb/HIV  
 
 
184 
 
 
Figure 5.14: Structural comparison of acylhydrazone HIV inhibitors, reported previously, with the M. 
tuberculosis inhibitors identified in this study. (A) Dihydroxy benzoyl naphthyl hydrazone (DHBNH) [495], 
(B) A dihydroxy analogue of DHBNH (BHMP03) [460], (C) A trihydroxy analogue of DHBNH (BHMP07) 
[460] and (D) An anti-mycobacterial compound identified in this study, NSC45382, and also previously known 
as HIV-RNase H inhibitor (PubChem database). Compound „C‟ with a carboxylate moiety in the distal phenyl 
ring, appeared to have the highest anti-viral activity [460]. This may be due to an extra „R‟ group or the 
functional group [OH] in its chemical structure. All compounds otherwise appear to be structurally similar 
(section 5.8.2). In this study NSC45382, (IC50 for M. tuberculosis of 25 µM), has a molecular weight of 439.87 
g/mol and has an additional sulphur and chloride group, yet it was found to have structural homology with these 
acylhydrazone inhibitors. 
The compounds shown in figure 5.14 (A, B and C) are derivatives of acylhydrazones [460], 
and they have been recently reported as anti-HIV RNase H compounds. These compounds 
bear structural resemblance to the RNase H inhibitors of HIV identified in this study, such as 
NSC45382. For example, NSC45382 has a reactive alkyl amine group (Figure 5.14-D), 
which is not recommended for a prodrug [496] and may need to be chemically removed prior 
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to further development of the compound. Another example includes NSC130796, which had 
an IC50 of 1.56 µM against M. tuberculosis H37Ra (Figure 5.15). 
 
Figure 5.15: Structural comparison of the (A) Acylhydrazone derivative with the (B) Mycobacterial 
inhibitor identified in this study, NSC130796, MF C19H12N4O6, MW 392.33 g/mol. Chemical structure of a 
dihydroxy analogue of an acylhydrazone derivative was retrieved from Gong et al. [460]. 
5.8.1.2. HIV RNase H Inhibitors that Do Not Inhibit the Human Enzyme 
From the NIH library NSC45382 (4-[(3-chloro-1,4-dioxonaphthalen-2-yl)amino]-N-pyridin-
2-ylbenzenesulfonamide), NSC83217 (3-amino-4-[(2-amino-4-sulfamoylphenyl)disulfanyl] 
benzenesulfonamide) and NSC112200 (2,5-dibromo-3,6-dimethylbenzene-1,4-diol) 
demonstrated reasonable anti-mycobacterial activity in dose-response assays against M. 
tuberculosis H37Ra (Table 5.1). These compounds are of particular importance because of 
their lack of inhibitory activity against human RNase H proteins. 
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 Figure 5.16: Chemical structures of (A) NSC45382, (B) NSC83217 and (C) NSC112200. MWs and MFs are 
439.88 g/mol - C21H14ClN3O4S, 406.52 g/mol - C12H14N4O4S4 and 589.89 g/mol - C16H14Br4O4, respectively.  
A more interesting HIV RNase H inhibitor NSC133457, identified in the present study, 
exhibited a reasonable anti-mycobacterial activity (Figure 5.3) and did not inhibit human 
RNase H (PubChem database). It also did not exhibit toxicity towards human cells (Figure 
5.4). Furthermore, it appeared to be remarkably similar to the previously reported anti-HIV 
compounds NSC727447 and β-thujaplicinol. NSC133457 has a low molecular weight 
(212.19 g/mol) and has less than two rings in its structures (Figure 5.17-D), and is in 
agreement with the two important Lipinski rules for demonstrating drug-like properties of a 
compound (section 2.6.8.1).  
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Figure 5.17: SAR of RNase H inhibitors identified in this study with previously reported compounds (A) 
NSC727447, (B) NSC727448 (C) β-thujaplicinol and (D) NSC133457. Wandeler et al. have previously 
identified compounds (A) NSC727447 and (B) NSC727448 from the NIH library as inhibitors of the RNase H 
enzyme from HIV [470]. (C) β-thujaplicinol has also been reported as an effective RNase H inhibitor of HIV 
[489]. NSC133457 (D) (blue square) was identified as an anti-mycobacterial inhibitor in the present study and 
shares structural resemblance with the previously reported anti-HIV inhibitors.  
Figure 5.17 illustrates the structural similarity among inhibitors. In particular, β-thujaplicinol 
and NSC133457 share considerable homology in their chemical structures (Figure 5.17-C and 
D, respectively). With one benzene ring along with common OH groups and their low 
molecular weights, a closer relationship is suggested in terms of their structure and their 
common inhibition of the RNase H in HIV. Given these structural similarities and the lack of 
published reports on anti-M. tuberculosis activity with the current and previously-known 
drugs, NSC133457 offers excellent potential to be developed further (section 5.4.3). 
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Figure 5.18: Structural similarity between an HIV RNase H inhibitor (A) illimaquinone and a 
mycobacterial inhibitor, (B) NSC133457. MW for „A‟ and „B‟ are 358.48 g/mol and 212.19 g/mol, 
respectively (section 5.8.1).  
NSC14543 (3,5-bis[(dimethylamino)methyl]-1,3,5-thiadiazinane-2-thione), NSC20410 ((1,3-
dimethyl-2,6-dioxopurin-7-yl)-[2-methoxy-3-(1,1,3-trioxo-1,2-benzothiazol-2-
yl)propyl]mercury) and NSC51535 (3,12-dinitroanthra[9,1,2-cde]benzo[rst]pentaphene-5,10-
dione) have different chemical structures and formula weights (Figure 5.19), yet these 
inhibitors exhibited a consistent anti-mycobacterial activity in dose-response assays against 
M. tuberculosis H37Ra (section 5.6). However, apart from inhibiting HIV-RNase H, all 
compounds presented in figure 5.19 (except NSC14543), also inhibit the activity of human 
enzyme (Table 5.1). An additional structural modification to these compounds may yield 
more effective derivatives with increased efficacy, and therefore such inhibitors may have to 
be chemically modified.  
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Figure 5.19: Chemical structures of (A) NSC14543, (B) NSC20410 and (C) NSC51535. MW and MF of the 
compounds are (A) 248.41 g/mol - C9H20N4S2, (B) 634.02 g/mol - C18H19HgN5O6S and (C) 546.48 g/mol - 
C34H14N2O6, respectively [497]. 
5.8.2. Effect of Hydroxyl Groups on the Activity of Mycobacterial Inhibitors 
All compounds with reactive hydroxyl groups [OH] were expected to exhibit some inhibitory 
activity against M. tuberculosis H37Ra. Streptomycin (Figure 7.10-A) is one of the most 
active second-line anti-Tb drugs and it has seven hydroxyl groups in its structure. An OH 
group at position 12 may be of critical importance in terms of it being anti-mycobacterial, as 
shown previously by Xu et al. [498]. Xu et al. identified a new compound, (+)-calanolide A, 
which is a natural product with anti-HIV properties. This compound was further tested 
against Tb strains and was also shown to inhibit M. tuberculosis growth in vitro as well as in 
vivo. Its activity was comparable to rifampicin, the most potent anti-Tb drug. Although it 
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inhibits nucleic acid synthesis like rifampicin, it was believed that calanolide A may have a 
different cellular target to rifampicin [498].  
Furthermore, the α-hydroxytropolones (NSC18806 and NSC310618) were reported as HIV 
integrase inhibitors [499]. These inhibitors also have OH groups in their structures and have 
comparable activity to NSC133457, identified in this study, which also has an OH group 
(Figure 5.18-B). These OH group patterns can be considered for designing a novel class of 
dual inhibitors, provided their functional group modifications are flexible to allow OH group 
substitutions.    
5.8.3. Description of Inhibitors Identified in this Study  
Over the last decade, new leads have been added to the anti-Tb drug pipeline (Figure 5.20). 
This became possible due to interaction between several disciplines including M. tuberculosis 
pathology, structural biology and mycobacterial genomics. One of the key ways to identify 
new leads is to perform SAR on novel anti-mycobacterial hits. After the initial discovery of 
antimicrobials, the evaluation of the pharmacokinetics and mechanism of action of identified 
leads are important phases of drug discovery. The inclusion of SAR studies helps to progress 
the new candidate drugs to the clinical trials stage. 
Many RNase H compounds exhibited consistent and similar inhibitory activity against M. 
tuberculosis H37Ra with an IC50 of 25 µM or less e.g. NSC14543, NSC20410 and 
NSC51535. While structures of these compounds are not related to each other (Figure 5.19), 
they inhibit HIV RNase H activity in HIV (Table 5.1). One interesting feature of most of the 
RNase H inhibitors identified in this study is that they have low molecular weights (Table 5.2) 
and follow some of impotant Lipinski‟s rules (section 2.6.8.1). Such leads may offer better 
pharmacokinetic properties and should be further tested for in vivo efficacy to determine 
Chapter Five – RNase H Inhibitors of Tb/HIV  
 
 
191 
 
whether or not they retain a good anti-infectious activity in animal models. To initiate 
preliminary investigations, it was deemed appropriate to further investigate these compounds 
for their sensitivity in Tb screening models in vitro (Chapter 4). A novel anti-Tb compound 
NSC402959 was identified, which served as an entry point for the discovery of a new class of 
M. tuberculosis inhibitors (section 5.1). Since, a biologically active compound should be 
stable, lipophilic (for improved absorption) and non-toxic to humans. The prioritized 
inhibitors are NSC112200 (Figure 5.16-C) and NSC133457 (Figure 5.5) based on their 
antimycobacterial activity. These inhibitors have anti-HIV RNase H activity but do not 
inhibit human RNase H activity. These compounds also inhibited M. tuberculosis growth in 
vitro at 6.25 µM and 50 µM concentrations, respectively (sections 5.3.4 and 5.5). In 
particular, NSC112200 appeared to be specific against mycobacterial RNase HI (Figure 7.14). 
Other inhibitors include NSC35676 and NSC668394, which need to undergo further 
experimentation, based on their activity that is unrelated to RNase H inhibition properties. 
For example, NSC35676 is also a known inhibitor of glucoseamine-1-phosphate acetyl 
transferase in M. tuberculosis (PubChem database), (MIC 12.5 µM in this study). This 
compound also inhibits aspartyl aminopeptidase in P. falciparum (PubChem database). 
NSC112200 is not only structurally different from the current anti-Tb drugs but also has a 
novel target in M. tuberculosis, and thus warrants further investigation (section 6.5).  
While previously known HIV RNase H inhibitors have also shown anti-mycobacterial 
activity in this study, these compounds share a significant structural homology with the active 
HIV RNase H inhibitors reported previously (Figures 5.15-5.20). Given an anti-RNase H 
activity, anti-mycobacterial activity and less toxicity to mammalian cells, NSC133457 
appears to have a comfortable safety margin and holds good potential for further 
development. 
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5.9. New Anti-Tb Clinical Drug Pipeline 
Koul et al. [500] have listed anti-Tb drugs that are currently in the clinical Tb pipeline under 
several phase trials (Figure 5.20). Among all the classes described in this summary, none of 
the drugs targets mycobacterial RNase H. However, a preliminary analysis of selected 
inhibitors (identified in this study) indicated specific activity against RNase HI in M. 
tuberculosis (Rv2228c) in an enzyme inhibition assay (section 5.4.3). An example include 
compound NSC112200 (Figure 7.14) which inhibited mycobacterial RNase HI at 5 µM 
concentration compared to untreated controls (also see Figure 5.10, in which NSC112200 
showed positive interaction with mycobacterial RNase HI in silico). A detailed kinetic 
analysis would be performed next to evaluate its potential to block RNase H activity in M. 
tuberculosis at nanomolar concentrations. Since inhibitors identified in this study (Table 5.1) 
targeted RNase HI enzyme in M. tuberculosis, there is a good possibility that a new class of 
M. tuberculosis inhibitors could be presented for Tb, a disease claiming over a million lives 
every year [501].  
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Figure 5.20: Current pipeline of new anti-Tb drugs. Figure was adapted with permission from Koul et al. 
[500].  
Fluoroquinolones, gatifloxacin, and moxifloxacin are expected to reduce the overall treatment 
time for Tb due to their improved bactericidal activities compared to current drugs [502] and 
because they are active against the drug resistant-strains of Tb [503]. Since the development 
of drug resistance is inevitable, it can be, at least temporarily, overcome by identifying a 
novel target in M. tuberculosis. This study has identified a number of interesting inhibitors 
that could be dually targeting HIV and Tb. In particular, NSC402959 exhibited inhibitory 
activity against M. tuberculosis H37Ra as well as against the virulent Tb strain, M. 
tuberculosis H37Rv in vitro (Figure 4.12). Since M. tuberculosis H37Ra and M. tuberculosis 
H37Rv behave almost similarly in drug susceptibility assays [352], it is expected that other 
RNase H inhibitors may also cause inhibition of the virulent M. tuberculosis strains. An even 
more effective series of compounds could then be generated through derivatisation and 
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appropriate modification of compounds like NSC402959 that are active against M. 
tuberculosis. 
Overlapping toxicities in a drug regimen for the treatment of Tb/HIV is a serious concern 
when a separate drug is used for each pathogen. It may be possible to be overcome this by 
having a single target in both species that allows a monotherapy for the simultaneous 
treatment of the two different diseases. RNase H inhibitors could therefore be developed and 
tested in an animal model to generate in vivo chemotherapy data in order to completely 
evaluate their positive therapeutic potential and scale their activity profiles as well as their 
potential to be developed as a novel class of inhibitors for the simultaneous treatment of Tb 
and HIV. 
Finally, previously known RNase H inhibitors of HIV were tested against M. tuberculosis in 
the present study to evaluate their in vitro inhibition against mycobacterial species. New 
RNase H compounds have been identified that have good anti-mycobacterial activity (Table 
5.2). Although a biochemical assay did confirm the specificity of HIV RNase H inhibitors at 
a preliminary scale, however, a detailed kinetic study will be required to scale up their 
activity against M. tuberculosis RNase HI and for further development of dual inhibitors of 
HIV and Tb RNase H. Novel compounds that are active against these dual infections and are 
also active against resistant strains would be preferred for subsequent clinical benefit.  
5.10. Conclusion 
In conclusion, this study has identified a small number of new RNase H inhibitors of M. 
tuberculosis (Table 5.2), such as NSC112200 and NSC133457 that show promise for further 
development as anti-Tb drugs. Since these compounds are known HIV RNase H inhibitors, 
they could be developed even further to dually target HIV and M. tuberculosis infections and 
Chapter Five – RNase H Inhibitors of Tb/HIV  
 
 
195 
 
thus may have implications for a combined Tb and AIDS therapy. To the best of our 
knowledge, these anti-HIV compounds together with their anti-mycobacterial properties have 
not been described before.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
196 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
Summary and Future Directions  
 
 
  
Chapter Six – Research Summary and Future Prospects 
  
 
197 
 
6.1. Research Summary 
The main focus and research rationale of this study was to discover new inhibitors of M. 
tuberculosis and to examine the possibility of identifying a novel class of inhibitor(s) from 
selected compound libraries that have the potential to be developed into anti-Tb drugs. A 
number of in vitro Tb models have been used for anti-Tb drug discovery, but no reports are 
available on which Tb model is best and most selective in drug screening programmes. This 
research identified M. bovis BCG as a more sensitive in vitro Tb model than previously used 
M. smegmatis. M. bovis BCG was considerably more selective in identifying inhibitors that 
were active against M. tuberculosis. A number of interesting mycobacterial inhibitors have 
been identified in this study during drug screening which could be pursued for further 
development in future research. NSC402959, a novel anti-mycobacterial compound identified 
from the NIH library and had an MIC value between 6.25 µM – 12.5 µM against M. 
tuberculosis. It not only exhibited significant inhibitory activity against the virulent strains of 
Tb but also demonstrated low toxicity in mammalian cells. 
The complete genome sequence of M. tuberculosis has helped researchers to develop more 
efficient diagnostic tools for Tb [356]. However, an in-depth knowledge is still required in 
persistent M. tuberculosis infection to understand the latent form of the disease. Anti-
mycobacterial compounds identified in this study were also tested in dormicidal assays to 
evaluate their ability to kill the persistent M. tuberculosis (non-replicating) cells from over 
four week old cultures. NSC402959 was not found to be dormicidal against both M. 
tuberculosis H37Ra and M. tuberculosis H37Rv compared to positive drug controls. 
The next aim of this study was to identify a dual in vitro inhibitor of Tb/HIV. Known HIV 
anti-RNase H inhibitors were retrieved from the NIH library and tested against M. 
tuberculosis for their anti-mycobacterial activity in dose-response assays. NSC133457 is an 
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HIV RNase H inhibitor and does not interfere with the human enzyme (PubChem database), 
it was identified as a mycobacterial inhibitor in this study (IC50 25 µM). It also did not exhibit 
toxicity against HL-60 cells. Despite structural differences between HIV and M. tuberculosis 
RNase HI proteins, in silico analysis performed in this study supported the binding of novel 
RNase H ligands NSC35676, NSC668394 and NSC112200 with M. tuberculosis RNase HI 
protein (Figure 5.10 and Table 5.4). Furthermore, a cell free assay confirmed the specific 
anti-RNase H activity of NSC112200 (Figure 7.14) and opened the door for the identification 
of a novel class of M. tuberculosis inhibitors that also inhibit HIV replication in vitro. RNase 
H enzyme appears to be essential to the life cycle of both M. tuberculosis and HIV. It is 
therefore possible that a dual inhibitor against both species can be developed that could 
modify the available treatment regimen and benefit dually-infected patients.   
A better understanding of the dual biology and a positive drug-drug interaction is the key to 
containing HIV/Tb co-infections [504]. If these compounds retain decent inhibitory activity 
against M. tuberculosis in vitro after performing the required chemical modifications, this 
research will be extended to in vivo assays to ascertain whether these agents work in infected 
animal models (section 6.5). Successful treatment outcome may be possible by inhibiting 
both HIV and Tb through a single-target dual inhibitor for these two pathogens. Dual 
inhibitory activity of compounds against HIV and Tb identified in this study make them 
attractive candidates for further investigation to demonstrate their clinical benefits.  
6.2. Overall Scientific Contribution of this Study 
 This research highlights the importance of selecting in vitro screens in PC2 
laboratories where facilities for screening against virulent Tb species are not available. 
 This study has demonstrated better screening ability of M. bovis BCG than M. 
smegmatis as a high throughput screening model for anti-Tb drug discovery. It has 
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also identified New Zealand plant species as a good source of novel anti-tubercular 
lead compounds [241]. 
 This work has identified a novel inhibitor of M. tuberculosis H37Rv (NSC402959) 
that has minimum toxicity towards mammalian cell lines and may hold potential as a 
lead anti-Tb agent [505]. 
 Furthermore, previously-known anti-HIV inhibitors of RNase H were selected in this 
study and compounds were identified that also possessed anti-mycobacterial activity 
in vitro i.e. NSC35676, NSC112200 and NSC133457. In silico analysis was 
performed to dock interesting HIV RNase H inhibitors on mycobacterial RNase HI 
(Rv2228c) to analyse if these inhibitors also possess better binding energies and have 
specificity for RNase HI.   
 Given the specific activity of NSC112200 against Rv2228c in an enzyme inhibition 
assay, RNase HI has been identified as a novel drug target in M. tuberculosis. 
 With in vitro data against M. tuberculosis and positive results from docking studies, 
this part of research defines a specific future prospect of generating better derivatives 
of compounds to be developed into a novel class of M. tuberculosis inhibitors. It also 
has opened a new window that may eventually lead to the development of dual 
inhibitors of Tb and HIV.  
6.3. Future Prospects for This Research 
6.3.1. Opportunistic Pathogens in Tb-HIV Co-infection 
Patients living with AIDS and Tb are vulnerable to various bacterial and viral pathogens that 
can cause respiratory problems (section 5.1). One common example is Chlamydia 
pneumoniae that causes pneumonia [506]. Other HIV opportunistic pathogens include 
cytomegalo virus (CMV) [507] and herpes virus [508]. 
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6.3.2. A Triad Inhibitor against Major Human Killers 
Infectious diseases have been a major human health concern for decades and more than 15 
million associated deaths are recorded due to infections from HIV, Tb and malaria [509]. 
Apart from the concerns about Tb and HIV co-infection [510], malaria alone appears to claim 
more than 2.5 million lives each year and is one the growing epidemics in the world today. 
Novel inhibitors are therefore also required for P. falciparum, the malarial parasite vector, as 
development of drug resistance to the available drug therapy is inevitable [511-515]. It is 
therefore necessary to develop novel and more effective drugs against all three of these 
infections. One way of containing such combined infections is to develop a single-target 
inter-kingdom inhibitor that could potentially inhibit the above three species (Figure 6.1). 
This combined pill would reduce the daily pill burden, improving compliance and reducing 
complexity of treatment regimens. Identifying inhibitor(s) that block the replication of M. 
tuberculosis and the life cycles of HIV and P. falciparum is plausible, since functional RNase 
H genes are present in M. tuberculosis [420], HIV [458] and P. falciparum [516]. Similarly 
TETD (Disulfiram) has previously been shown to inhibit the glycolytic pathway in P. 
falciparum [517]. Given the glycolytic inhibitory activity of TETD against M. tuberculosis as 
well, a co-inhibition of both infections could be achieved simultaneously by using a single 
inhibitor. Although, the cellular target of TETD in M. tuberculosis is not known but it 
inhibited the growth of M. tuberculosis H37Ra and M. bovis BCG in this study (Table 3.4). 
Other examples of drugs that may show multiple activities are aklavine HCl and 
mitoxantrone, that were both characterized as anti-mycobacterial compounds in this study 
(Table 3.5) and had previously been shown to inhibit P. falciparum growth as well (section 
3.3.1.2.4).  
Furthermore, during compound screening in this project, NSC668394 was identified as a 
mycobacterial inhibitor with an in vitro MIC value against M. tuberculosis of 1.56 µM (this 
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study) from the NIH chemical library. It also has previously been shown to have activity 
against HIV and P. falciparum (PubChem). Given its low MIC against M. tuberculosis and 
the fact that RNase HI is present and essential in these species, it may be possible to develop 
a triad inhibitor (section 6.3.3), which is not only active across these species but may also be 
effective against the suit of opportunistic infections of HIV/AIDS (Figure 6.1). Further 
experimental studies in vivo therefore would be needed to see if this is achievable.  
6.3.3. An Ultimate Goal for Future Research 
The goal of this research would be to provide a means to minimise some of the problems that 
can occur when HIV and common opportunistic diseases, such as Tb, candidosis and 
pneumonia, are treated simultaneously. By targeting a single enzyme that is common to HIV 
and co-infecting pathogens, toxic and interference activities that can occur between different 
drugs may be reduced. This new class of drug would offer important benefits to patients with 
HIV and other related diseases by reducing side effects and improving treatment success rates. 
Since RNase H is present in most bacterial, viral and fungal species, including major 
parasites (section 6.3.2) and is essential to their life cycles, it may be possible to develop an 
inhibitor common to both HIV and Tb that is also active against a range of other pathogens 
which only emerge under conditions of severe immuno-deficiency as occur in AIDS. 
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Figure 6.1: Future prospects for the development of an inter-kingdom, single-target RNase HI inhibitor 
against bacterial, viral, and fungal species for the simultaneous inhibition of Tb, HIV and their opportunistic 
infections.  
 
6.4. Possible Problems with Successful Drug Development 
 In vitro active inhibitors may not be active in vivo as hypothesised [343]; therefore, 
inhibitors identified in this study (though active against virulent strains in vitro) must 
be tested in a mouse models to completely evaluate their potential and efficacy in vivo.  
 Although some of the inhibitors were highly active against M. tuberculosis in vitro 
and also have activity against clinical strains (S. aureus) e.g. NSC668394 (Chapter 5). 
Some of the inhibitors also appeared to be active in a range of other assays suggesting 
that such inhibitors may have multiple targets including human enzymes. A broad 
activity profile makes these compounds less important in the drug-discovery process. 
Another possibility, however, is to make them effective against a single target by 
performing derivatisation to generate single-target active analogues (section 6.5).  
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6.5. Future Research  
A number of interesting mycobacterial inhibitors were discovered in this work. Some of these 
inhibitors also possess known anti-HIV RNase H activity and require further experimentation 
in vivo. Derivatisation of important inhibitors could be performed to generate more effective 
compounds that could potentially achieve a dual inhibition of HIV and M. tuberculosis. 
Selected compounds will then be tested in an infection assay [518], to evaluate their 
intracellular anti-M. tuberculosis efficacy. While induction of M. tuberculosis-infected-
macrophages and pneumocytes apoptosis is known, it is not clear whether M. tuberculosis 
drives cellular necrosis or if the apoptosis represents a host immune strategy to halt M. 
tuberculosis replication [519-520].  
An RNase HI knockout mutant will be generated to validate this protein as a viable target in 
M. tuberculosis. This should help defining a link between simultaneous inhibition of both 
HIV and Mtb RNase H. Finally, inhibitors with ideal pharmacophores will be tested for in 
vivo efficacy. While no model mimics the disease condition in humans [239], animal models 
of infection are only expected to be predictive of the infection state [521]. AgResearch, 
Animal Research Centre, Wallaceville, New Zealand has an established facility for in vivo 
studies using a validated guinea pig model, which could be used to evaluate potential in vivo 
activity of anti-Tb compounds identified in this study. Inhibitors that can target interacellular 
M. tuberculosis, will greatly aid reducing bacterial load and clearing infection as well as in 
disease eradication. 
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7.1. Miscellaneous Tables: 
Table 7.1: Recommended chemotherapy for active pulmonary Tb 
Standard Drug                 
a
Recommended Regimen for Tb 
  
b
First Two Months   
c
Next Four Months 
Rifampicin   +    + 
Isoniazid   +    + 
Pyrazinamide   +    – 
Ethambutol   +    – 
aWorld Health Organization (Treatment of Tuberculosis). bInitial intensive phase with combination therapy. 
cContinuation phase for next at least four months depending on stage of the disease. (+) indicates required, (-) 
indicates, not required. 
Table 7.2: PCR steps used to amplify M. tuberculosis genes 
PCR Step  Temperature   Time   No of Cycles 
Initial Denature  95 
o
C   5 min    1  
Denature   94 
o
C   1 min 
Anneal    55 
o
C   30 sec    25x 
Extension   72 
o
C   1 min 
Final Extension  72 
o
C   5 min    1 
Hold    4 
o
C         
DNA quantity was confirmed by NanoDrop® ND-100 Spectrophotometer (NanoDrop Technologies, New 
Zealand) using the software 3.1.0. () indicates infinity. 
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Table 7.3: Concentrations for restriction digestion 
Reagent  Stock Conc.   Final Conc.  
Enzyme  10,000 U/µL  0.5 U/µL 
NEB buffer  10 x   1 x 
BSA   10 x   1 x 
Vector   ~ 1 µg   25-50 ng/µL 
 
 
Table 7.4: Reaction set up for double restriction digestion 
Reagents   PCR Product   Vector 
ddH2O    5 µL    5 µL 
Buffer 4 (10x)   2 µL    2 µL 
BSA (1x)    1.0 µL    1.0 µL 
DNA    10 µL    10 µL 
EcoRI    1.0 µL    1.0 µL 
XhoI     1.0 µL    1.0 µL 
A total of 20 µL reaction was used for restriction digestion experiments and all reagents are in order of addition. 
Different vector-to-insert molar ratios were tested in order to evaluate the appropriate transformation efficiency. 
Positive control (uncut pET28a (+) into DH5α e-) and negative control (water instead of plasmid) were included 
in each experiment.  
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Table 7.5: Conditions for gel electrophoresis  
Conditions  PCR Products   Restriction Digests  
Agarose conc.  1%   0.8% 
Buffer   1x TAE  1x TAE 
Time   40 minutes  80 minutes 
Voltage  120-140 V  80 V 
Amperes   400 A   300 A  
 
 
Table 7.6: DNA concentration of PCR_Rv2228c 
Tube No.
 
Volume  DNA Conc.  DNA Purity 
260/280
 
1  50 µL   36.3 ng/µL    1.78 
2  50 µL   39.1 ng/µL   1.81 
3  50 µL   37.4 ng/µL   1.79 
As per supplier‟s recommendations, a maximum of 1 µL of restriction enzyme was used in restriction digestion 
experiments because pre-added glycerol (for storage) can affect the working efficiency of restriction enzymes.  
Four eppendorfs averaging 50 µL of pET28a (+) was recovered from DH5α cells after 
overnight incubation at 37 
o
C.  
Results for pET28a (+) Miniprep 
Plasmid was extracted using plasmid extraction kit.  
 
Appendices  
 
  
 
255 
 
7.1.1. DNA Concentration and Quantification 
Quantity of DNA was confirmed through NanoDrop, which was zero blank against DNA 
concentration at 0.0 ng/µL with water prior to take readings. Plasmid preparations were 
cleaned using a plasmid clean kit and DNA and DNA was quantified using a NanoDrop™  
(NanoDrop Technologies, Auckland, New Zealand). Concentrations of plasmid DNA is 
given below. 
Table 7.7: DNA concentration of an extracted recombinant plasmid 
Tube No.
 
Volume  DNA Conc.  DNA Purity 
260/280
 
   1   50 µL   21.4 ng/µL    1.89 
   2   50 µL   20.6 ng/µL   2.2 
   3   50 µL   23.7 ng/µL   1.87 
   4   50 µL   22.1 ng/µL   2.0   
Plasmid DNA was extracted using High Speed MiniTM plasmid DNA extraction kit  
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Table 7.8: DNA sequence for M. tuberculosis genes encoding RNase HI/II 
Mtb ORF Rv2228c     Length DNA Sequence (1095 base pairs) 
GTGAAAGTTGTCATCGAAGCCGACGGCGGATCGCGGGGCAATCCCGGACCGGCCGGATACGGCGC
GGTGGTGTGGACCGCCGATCACTCCACCGTGCTGGCCGAGTCCAAGCAGGCGATCGGCCGGGCGA
CGAACAACGTCGCCGAATACCGCGGCCTGATAGCCGGTTTGGACGACGCCGTGAAACTAGGTGCC
ACCGAGGCCGCGGTGCTGATGGACTCCAAGCTGGTGGTGGAGCAGATGTCCGGGCGGTGGAAGGT
CAAGCACCCGGATCTGCTGAAGCTCTATGTCCAGGCTCAGGCGTTGGCGTCCCAGTTTCGCAGGAT
CAACTACGAGTGGGTTCCGCGTGCCCGGAACACGTATGCAGACCGGTTGGCCAATGACGCGATGG
ACGCCGCCGCGCAATCGGCTGCGGCGGATGCGGATCCTGCCAAAATCGTTGCGACCGAGTCACC
GACATCTCCCGGCTGGACCGGCGCCCGCGGTACACCCACCCGACTACTTTTGTTGCGCCACGGGCA
GACGGAGCTGTCGGAGCAACGCCGCTATTCGGGGCGCGGCAACCCGGGGTTGAACGAGGTGGGGT
GGCGCCAGGTTGGTGCGGCGGCCGGGTATCTGGCGCGGCGCGGCGGGATCGCTGCGGTGGTCTCC
TCGCCGCTACAGCGGGCTTACGACACCGCGGTGACCGCCGCCAGAGCCCTGGCCCTGGACGTGGT
CGTCGATGACGACCTGGTCGAGACCGACTTCGGCGCCTGGGAGGGGCTGACGTTCGCGGAGGCCG
CAGAACGCGATCCCGAGCTGCACCGTCGCTGGCTGCAGGACACCAGCATCACGCCCCCGGGTGGG
GAAAGCTTCGACGACGTGCTGCGGCGGGTTCGGCGGGGACGTGATCGGATCATCGTTGGCTACG
AAGGCGCGACGGTGCTGGTGGTGTCACATGTCACGCCGATCAAAATGTTGTTGCGGCTGGCGTTGG
ATGCCGGGTCGGGCGTCCTATATCGGTTGCATCTTGATCTGGCATCGCTGAGCATCGCCGAGTTCT
ACGCCGATGGGGCATCGTCGGTGCGATTGGTGAATCAG 
Mtb ORF Rv2902c      Length DNA Sequence (795 base pairs) 
ATGACCAAGACCTGGCCACCGCGGACGGTGATCCGTAAATCTGGGGGTTTGCGGGGAATGCGCAC
CCTGGAGTCCGCGCTGCATCGTGGTGGTCTGGGGCCGGTGGCCGGGGTCGACGAAGTGGGTCGCG
GCGCCTGCGCTGGCCCGTTGGTGGTCGCGGCCTGCGTGCTTGGCCCCGGGCGGATAGCAAGTCTTG
CCGCCCTTGATGATTCGAAGAAGCTCAGCGAGCAAGCGCGGGAGAAGCTGTTCCCGCTGATCTGC
CGGTATGCGGTGGCCTATCACGTGGTGTTCATCCCGTCGGCCGAGGTCGACCGCCGCGGCGTGCAC
GTGGCCAATATCGAAGGTATGCGGCGCGCGGTGGCCGGTCTGGCGGTGCGGCCCGGTTATGTGCT
CAGCGACGGCTTTCGCGTGCCAGGACTGCCGATGCCGTCGTTGCCGGTGATCGGTGGCGACGCGG
CAGCCGCCTGCATCGCCGCGGCTAGCGTGCTCGCCAAGGTCAGCCGGGACCGCGTGATGGTTGCG
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TTGGACGCCGATCACCCCGGGTACGGTTTCGCGGAGCACAAGGGTTACAGCACCCCGGCGCACAG
CCGGGCGCTGGCCCGATTGGGACCCTGCCCGCAGCACCGTTACTCGTTCATCAATGTTCGCCGGGT
GGCGAGTGGGTCGAACACCGCAGAGGTCGCCGACGGCCAACCCGACCCTCGGGACGGGACGGCA
CAGACGGGTGAGGGAAGATGGAGCAAGAGTTCCCACCCAGCGACAATGCGGGCCACGGGTCGCG
CTCAGGGCACTTAG 
For Rv2228c, BamHI and HindIII restriction sites at 423 bp and at 849 bp, respectively were found in gene 
sequence that encodes for RNase HI in M. tuberculosis (indicated in bold) therefore these restriction sites were 
not used for cloning Rv2228c. Gentle Software was used to design primers required for cloning experiments and 
DNA sequences of Rv2228c and Rv2902c were retrieved from [522]. Mtb, M. tuberculosis. ORF, Open reading 
frame. 
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7.2. Disinfectants for Bench Work 
Routine laboratory disinfectant techniques were practiced each time while dealing bacterial 
cultures and prior to assay set up with mycobacteria i.e. 
 Use of bench-top 70% ethanol. 
 Trigene solution (for mycobacteria). 
 UV light for at least 15 minutes followed by disinfection of hood area. 
 5-10% bleach is used to inactivate/kill bacterial cultures after assay has been set up, 
before washing and autoclaving each time. 
A routine laboratory practice of wiping surfaces and Biological Safety Cabinets with 70% 
ethanol may not be sufficient for inactivating M. tuberculosis, due to its thick cell wall, it can 
withstand weak disinfectants [46]. However, Trigene 50% (v/v) or Hydrogen Peroxide 
Vapour (HPV) is effective to completely disinfect surfaces and hood facility from M. 
tuberculosis contamination [523]. Therefore, all safety precautions including a thorough 
disinfection and prior sterilization of materials were achieved before setting up assays with M. 
tuberculosis. All surfaces were wiped afterwards with 70% ethanol and a UV light was left 
on for about half an hour. All cultures plates, flasks and troughs were suspended in 10% 
bleach before they were washed in a dishwasher and autoclaved for reuse. 
7.2.1. Culture Purity for Mycobacteria 
Due to a prolonged time period for mycobacterial cultures, contamination of M. bovis BCG 
with M. smegmatis is common in laboratories. Purity of the slow-growing mycobacterial 
culture was initially confirmed by performing a Zn stain and visualizing under oil immersion 
(100 x) objective (Figure 1.3). In order to differentiate from M. smegmatis growth, M. bovis 
BCG (or M. tuberculosis) culture was aseptically plated out on Luria-Bertani (LB) agar plates 
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without antibiotics and plates were incubated at 37 
o
C for up to for 72 hours. Unlike M. 
smegmatis, M. bovis BCG requires additional growth nutrients (OADC), it does not grow on 
simple LB plates. Therefore, no growth on M. bovis BCG plates after 2 days confirmed 
culture purity and indicated no contamination with M. smegmatis or E.coli. In contrast, both 
E.coli and M. smegmatis start to grow on LB agar plates between 24-48 hours.  
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7.3. Miscellaneous Figures  
  
 
 
Figure 7.1: (A) Map for pCG79 [248]. 
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Figure 7.1: (B) Map for pET28a (+) [524]. 
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Figure 7.2: Sequencing results of cloned Rv2228c into pET28a (+). Red arrows show mis-matches, gaps and 
substitutions within in the insert (Rv2228c) due to low fidelity of the polymerase enzyme used in the PCR-
amplification of Rv2228c. Analysis was not taken further to the protein purification stage as the mutations might 
have truncated the desired protein. However, a biochemical assay at the University of Auckland was used 
instead to confirm the target for selected RNase HI inhibitors and results have been added in section 5.4.3. See 
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Figures 5.10 and 7.14 for more details regarding in silico interaction of inhibitors with RNase HI and 
confirmation of this protein as a target for these inhibitors in M. tuberculosis, respectively. 
 
Figure 7.3: (I) Types of mycolic acids in M. tuberculosis showing cis and trans configuration. Figure adapted 
with permission from Takayama. et al. [525]. 
 
Figure 7.3: (II) M. tuberculosis H37Ra growth on solid media, 7H10 plates supplemented with 10% 
OADC (A) Negative control - no growth and (B) mycobacterial growth after three weeks of incubation. 
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Figure 7.4: (A) Carbon starvation in M. bovis BCG. Different concentrations of OADC were used with no 
glycerol. BCG growth was significantly reduced by keeping 10% OADC but removing glycerol, compared to 
standard nutrient conditions (100% cells control). 
 
 
Figure 7.4: (B) Carbon starvation in M. bovis BCG. Different concentrations of OADC were used along with 
0.05% glycerol. 
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Figure 7.4: (C) Carbon starvation in M. bovis BCG. Different concentrations of OADC were used along with 
0.25% glycerol. Glycerol appeared to be the nutrient-limiting factor for BCG growth. OD represents OADC in 
the figure (see section 2.2.1.1 for more detail on mycobacterial growth supplements). 
 
 
Figure 7.4: (D) Carbon starvation in M. bovis BCG. Different concentrations of OADC were used along with 
0.5% glycerol. OD represents OADC in the figure. 
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Figure 7.5 (A-F): Dose-response curves for standard anti-Tb drugs against M. bovis BCG.  
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Figure 7.5 (A-F): Dose-response curves for standard anti-Tb drugs against M. bovis BCG. 
 
 
Figure 7.6: Cytotoxicity of NSC402959 toward the Vero cell line compared to the front-line anti-Tb drug, 
rifampicin. Both compounds exhibited toxicities in an acceptable range (IC50 >100 µM).  
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Figure 7.7: Anti-mycobacterial activity of NSC402959 against M. tuberculosis H37Ra under standard 
nutrient-rich conditions. Anti-mycobacterial activity of NSC402959 was found to be within the range of 6.25 
µM to 12.5 µM in dose-response assays with nutrient-rich conditions. 
 
Figure 7.8: Cytotoxicity of NSC402959 against the J774.A1 cell line. 
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Figure 7.9: Dormicidal activity of M. tuberculosis inhibitor, NSC402959 and a standard Tb drug, 
rifampicin. No dormicidal activity for NSC402959 was observed against H37Rv cells at concentrations up to 
100 µM. The results for NSC402959 were comparable to rifampicin which was tested in parallel and it inhibited 
growth of all mycobacterial strains at 12.5 µM in the growth inhibition assays.   
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Figure 7.10: Standard second-line anti-Tb drugs (A) Streptomycin, MF C21H39N7O12   and MW 581.57 
g/mol (B) Ciprofloxacin, MF C17H18FN3O3 and MW 385.8 g/mol  (C) Ethionamide, MF C8H10N2S and MW 
166.24 g/mol and  (D) Capreomycin IIA, MF C19H32N12O7 and MW 540.53 g/mol (PubChem database).   
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Figure 7.11: M. tuberculosis cell wall revealing a complex structure and arrangement of glycolipids and 
capsule. Figure reproduced with permission from Riley LW, 2006 [526]. 
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Figure 7.12: Plate map for validation of growth inhibitors in bacteriostatic assays. The arrangement of 
positive (anti-Tb drug + cells) and negative controls (medium only) used in bacteriostatic and dormicidal assays 
was similar. 
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Figure 7.13: Genomic map of M. bovis BCG Pasteur 1173P2. (Figure was adapted with permission from 
[357]). 
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Figure 7.14: Activity of RNase H inhibitors (A) NSC112200 and (B) NSC668394, against purified RNase 
HI (Rv2228c) from M. tuberculosis. Both inhibitors were tested at two test concentrations (100 µM and 5 µM) 
with controls. A preliminary analysis of the activity of these inhibitors indicated that NSC112200 (MIC 6.25 
µM against M. tuberculosis in dose response assay) specifically inhibits the RNase HI (Rv2228c) from M. 
tuberculosis H37Rv compared to NSC668394 (MIC 3.125 µM against M. tuberculosis in dose response assay). 
NSC112200 does not interfere with human RNase H (PubChem database). The 100% positive control (same 
WT enzyme at 4 nM) and blank (DNA/RNA hybrid at 100 nM) curves have been superimposed on each set of 
inhibitor data. Assay was carried out at 21°C for 36 minutes with readings every 30 seconds. It is an initial 
assessment of these inhibitors for the identification of RNase HI as their primary target in M. tuberculosis and 
results are based on one experiment only (Figure courtesy of Dr. Stephanie Dawes), also see figure 5.10 for 
compound NSC112200.  
 
 
 
